The Texas Medical Center Library

DigitalCommons@TMC
UT School of Public Health Dissertations (Open
Access)

School of Public Health

Fall 12-2018

CHAGAS DISEASE AWARENESS AMONGST TEXAS PHYSICIANS
Gerardo J. Pacheco
UTHealth School of Public Health

Follow this and additional works at: https://digitalcommons.library.tmc.edu/uthsph_dissertsopen
Part of the Community Psychology Commons, Health Psychology Commons, and the Public Health
Commons

Recommended Citation
Pacheco, Gerardo J., "CHAGAS DISEASE AWARENESS AMONGST TEXAS PHYSICIANS" (2018). UT School
of Public Health Dissertations (Open Access). 8.
https://digitalcommons.library.tmc.edu/uthsph_dissertsopen/8

This is brought to you for free and open access by the
School of Public Health at DigitalCommons@TMC. It has
been accepted for inclusion in UT School of Public Health
Dissertations (Open Access) by an authorized
administrator of DigitalCommons@TMC. For more
information, please contact
digitalcommons@library.tmc.edu.

CHAGAS DISEASE AWARENESS AMONGST TEXAS PHYSICIANS

by
GERARDO JESUS PACHECO, MPH, MS

APPROVED:

MELISSA A VALERIO, PHD

PAULA E STIGLER GRANADOS, PHD

JOHN HERBOLD, DVM, MPH, PHD

JOSE BETANCOURT, DRPH

DEAN, THE UNIVERSITY OF TEXAS
SCHOOL OF PUBLIC HEALTH

Copyright
by
Gerardo Jesus Pacheco, BS, MS, MPH, DrPH
2018

DEDICATION
To Crystal and Olivia Pacheco

CHAGAS AWARENESS AMONGST PHYSICIANS IN TEXAS

by
GERARDO JESUS PACHECO
BS, University of Texas at El Paso, 2006
MS, University of Texas at San Antonio, 2009
MPH, University of Texas Health Science Center at Houston, 2012

Presented to the Faculty of The University of Texas
School of Public Health
in Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PUBLIC HEALTH

THE UNIVERSITY OF TEXAS
SCHOOL OF PUBLIC HEALTH
Houston, Texas
December, 2018

PREFACE
I am fortunate and grateful for the mentorship that first introduced me to public health
and the encouragement to continue on this journey. My late father has been my inspiration
throughout this degree and my public health training. He is the reason for my passion and
interest in health disparities and addressing the impact of delayed medical diagnosis.

ACKNOWLEDGEMENTS
First and foremost, I am forever grateful for the guidance, patience, and expertise of
my committee. I appreciate the support from Dr. Melissa Valerio throughout my doctoral
training and for pushing me to see this through. I thank Dr. John Herbold for always
reminding me of the “big picture” and Dr. Jose Betancourt for his detailed feedback and
encouragement. I am in Dr. David Gimeno’s gratitude, for his words of encouragement and
assistance with the transcription of my qualitative data. I would like to also thank the
administrative staff at the San Antonio Campus for helping me with all the logistics (and for
their kind words of encouragement and faith in me!). And last but definitely not least I am
indebted to Dr. Paula Stigler Granados for her mentorship, pragmatism, time, and for taking a
chance with me. If she had not recruited me to assist her in her funded Chagas project, this
research would not have been possible.
Next, I would like to thank the Texas Chagas Taskforce members, including: Drs.
Leo Cropper and Sarah Gunter for serving as reviewers; Dr. Melissa Nolan for outreaching to
her wide network of physicians to help with the recruitment; Dr. Sue Montgomery for
proving her content expertise; and all of the other members who reviewed instruments and
helped disseminate my questionnaires.
Finally, I would like to thank my friends and family for helping me stay on track and
grounded (and stay sane!). To my wife: thank you for seeing this through and always having
confidence in me, especially in those moments of self-doubt. To my family: thank you for
understanding my reclusiveness and for your support.

CHAGAS DISEASE AWARENESS AMONGST PHYSICIANS IN TEXAS

Gerardo J. Pacheco, MS, MPH, DrPH
The University of Texas
School of Public Health, 2018
Dissertation Chair: Melissa A. Valerio, PhD
An estimated 300,000 people in the U.S. are living with Chagas Disease (CD), many
of whom may not yet know they are infected. Approximately 20% to 30% of individuals with
CD are expected to develop clinical symptoms that may manifest as heart disease and result
in death if left untreated. The prevalence of CD in humans is not well understood. Given its
asymptomatic manifestation and the rarity in cases seen by physicians in general, CD may be
under-recognized by physicians.
The purpose of this research was to explore the understanding and knowledge of CD
in Texas HCP populations (cardiologists, infectious disease specialists, and general/ family
practice providers) and identify provider-based education and practice recommendations to
reduce the prevalence of undiagnosed CD.
Texas quarterly Inpatient Public Use Data Files (IPUDF) for 2013 to 2016 were used
to identify ICD heart-related missed CD diagnosis and CD diagnosis and map the cases.
Counties with a high burden of heart-related diagnosis were indicative areas with CD
diagnosis, as shown by the ICD codes and by the TDSHS CD-reported cases. Heart-related
diagnosis and age demographics indicate the possibility of missed CD diagnosis throughout
the state.

Self- administered online knowledge, attitudes, and practice (KAP) questionnaires
were used to quantify knowledge deficits by physician specialty (n= 43): family or general
practice (n= 21); infectious disease (n= 19); and cardiology (n= 3). ID specialists had a
greater grasp on the nuances of CD and were more confident than family providers in
recognizing risk factors and the vector and were more knowledgeable overall.
Key informant (KI) telephone interviews were conducted (n= 13) among infectious
disease specialists (n= 8), cardiologists (n= 4), and one family physician to explore barriers
and recommendations to improve awareness and knowledge. Training and experience,
according to the KI, were essential in shaping physicians’ understanding of CD in Texas.
Specific physician recommendations to enhance awareness and improve knowledge on CD in
Texas include: 1) engage patients and physician leadership; 2) increase surveillance to better
understand prevalence; 3) improve access to physician resources and how materials on CD
are disseminated; and 4) improving and updating physician resources.
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BACKGROUND
Chagas Disease (CD) is a neglected zoonotic disease1 of the Americas that can be fatal if
not diagnosed and treated in its early stages. CD was first discovered in 1909 by Carlos Chagas
in Brazil and is endemic in Latin America.2 The World Health Organization (WHO) recognizes
CD as a neglected tropical disease3 that continues to widen its global reach beyond the American
tropics. Its impact and burden 4-7 are beginning to be seen in non-endemic regions from imported
cases, including Europe and Asia. American trypanosmiasis,8 infection from the hemoflagellate
protozoan parasite Trypanosoma cruzi (T. cruzi), causes CD.1,9 CD accounts for the highest
burden of any parasitic disease in the 22 Latin American countries where it is endemic (Figure
1). T. cruzi is endemic throughout Central and South America and is found in North America,
including in Mexico and in the Southern United States (U.S.).10 An estimated 8 million people in
Latin America have CD.11 Over 28,000 people are infected each year in Mexico, Central
America and South America, accounting for at least 12,000 deaths per year.12
Kissing Bugs and Trypanosoma cruzi
Trypanosoma cruzi, infects invertebrate and vertebrate hosts during its various life
cycles. The complex life cycle of T. cruzi is described in Figure 2.8 Reduviids, also known as
triatomines or kissing bugs, are blood-feeding insects that transmit the parasite (mainly through
their feces) that causes CD. The kissing bugs are unaffected by T. cruzi but act as the vector for
the parasite. Kissing bugs transmit the parasite to mammals including humans,1 but can also
infect reservoir hosts such as canines, opossums, raccoons, and other domestic8,13 and sylvatic
animals.14 Although CD is a zoonotic disease, the focus of this dissertation will be on the human
health aspect.

1

Figure 1: World-wide prevalence of Chagas Disease 1

Figure 2: Lifecycle and transmission of Trypanosoma cruzi in human hosts 2

1

Source: Drugs for Neglected Disease initiative (DNDi) - https://T. cruzi.dndi.org/diseasesprojects/chagas/
2
Source: Rassi et al. (2010). Chagas disease. The Lancet, 375: 402

2

Geography of Vectorial Transmission to Humans
Vectorial transmission is most common among children and adolescents in endemic
countries.8 In Latin American communities, transmission usually occurs during childhood as a
result of limited or nonexistent vector control eradication and screening interventions coupled
with poor housing conditions.15 The U.S. is not considered an endemic area, however kissing
bugs infected with T. cruzi have been found throughout the South (i.e., from California to
Georgia) and local transmission have been reported (Figure 3) in these states.10 However, the
burden of T. cruzi infections from triatomine exposure in the states where the vector has been
reported (Figure 3) has not been assessed. In Texas alone, eleven different species (from the
genus Triatoma, Rhodnius, and Panstrogylus ) of the vectors are able to transmit the parasite and
are found throughout the state.16 Other routes of transmission include: vertical or congenital;
blood-borne; organ-derived; and oral.10 Kissing bugs can be found indoors and outdoors,
including the following: “beneath porches; between rocky structures; under cement; in rock,
wood, brush piles, or beneath bark; in rodent nests or animal burrows; in outdoor dog houses or
kennels; and in chicken coops or houses”.17

3

Figure 3: Triatomine prevalence in the U.S., by state 3

Congenital Transmission
Congenital transmission occurs in both endemic and non-endemic countries.8 Pregnant
women are a specific concern since they may transmit the parasite to their children unknowingly.
Even in Mexico, Central America and South America where CD is prevalent, residents may not
be aware of their infection status nor know how or where to seek and access treatment if they
believe they are infected.18 In Latin America, over 14,000 congenital CD cases occur each year.19
An estimated 20 to 183 congenital CD cases per year are expected in Europe.20 According to
Centers for Disease Control and Prevention (CDC), 63 to 315 congenital infections occur in the
U.S. each year.21 With an estimated 40,000 women of childbearing age infected with T. cruzi, the
risk of transmission from an infected mother to child in the U.S. is between 1% to 5%.22 In the
U.S., there are no requirements, similar blood screening, or recommended guides to prompt
healthcare providers (HCP’s) to screen all pregnant women at risk for T. cruzi infection.

3

Source: Centers for Disease Control and Prevention (https://T.
cruzi.cdc.gov/parasites/chagas/gen_info/vectors/index.html)
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Transmission from Blood Transfusions
In contrast to the lack of compulsory screening and testing in the general population or
with pregnant women, the blood supply in the U.S. has been screened for CD antibodies since
2007.1 Blood donation screening is the most common means by which individuals learn about
their CD diagnosis in the U.S.23 From 2007 to 2017, a total of 2,269 confirmed serological
positive donations have been identified throughout the U.S.24 As shown in Figure 4, California,
Texas, Georgia, North Carolina, Virginia, Florida, and New York had the highest prevalence.
Nationwide, 1 in 27,500 blood donations tested positive for T. cruzi from 2008 to 2012.25 For
that same period, 1 in 6,500 blood donations in Texas were T. cruzi positive.26 Approximately
11% of suspected cases will follow-up with a HCP to receive treatment.25 In general, blood
donors testing positive for T. cruzi will receive a letter notifying them of their potential CD
serostatus. However, most infected persons (both globally and in the U.S.) are unaware of their
status.1

5

Figure 4: Lab-confirmed Chagas cases in blood donations, 2007 – Aug. 2017 4

Chagas as a Global Threat
As a result of globalization, human migration has changed the distribution of CD in
endemic and non-endemic countries: CD is both a re-emerging and a neglected tropical disease.4
Figure 1 shows the impact to European countries, Japan, and Australia. For example, a recent
literature review notes that while Japan’s prevalence may reach up to 4,000 CD cases yet only 7
have been reported in medical literature.27 In the U.S., both autochthonous (or locally-acquired)
infections and imported cases from Latin America have been recorded and reported.23,28,29 Two
case studies presented by Hsu and colleagues describes how both CD patients were Central
American immigrants identified in a New Orleans hospital. 30 Reports from locally-acquired
infections are rare in Texas,29 yet documented reports from autochthonous cases date back to the

4

Source (formerly known as) the American Association of Blood Banks (AABB): http://T.
cruzi.aabb.org/research/hemovigilance/Pages/chagas.aspx
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1930’s.23 Nonetheless, most infections are due to imported cases from areas of endemicity in
Latin America given the prevalence of the vector.21
Phases and Clinical Manifestations
Acute infection
CD includes two main phases: acute and chronic.1,2 Acute infections occur up to the first
two months of the initial infection, which may manifest with mild flu-like symptoms or febrile
illness31. Other symptoms may include: malaise, enlarged spleen, liver, and lymph nodes;
localized or generalized edema; chagomas or breaks in the skin; and result in abnormal
electrocardiogram (ECG).8 The hallmark characteristic, though not always present, is the
swelling of the eyelids, or Romaña’s sign, the site where the kissing bug feces was deposited or
rubbed into the eye.11 Acute infection may manifest as early as one week after exposure and
may be self-limiting in most individuals.8 The patient may not seek medical attention since the
symptoms are mild and not unique to CD. Figure 5 shows the acute and chronic phases of a T.
cruzi infection and the onset of the immunological response.
Chronic infection
During the chronic stage, two presentations are possible: the indeterminate form, which is
commonly asymptomatic; and the determinate which include cardiac (e.g., cardiomyopathy,
heart failure, altered heart rate or rhythm) and intestinal complications2. The majority of infected
individuals (70%-80%) 2,15 will advance from the acute phase and remain in a latent or
indeterminate chronic form of the disease (mostly asymptomatic), which may persist as a
lifelong infection. The danger of this asymptomatic status is that once symptoms do manifest,
eliminating the parasite becomes more difficult or impossible and often results in death.

7

Chronic determinate phase
Conversely, only 20-30% of infected individuals will progress from the indeterminate
chronic phase to a “clinically evident disease” or chronic determinate phase, months to decades
after becoming infected.15 Chronic determinate CD often corresponds to the organ involved
(heart; esophagus; and/or colon): cardiac, digestive, or both.8 The digestive manifestation is
typically found manly in South America or in persons infected in that region.8 Heart failure
occurs usually towards the latter phase of Chagasic heart disease.8 Sudden death due to cardiac
complications can occur.11 The parasite is classified into six types with Strain I being wild, Strain
II being domestic; both of which are “pure”, while Strains III through VI are considered
hybrids.32 TcI has a “wide distribution”—from the Southern U.S. to Northern Argentina and
Chile.33 The strain classification relates to the pathogenicity and distribution of the parasite and
its association to sudden death in infected persons.
Figure 5: Acute and chronic phases of Chagas disease infection 5

5

Source: Susan Montgomery, DVM, MPH
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Cardiomyopathy
For the scope of this study, heart-related symptoms were the primary focus, given that the
digestive manifestation is a hallmark of South American infections. In the Southern Cone of
South America (i.e., Argentina, Bolivia, Chile, Paraguay, Uruguay, and parts of Brazil)
gastrointestinal CD is more common than CD cardiomyopathy, as the latter is more commonly
seen in Central America and North America.34 According to the National Institutes of Health
(NIH), cardiomyopathy, “refers to diseases of the heart muscle…as it becomes enlarged, thick,
or rigid…the heart thus becomes weaker pumping less blood and beating irregularly”.35 Chagasic
cardiomyopathy includes “cardiac arrhythmias, heart failure, and risk of sudden death from
ventricular fibrillation or tachycardia or thromboembolic events”8 and an estimated 5.4 million
people will develop these symptoms.36 Cardiovascular disease in CD patients is believed to be
the result of “parasite persistence in cardiac tissue and immune-mediated myocardial injury.”37
CD may present as idiopathic cardiomyopathy and be overlooked by many or most HCPs as a
diagnosis. Some estimates considering that the Latino immigrant population is younger than the
current U.S. population, suggest that, 10 – 15% of the total U.S. population (or 30,000 to 45,000
individuals) is living with undiagnosed CD cardiomyopathy.21
Epidemiology and Surveillance
In the U.S., currently there is no federal mandate requiring each state to report human CD
cases,38 though currently it is a reportable disease in Arizona, Arkansas, Louisiana, Mississippi,
Tennessee, and Texas.1,39 As such, no national registry or database of confirmed human CD
cases exists in the U.S., except through the case tracking and reporting by the CDC. In turn, the
CDC tracking is limited by the reports they receive directly from the state health departments
and individual HCP’s.
9

Excluding blood donor screening, no active surveillance for T. cruzi infections in the U.S.
exists at this time.40 Though reportable since 2013,2 the Texas Department of State Health
Services (TDSHS) currently does not actively surveil for CD, T. cruzi infections, or CD-related
symptoms (i.e., syndromic surveillance).23,41 In the absence of systematic national and Statelevel surveillance,1 the disease burden, distribution, and populations at higher risk cannot be
accurately quantified or described.10,23 The lack of epidemiological data also highlights the gaps
in detecting chronic Chagas cases.
The CDC estimates that 300,000 infected individuals are living in the U.S., however this
is only based off of a formula using the number of Latin American immigrants in the U.S. and
average prevalence found in Latin America. 42 Since becoming reportable in 2013, there have
been 91 confirmed cases of CD in Texas. Of those cases, 20 were locally acquired, 61 were
imported and 10 were from unknown origins.43 In Texas, between 2013 and 2015, a total of 439
canine Chagas cases were reported.44
Screening and Diagnosing
For the scope of this dissertation, screening refers to the process by which HCP’s
determine if further laboratory diagnostics are required. During the initial screening, the HCP
discusses the patient’s medical history, “including questions about travel and living conditions,”
and performs a physical examination and possibly an ECG.15,31 The diagnosing of CD represents
the clinical and serological testing required to confirm the presence of T. cruzi. In the U.S., the
CDC requires confirmatory laboratory diagnosis for T. cruzi using at least two different
immunoassay procedures (i.e., enzyme-linked immunosorbent assay [ELISA] and
immunofluorescent antibody test) prior to treatment.15 At least two different serological tests are
required given the lack of specificity and sensitivity obtained from one single procedure. Such
10

laboratory assays are used to detect IgG or IgM antibodies to the parasite are available from
major commercial laboratories (e.g., Mayo Medical Lab, ARUP, and Quest Diagnostics).45
Nonetheless, no standardized protocol (at the national, State, or local/county level) is available
for physicians to reference when attempting to request the laboratory codes. Recent statistical
modeling demonstrates the value of screening Latin American immigrants in non-endemic
countries.46 Women are recognized as a target population for community screening programs in
non-endemic countries in Europe (e.g., Spain and Italy) due to the risk of transmitting the
parasite to their children.47,48 No commercially-available rapid screening kit is available for
HCP’s to routinely use that provide an immediate confirmatory results for T. cruzi. In contrast to
other chronic diseases49 (i.e., type II diabetes, heart disease, cancer, etc.), screening and
diagnosing for CD is not routinely performed.
Drug Treatment
Antiparasitics (antitrypanosomal drugs) are currently not commercially available to the
public in the U.S. and are only released by the CDC through investigational protocols. These
drugs have been extensively used in Latin America. Nifurtimox and benznidazole are the two
antiparastics used to eliminate T. cruzi.11 The drugs are generally better tolerated by younger
individuals because side-effects are less frequent and severe.15,31 Benznidazole is the first line
treatment because it has less side-effects.15 Each drug has specific side-effects that tend to
increase as the patient becomes older. As of 2017, benznidazole has been FDA-approved in the
U.S. for use in children aged 2-12 years.38
Prevention Programs
For over a century, Latin American countries have been trying to understand CD, the
prevalence, and how to prevent and mitigate the adverse health outcomes. Currently, education
11

campaigns in Latin America primarily target rural and low-income communities and provide
prevention messages. Most interventions in these regions have focused on vector control and
improving housing conditions,50 as highlighted in Figure 6. The known prevalence of CD in
Latin America is likely higher than in the U.S. due to poorer housing conditions, pathogenicity of
vector, and higher quantities of the vectors in large urban areas. Although CD diagnostics and
eventual treatment in Latin America can be challenging due to limited resources and access to
health care,51,52 physicians in Latin America are more aware of CD screening and recommended
guidelines for diagnosis and treatment than those in the U.S. Furthermore, international
cooperation has made vector surveillance possible. The southern Cone Initiative, for example,
was one of the first collaborative programs in the 1990’s that focused on vector control and
educating the community about kissing bugs.50 Similar international efforts to the southern Cone
Initiative have been sustain by Central and South American countries and have resulted in
reducing the rate of new (acute) infections in some regions.

12

Figure 6: Example of Campaigns in Latin America 6

Role of Healthcare Providers
Due to the number of cases, its asymptomatic nature, urgency for early diagnosis and
treatment and unknown prevalence in the U.S., CD should be a concern for HCP’s. Many
physicians currently practice medicine within their subspecialty and in isolation from other HCP
specialties.53 Even fewer communication exchanges occur with other scientists (i.e.,
veterinarians, entomologists, ecologists, policy scientists, etc.). The lack of collaboration and
engagement may prevent the exchange of new ideas and innovations. In turn, this is a barrier for
an accurate and timely diagnosis for a patient.53 Recent epidemiological trends in the vector, or
in zoonotic populations, for example, can shed light about the potential threat to human health.
As we move towards a healthcare model in which the patient, as the consumer, is more informed
and encouraged to participate in decision-making process, he or she may be a stronger advocate

6

Source: http://T. cruzi.taringa.net/posts/salud-bienestar/12344378/Que-es-la-Vinchuca.html
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to improve the likelihood of testing and diagnosis, rather than rely solely on the physician as the
gatekeeper for information. It is unclear how medical training and continuing education among
the various specialties and sub-specialties shape how individual physicians receive, synthesize,
and apply information regarding emerging or rare diseases like CD.
Health System Barriers
According to the WHO, an effective health system “delivers quality services to all
people, when and where they need them.”54 Although their configuration is diverse and specific
to meet the needs of each individual country, it still “requires a robust financing mechanism; a
well-trained and adequately paid workforce; reliable information on which to base decisions and
policies; well-maintained facilities and logistics to deliver quality medicines and technologies.”54
The emerging literature frames health system barriers to diagnosing and treatment of CD at the
national, community, and individual levels, specific to the countries and population
described.42,55-58 Nonetheless, elements regarding the patient, provider, and health system
barriers are applicable in understanding the screening, diagnosing, and treatment barriers of CD
in Texas.
Patient level
The first challenge is that CD is rarely diagnosed during the acute phase of the
infection.23 The latency and asymptomatic nature of the disease may not prompt individuals to
seek immediate medical consultation or treatment. Cultural beliefs and systemic barriers may
also prevent or delay a patient from seeking medical care, particularly as documented in Central
and South American groups.55,58 For instance, an individual distrusts the medical system, while a
systemic barrier may include the lack of drugs or HCP’s.32,48,55,56 Individuals in impoverished
communities in Latin America and in the U.S. lack health insurance or the means to access
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medical care, even if they wanted to get diagnosed and treated.57 These challenges are also
reflected in the Latin American immigrants in the U.S. and other non-endemic countries. In rare
occasions, individuals recognize the exposure to a kissing bug or develop clinical manifestations
(i.e., a chagoma) that may prompt medical attention. Figure 7 summarizes some of the
individual-level barriers.
Figure 7: Patient barriers and strategies for coping with Chagas disease 7

System and provider level
Due to the rarity in reporting autochthonous cases, there is still a lack of overall
awareness among HCP’s in the U.S., including in Texas.23 HCP’s may consider CD only as a

7

Source: Forsyth, C.J. (2017) “I Cannot Be Worried”: Living with Chagas in Tropical Bolivia.
PLoS Neglected Tropical Disease, 11:1
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neglected tropical disease and not recognize the risk factors for local and acquired infections in
Texas. They also may not consider their patients from Latin America or from mothers from Latin
America at risk if they have never encountered the disease before and know very little about it.
According to the 2015 American Community Survey, Hispanics/ Latinos represent 38.4%
(which represent 10,196,367 persons) of the total population for the State.59 Furthermore, in
2010, the Hispanic/ Latino population made up 37.6% of the total State population (an increase
of 735,446 from 2010 to 2015).59 In 2010, Hispanics/ Latinos in Texas from Mexico accounted
for 31.6% (or 7,951,193 individuals) of the population, while persons from Central America
accounted for 1.7% (or 420,683 individuals), and persons from South American represented
0.5% (or 133,808 individuals).59 These data indicate the increase in Hispanic/ Latino immigrants
in the State and also highlight the opportunities for missed screening and diagnosis for this
specific population.
There are few comprehensive resources targeting HCP’s that illustrate the clinical criteria
used to evaluate and diagnose CD.8,15 The TDSHS and the CDC have outlined general
recommendations for the clinical diagnosis and treatment of CD.2,15 However, there are no
specific recommendations in Texas for HCP’s to target screening to Latin American immigrants
or women of child bearing age. A patient profile could help frame the risks of exposure to guide
HCP’s in deciding if further screening or serological testing is needed. No patient profile
currently exists that identifies populations in Texas (or the U.S.) with a higher risk of exposure or
transmission. Without such guidance, HCP’s may not perform a thorough medical history (i.e.,
discuss potential exposure to the vector and parasite).60-62 For example, the HCP’s may not ask
the patient about travel history or previous place of residence. Thus, even if a HCP is more
familiar or aware of CD, s/he may have limited experience in identifying infected individuals
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with the indeterminate form; performing clinical evaluations; ordering appropriate laboratory
tests; or coordinating with health officials. Consequently, lack of awareness or experience may
delay a patient from receiving adequate treatment.
Public Health Significance
The WHO ranks Chagas as the top global neglected parasitic disease, five times greater
than the number of disability adjusted life years (DALY) when compared to malaria. Although
generally regarded as a rare neglected tropical disease1, current vector surveillance,28,29 the
increased frequency of Chagas positive blood donors, 26,40,63 and population migration,3,4
demonstrate why more Chagas cases may be on the rise in the U.S., including Texas. It is
estimated that at least 300,000 people in the U.S. are living with CD, many of whom may not yet
know they are infected. Approximately 20% to 30% of individuals with CD are expected to
develop clinical symptoms that may manifest as heart disease and result in death if left untreated.
With more than 60 cases of Chagas reported in Texas between 2013 and 2015 alone, it is
becoming clear that HCP’s must be aware of CD and not dismiss the accumulating body of
evidence. HCP’s may not be familiar or prepared to correctly and timely screen and diagnose
suspected cases. In turn, the lack of awareness and skill may lead to underdiagnosing and underreporting. Chagas-related deaths can be prevented if more CD cases are diagnosed and treated at
the early onset of the disease.
Reducing the morbidity and mortality associated with CD is the impetus for the CDC to
recognize CD as public health concern in the U.S. The CDC created a funding mechanism to
support multi-site projects aimed to inform and educate HCP’s about CD as well as to encourage
collaboration and facilitate access to information and resources. Through community based
participatory research (CBPR) and community engagement activities, the Texas Chagas
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Taskforce was created in late 2015 with funding from the CDC. Various stakeholders were
recruited throughout the State of Texas representing a variety of sectors, local and state health
departments, organizations, and expertise.
Understanding the level of knowledge and awareness of CD among the HCP’s
throughout the State, specifically physicians who may routinely come in contact with those
patients at higher risk, will help identify learning gaps in the medical curriculum and provide
insight into how best to target HCP’s serving high-risk populations. The overall objectives of this
study were to: 1) examine the level of knowledge and awareness of HCP’s in Texas regarding
screening, diagnosis and treatment of CD; 2) describe the prevalence of reported cases in Texas;
and 3) illustrate the potential missed cases for CD diagnosis in Texas.
The research expands on the knowledge of U.S. physician awareness and attitudes
regarding Chagas and contribute to the literature on the frequency of diagnosis and possible
missed diagnosis of Chagas. To the best of our knowledge, no other study has examined ICD-9
CD and ICD-10 CD data for both Chagas and other possibly undiagnosed forms of chronic
determinant forms of Chagas (e.g., cardiomyopathy, idiopathic myocarditis). The data was
mapped together to identify possible regions within the state where missed diagnoses are more
likely to occur. The level of awareness of Chagas throughout the State of Texas has not been
assessed previously to be able to make meaningful recommendations (i.e., convenience
sampling).
Statement of the Problem
Strategies and decisions derived from high-quality1 and up-to date data are needed to
minimize the threat of CD. However, there has been limited research on U.S. physicians’
knowledge and awareness of CD despite evidence CD presence in the U.S. patient population
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and blood supply. This poses the following questions: 1) what do physicians know about and
understand regarding the screening, diagnosis and treatment of CD and 2) how many missed
diagnoses of CD may be occurring in patients, both asymptomatic and symptomatic.
Frameworks
Diffusion of Innovations
In an effort to better understand why some physicians may serve as early adopters of the
idea of screening for a neglected disease such as CD, the Theory of Diffusion of Innovations
may help to frame the issue.64 In this model, diffusion is the “process by which an innovation or
“new” practice is communicated through certain channels over time, among members of a social
system,” and is then maintained or becomes accepted as practice over time.64 CD is often
overlooked as a possible diagnosis in part due to its asymptomatic nature, but also because of the
lack of knowledge surrounding the testing and treatment, the innovation. Innovation, in this
context, reflects the ideas and practices related to CD testing, screening, and diagnosing and the
skills and experience needed to ensure timely diagnosis and treatment. Better understanding of
how to diffuse the practice of screening patients for CD could be helpful for shaping practices
and policies that prevent under or missed diagnoses of not only CD but other neglected tropical
diseases that may be present on our ever-changing global environment.
Reducing or eliminating diagnostic errors
A diagnostic error is the “failure to: a) establish an accurate and timely explanation of the
patient’s health problems; or b) communicate that explanation to the patient.”53 The Institute of
Medicine’s (IOM) recommends that in order to reduce diagnostic errors and improve diagnosis
in healthcare it is important to “consider a patient-centered perspective.”53 According to the
IOM, the diagnostic process must start with the patient engaging in the health system. In turn, the
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HCP engages in a decision process that includes gathering information to synthesize what is
observed through physical examinations and discussed between provider and patient to develop a
working diagnosis.
Engaging with patients is key in screening and diagnosing CD given the nature of the
disease and the limited awareness by HCP’s. Failure to obtain a complete medical history, for
example, will yield incomplete information. Conversely, even if a complete medical history is
performed, but the HCP is unable to synthesize the information, then a missed diagnosis may
occur. Figure 8 illustrates the conditions necessary for a CD patient to receive treatment.
However, most physicians lack the training or have never considered risk factors specific
to Texas because they have never tested a patient for CD before. These scenarios present missed
opportunities in which the HCP’s may not be screening patients and following up with the
corresponding testing to ensure a timely diagnosis of CD. Death and morbidity from CD can be
prevented if more cases are screened during the initial phases of the disease, when the drug
treatment is more effective. Thus, it is crucial for infected patients (i.e., those recently exposed or
with a letter from the blood-bank stating a positive screen) to get tested immediately to confirm
diagnosis and receive treatment.
Furthermore, HCP’s may fail to accurately describe a Chagas diagnosis using the
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).65
ICD-9-CM is “the official system of assigning codes to diagnoses and procedures associated
with hospital utilization in the United States.”66 Effective October 1, 2015 the tenth version,
ICD-10-CM, replaced ICD-9-CM.65 The ICD coding system may allow for estimates of
incidence of diseases. The ICD-9 and ICD-10 codes can be used to specify diagnosis based on
physician reimbursement coding.
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Systems-level perspective
The previously discussed health system models and a conceptual model used by Yang et
al frame the barriers to screening and diagnosis to CD in the continuum of treatment through a
socioecological perspective. Figure 9 illustrates recurring themes at both provider and the patient
levels. The figure is an adaptation of a conceptual model for delayed tuberculosis (TB) diagnosis.
Both TB and CD have asymptomatic/ latent phases that as shown in the figure, and have a salient
effect on the health outcome. If no symptoms overtly manifest, then the patient may not seek
medical consultation in a timely manner. For CD, delayed medical consultation has deleterious
impact since treatment may not be as effective once cardiac-related complications manifest. The
model also illustrates how the lack of HCP awareness plays a key role in CD screening and
diagnosis.67 Similar to TB, HCP’s lack of suspicion for the CD will delay confirmatory diagnosis
and treatment.
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Figure 8: Patient Engagement in the Medical Health System to Receive a Chagas Diagnosis and Treatment
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Figure 9: Systems-level Conceptual Model for Barriers to Chagas Screening, Diagnosis, and Treatment
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Specific Aims
I posited that HCP’s in Texas are generally unaware of CD as a diagnosis and
therefore may miss crucial opportunities to screen and diagnose the disease amongst their
patients. This remains true despite current initiatives to educate HCP’s (i.e., Texas Chagas
Taskforce), vector surveillance, and mainstream media attention (e.g., local media and
national news coverage on kissing bugs). Because of the potential longevity of the disease
and its asymptomatic (chronic indeterminate form) nature, persons with CD are more likely
to remain undiagnosed by their HCP than patients with other infectious diseases that may
present with clinical symptoms. Also, because only 20 – 30% of CD positive patients will
ever present with symptoms (e.g., cardiomyopathy, megacolon, etc.), it can often be a missed
diagnosis or go under-reported. The extent of CD knowledge deficits throughout the State of
Texas remains unstudied. How, when, and if providers screen and diagnose for CD in Texas
is important to understand so that missed diagnoses are prevented and prevalence of the
disease is better understood. This is especially important since treatment is only available for
patients who are positive for CD but are not yet symptomatic and can potentially be a lifesaving treatment.
The overall objective of the study was to explore the understanding and knowledge of
CD in Texas HCP populations and identify provider-based education and practice
recommendations to reduce the prevalence of undiagnosed CD.
The aims of the proposed study are as follows:
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1. To better estimate prevalence and possible missed diagnoses of CD, map CD cases in
Texas using DSHS and ICD coding data and compare with non-CD cardiomyopathy
cases using ICD diagnosis
a. Map all DSHS and ICD code reported cases of CD
b. Map non-CD cardiomyopathy ICD code reported cases in Texas along with
additional risk factors (e.g. age, ethnicity)
2. Used a mixed methods design to identify and describe gaps related to knowledge,
attitudes, and practices in the screening, diagnosis and treatment of CD among
practicing physicians in Texas
a. Used an online questionnaire to quantify and describe knowledge among
specialists, including: cardiologists, infectious disease specialists and family
practice physicians
b. Conducted key informant interviews to explore the barriers to screening,
diagnosis and treatment amongst physicians who have treated CD and those
who have not treated CD
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METHODS
Overall Study Design
Overall, this study included elements of a concurrent (embedded) and sequential
explanatory study design. The mapping aim was embedded within the overall explanatory
mixed methodology in establishing a baseline for the knowledge, attitudes, and practices
among physicians. In the explanatory design, data collected from the knowledge, attitudes,
and practices questionnaires were collected and analyzed first, followed by the collection and
analysis of qualitative data from the key informant interviews to “help explain the initial
quantitative results.”68 The purpose was to identify themes related to barriers in diagnosing
CD and discuss potential statewide recommendations. Also, maps were created to show the
potential burden of CD in the state by comparing the overall frequency in ICD-9/10-CM
reporting of idiopathic and ischemic heart disease to the confirmed TDSHS reported Chagas
cases.
Human Subjects Protection
There were no direct risks associated with this study. The research was reviewed by
the Committee for the Protection of Human Subjects (CPHS) at the University of Texas
Health Science Center (UTHealth) and approved on February 5, 2018 (HSC-SPH-17-1039).
The key informant script and the online questionnaires were revised and resubmitted for IRB
approval. Final approval was received on July 2, 2018.
Informed consent was obtained verbally for key informant participants prior to
conducting the interview. A prompt was included in the online questionnaire to obtain
informed consent electronically (i.e. a specific item with the answer choices of “Yes, I agree
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to participate” “No, I do not agree to participate” was included). Administrative data from the
hospital inpatient public use file were de-identified.
Methodology for Aim 1: Mapping
Data sources
The Inpatient Public Use Data File (IPUDF), maintained by the TDSHS, and the
number of Chagas confirmed cases data were used to create maps for this aim. The Texas
Health Care Information Council (THCIC) is responsible for collecting and maintaining
updates to the PUDF.69 Information is collected from every licensed hospital in the state
other than hospitals in a county with a population of fewer than 35,000, or those in a county
with a population greater than 35,000 and with fewer than 100 licensed hospital beds and not
in an area designated as an urbanized area by the U.S. Bureau of Census, or those that do not
seek insurance payment or government reimbursement. Updates to the PUDF are quarterly;
the third quarter for 2016 is the most recently available dataset and the earliest is 1999.
Datasets contain patient demographics, hospital information and length of stay, principal and
secondary diagnosis, hospital charges. However, no personable identifiable information is
recorded in the reports (e.g., no dates of birth, address, social security number). CD became
reportable in 2013. Thus, the hospital inpatient PUDF for 2013 to 2016 was requested.
Confirmed and reported CD cases (local, imported, and unknown source of transmission)
were mapped using data from TDSHS Zoonotic Control division for that same time period.44
Census data (i.e., American Fact Finder web application) was used to download the
American Community Survey (ACS) 5-year Texas population estimates for 2016.70 This
included Texas demographic data on age and Hispanic status by county. A basemap was
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created by downloading the shapefile for the Texas counties from the U.S. Census Bureau
(i.e., TIGER/Line Web interface).71
Variables
The following patient demographics from the raw quarterly base inpatient data files
were kept: patient’s age group (i.e., <18; 18 to 44; 45 to 66; 65 to 74; and ≥75); ethnicity
(Hispanic or non-Hispanic); race (American Indian/ Eskimo; Asian or Pacific Islander;
Black; White; or Other); and sex code (male or female). All of the principle diagnostic codes
(i.e., 1—24) were coded to determine if that particular patient record contained any of the
ICD-9 or 10 diagnostic codes of interest. Additional variables that were kept from the initial
raw IPUDF included: record identification number for each hospital admission; patient’s
county and zip code of residence; provider ID; and type of admission.
Case definitions
A cardiologist was consulted to identify and review the diagnostic codes. Dummy
variables were created using the Chagas diagnosis in the IPUDF for: ICD-9-CM (i.e., 086.0,
086.1, and 086.2) for 2013 through 2015 (third quarter); and for ICD-10-CM codes (B57.0,
B57.1, B57.2, and B57.5) for the last quarter of 2015 and for 2016. These seven ICD9/10 CD
diagnosis codes were collapsed as either CD-heart, or CD-non-heart related diagnosis. One
additional variable for the total of all CD diagnosis was created and was used in the maps.
Eight ICD-9/10 diagnostic codes were used to create the heart-related diagnosis (i.e., the
proxy for potentially missed CD). Table 1 shows the diagnostic code utilized from each
version.
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Table 1: Chagas and cardiomyopathy-related ICD-9 CM and ICD-10 CM codes
Case

ICD Version

Chagas-related

ICD-9-CM
ICD-9-CM

Diagnostic
Code
086.0
086.1

ICD-9-CM

086.2

ICD-10-CM
ICD-10-CM
ICD-10-CM
ICD-10-CM

B57.0
B57.1
B57.2
B57.5

ICD-9-CM

414.8

ICD-9-CM
ICD-9-CM
ICD-9-CM
ICD-10-CM
ICD-10-CM
ICD-10-CM
ICD-10-CM

422.91
425.8
425.4
I42.5
I42.8
I25.5
I42.9

Heart-related

Description
Chagas with heart involvement
Chagas with other organ
involvement
Chagas without mention of organ
involvement
Acute CD, heart
Acute CD, without heart
Chronic CD, with heart
Chronic CD with other organ
involvement
Other forms of chronic ischemic
heart disease
Idiopathic myocarditis
Cardiomyopathy, excludes Chagas
Cardiomyopathy, includes idiopathic
Other restrictive cardiomyopathy
Other cardiomyopathies
Ischemic cardiomyopathy
Cardiomyopathy, unspecified

Data collection and management
Initially, each of the quarterly IPDUF were exported as a comma separated value file
(CSV) to Excel. Stata was used to create the indicator or dummy variables (i.e., flag the case
definitions), drop variables that were not of interest for this study, denote the steps performed
and run quality checks, and merge quarterly datasets to corresponding years. “If statements”
were used on Stata to flag each of the admitting, principal, and other diagnosis codes for any
Chagas or heart-related ICD 9/10 codes prior to merging quarterly datasets into the
corresponding yearly datasets. Patient records that did not contain the case definitions were
eliminated from the dataset. The combined raw IPUDF contained over 12 million hospital
admissions, yet 3.1% were eligible for the geospatial analysis (i.e., contained a heart related
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and or Chagas disease diagnosis code). Appendix D shows the frequency for each code, by
year.
Four datasets (for 2013, 2014, 2015, and 2016) and the corresponding codebooks
were created on Stata and Excel, respectively. Additionally, demographic indicator variables
were created for age, race, ethnicity, and sex code. For age, the categories were collapsed
from 22 groups to create 5 age group variables: children (individuals under 18); 18 to 44; 45
to 64; 65 to 74; and 75 and over. This re-grouping allowed for inclusion of the patient
populations with HIV, alcohol, and drug use populations given their categorization into these
5 age groups. Five race indicator variables were created for: American Indian/ Eskimo; Asian
or Pacific Islander; Black; White; and Other. Two indicator variables were coded for
Hispanic origin and for those of non-Hispanic origin. Male and female indicator variables
were created.
The tabulations by county and case definition, and by county, case definition, and
demographic characteristic (i.e., age group, ethnicity, race, and sex) were inputted to an
Excel spreadsheet for each corresponding year. The counties were listed as rows and the
variables as numbers. An additional spreadsheet was created to summarize the sub-totals for
the corresponding ICD 9/10 Chagas disease diagnostic codes (both heart and other organ
involvement) and for the heart-related diagnostic codes for all four years. Thus, there were
multiple iterations of data management to create a final dataset and ultimately a table with
the counties by enumerating the totals for each of the cases, as shown in the Appendix E. A
total of 78 heart-related Chagas codes was identified and 29 that were not related to heartcomplications that could be mapped to a county. There were 366,575 heart-related diagnostic
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codes that were mapped to a county. The Federal Information Processing Standard (FIPS)
code was listed for each county in the final table to link up to the county shape file.
Demographic data for the state was downloaded using the American Fact Finder web
application as CSV files. The five year 2016 estimates were chosen for the Hispanic
population and age categories. Excel was used to import the CSV files, clean up the variables
(i.e., rename columns for ArcMap usability; remove extraneous data). An Excel workbook
was created for each variable. To calculate the Hispanic proportion, the number of Hispanics
was divide by the total population for each county. To create the table for age groups, only
the population estimates for males, females, and all, aged 20 to 59 were summed for each
respective group (i.e., a column for each: males, females, and total).
Mapping
ArcMap GIS (Version 10.6.0), a software application used to map and analyze a
geographic information system (GIS), was used to visualize the ICD 9/10 inpatient hospital
diagnostic codes and illustrate the salience of potentially missed Chagas disease diagnoses
(e.g., cardiomyopathic diagnoses).72 GIS maps are useful in illustrating issues or particular
situations and contextualize environmental factors.73 Given that the vector is found
throughout the state as demonstrated from emerging animal and entomological surveillance74
this study aim can help visualize where the potential for missed diagnoses is the most
prevalent throughout the state and serve as exploratory for further research to map the vector
ecology with findings from this research.
A total of 5 maps were created. First, the table of Chagas disease counts reported to
TDSHS (by local, imported, or unknown transmission). Each value was set to represent one
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count. Next, the table with the heart-related ICD (9 and 10) total counts for each county was
added in order to output a choropleth map, that is as each range of values increased so did the
corresponding color intensity. The natural breaks (or Jenks) classification was initially used
in order to minimize variance within groups but maximize it between them, followed by
manual adjustments to categorize the data into 5 groups. The demographic tables from the
ACS estimates were then loaded to ArcMap. For each map, the heart-related ICD diagnoses
were represented as graduated symbols (i.e., red triangles) using the same group
classification as before (e.g., Jenks). Graduated colors were used to show the proportion of
Hispanics and the proportion of the county population aged 20 to 59. A final map was
developed, which adjusted for the county populations and used a Jenks classification for the
categories, which were per 10,000 persons. All tables were linked to the county shapefile
(i.e., the basemap) using the FIPS county code.
Methodology for Aim 2a: Questionnaire
Study design and population
The study design for Aim 2a was cross-sectional, in which data was collected from
three online questionnaires from July 5, 2018 through October 1, 2018. Having a baseline to
quantify general knowledge on CD, as well as specific diagnostic procedures, practices, and
overall attitudes on CD is crucial for the development of targeted HCP educational efforts
and the dissemination of resources.
Infectious disease HCP’s were hypothesized to be the most aware of CD compared to
cardiologists and family/ general practice physicians given their experience in diagnosing
related parasitic diseases. Infectious disease HCP’s were thus a focal group since other
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general practice HCP’s may refer patients to them. Cardiologists were hypothesized to also
be aware and knowledgeable of CD since the chronic phase of the disease involves heartrelated complications. However, in general, cardiologists may lack the awareness to
recognize the acute or chronic asymptomatic CD cases and understand the importance or
value of screening high risk populations. Cardiologists may facilitate the communication
between other provider specialties, since they may be somewhat more familiar and aware of
CD than other general practitioners.
In previous CD awareness questionnaires aimed at HCP’s, the response rate has been
between: 40.1% and 41.7%.60,61,75 Finally, family practice physicians were chosen as a target
population given the lack of research and thus the inability to establish a baseline knowledge
among this population. Moreover, this specialty is more likely to engage with patients
worried about the risk of triatomine exposure or be the first points of contact for recipients of
blood donation letters, prior to consulting with ID specialists.
Thus, similar to the recent study assessing CD awareness among Ohio HCP, the
questionnaires focused on cardiologists, infectious disease specialists, and family care
physicians. The rationale was that these providers as are more likely to provide medical care
to most patients. Although primary care physicians and other primary healthcare workers
such as physician assistant and nurse practitioners act as gate keepers in referring their
patients to specialized care, due to time constraints and limited resources the scope of this
research was only on licensed practicing physicians in Texas who were listed with a primary
specialty in cardiology, family medicine/ general practice, or infectious disease medicine. I
expected the sample will be representative and reflect the knowledge, attitudes, and beliefs of
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the targeted population, but findings may not be necessarily generalizable to all HCP’s in
Texas. However, given, the design of this research, the findings will guide future research
and outreach efforts for specific HCP populations and specific Texas geographical locations.
In turn, this target population will engage with patients seeking primary care as a result of
vector exposure, blood donation letters, or from exhibiting clinical symptoms.
Instrument development
A questionnaire was developed to describe: 1) the overall awareness of CD; 2)
screening, diagnosis, and reporting procedures; 3) and risk and exposure factors specific to
Texas. Questionnaires used to collect information related to knowledge, attitudes, and
practices (KAP) have been used by the WHO, particularly in developing countries to better
understand the community members’ perceptions about specific health concerns.76 Multiple
choice items and ordered-category items (i.e., Likert scales) are ways to objectively assess
the knowledge.77
Prior to this research, no tool was available to assess Chagas KAP among physicians
to measure specific domains (e.g., recognizing risk factors, performing screening and
diagnostic practices, frequency of CD-related resources). Thus, specific questions were
formulated to ensure physician attitudes about CD as well as their experience and selfefficacy in making a CD diagnosis were captured. The questionnaire was tailored to the three
clinically-focused specialties. Survey questions from published research62 as well as from an
online continuing education course from the CDC78 were used to create the items.
Questionnaire items included: physician demographics (i.e., practice type and years
since graduation); clinical manifestation; risk of transmission; and whether a Latin American
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immigrant population is served/ proportion served. The questionnaire will include both right/
wrong items as well as self-reported level of confidence scales.
The three instruments were piloted among Texas Chagas Taskforce members, and
practicing physicians (cardiologist, infectious disease specialist, and general practice
provider), and non-CD experts to ensure reliability, validity of questions, and address any
issues including completion time and ease of use across various platforms including smart
phones. Follow-up meetings were conducted to discuss issues and revisions to questions and
responses. For instance, after discussing with the physicians and other individuals who
piloted the questionnaire, the response choices for various knowledge items were revised to
eliminate similar or confusing answers, and thus make it easier to assess whether or not the
concept was known to the physician.
Sampling and recruitment
First, the Texas Medical Association (TMA) leadership was engaged. The TMA is a
professional medical society that includes over 50,000 physicians and medical students.79 I
will contact TMA staff and leadership about collaborating in this project to recruit
questionnaire participants while pending feedback from the taskforce and from other HCP’s
to improve the questionnaire tool.
Two TMA staff members who were active Chagas Taskforce members served as
points of contact to facilitate coordination with TMA leadership. After meeting, discussing,
and reviewing the questionnaires, they agreed to forward my request via email to their
respective chairs. The email provided the rationale, aims, and my contact information. A link
to each specific online questionnaire was included. I did not receive access to the sampling
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frame or was I copied in the direct communication to be able to follow-up with physicians.
After two weeks, no new responses were initiated. I reached out to additional professional
medical networks, societies and groups with access to physicians throughout San Antonio
and the state (e.g., the Bexar County Medical Society, Harris County Health, Metropolitan
Health District, and TDSHS, the Bexar County Health Collaborative, UT Health in San
Antonio, UTHealth Tyler Population Health at the UT System). I also disseminated my
request to professional colleagues who had access or worked with physicians. Finally, I
reached out to physicians who participated in the Texas Chagas Taskforce webinar or
workshop. A total of 5 followed up with me replying their ineligibility to participate in the
research (i.e., practiced in other states; had a primary specialty that was outside the scope of
this research).
Sample size
In the past, TMA conducted two annual questionnaires that supported state and
legislative advocacy efforts. A 2015 Questionnaire on meaningful use program for the Center
for Medicare and Medicaid Services (CMS) had a 4.96% (n= 543) response rate based on
10,943 eligible participants.80 However, a 2016 questionnaire on electronic health record
(EHR) usage and experiences with a sampling frame of 39,165 (Texas physicians with email
address in the TMA database) had a lower response rate of 2.77% (n=1,084).81 Initially,
response rate between 2.0 and 5.0% was expected. If the response rate within this range is
not achieved, other professional medical societies will be contacted (i.e., Texas Infectious
Disease Society; Texas Chapter of the American College of Cardiology).
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Moreover, a 2015 physician workforce study in Texas indicated that there were
63,000 licensed physicians in Texas but only 46,953 were active in patient care.82 From this
research 453 practicing infectious disease specialists, 1,027 cardiologists, and 6,367 general/
family practice physicians were identified for 2015.82 Taking into account the number of
each provider in the respective specialties and the collective TMA questionnaire response
rate (between 2.0 and 5.0%), I expected the following response rate if all eligible physicians
were emailed the link: 9 to 23 among infectious disease specialists; 20 to 51 among
cardiologists; and 127 to 318 for family/ general practice physicians. This was a particular
challenge given that a research study like this has not been previously done before to guide
the decisions in statistical sampling and power. Using sample size calculations with a margin
error of 10% and a confidence level of 90% resulted in a sample size of 59 for infectious
disease, 64 cardiologists, and 67 general/ family practitioners.83 The low threshold was to
collect at least 30 participants from each group (for a total of n= 90). The reasons for the low
power was that this research was explanatory in that findings would guide the development
of grounded theory. In turn, specific hypotheses could be generated and tested, and the
experiences of working with this challenging population could also improve sampling and
response rate. No other study has demonstrated the response rate throughout the state,
especially as it relates to an infectious disease specialists and cardiologists.
Data collection and management
Qualtrics (Research Core), an online application, was used to design, manage, and
implement the questionnaire.84 The questionnaires were anonymous and self-administered.
Participants had a month to complete the questionnaire. The response rate was monitored
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weekly. The recorded responses from the Qualtrics repository were exported as a CSV file
for each questionnaire. The raw dataset was managed using Microsoft Excel with each
question response that was initially coded as text numerically recoded to dichotomous or
categorical values. Individual data dictionaries were created for each questionnaire. Copies of
the original data files were saved in order to facilitate corresponding changes. A Do file
(using Stata) was created for each questionnaire to denote changes made to the original
dataset.
The participants’ eligibility was checked. Table 2 summarizes the number of
physicians sampled, the number who consented, and the number excluded. Among the 27
sampled ID specialists, 4 did not consent to participate and 3 additional participants were not
licensed by the TMB. One participant indicated that s/he was a cardiologist, so the responses
were grouped in the cardiology group. A total of 34 physicians were sampled for the family/
general practice questionnaire. Nine did not consent, three additional participants were not
licensed by the TMB, and one did not complete any questionnaire items other than the
specialty. Thus a total of 11 ID specialists was excluded from the analysis. There were 11
sampled cardiologists (including the response from captured in the ID questionnaire), 6 of
which did not consent and only 4 were licensed by the TMB. Only three were included in the
analysis.
Table 2: Sampling and Participation, by Specialty

Stage
Sampled

Total

Infectious
Disease

71

26

38

Family or
General
Practice
34

Cardiology
11

Consented and agreed to
52
22
25
5
participate
Licensed by TMB
45
19
22
4
Included for analysis*
43
19
21
3
*Not all of the participants answered each question, hence the missing data in the analysis.
Data analysis
Descriptive statistics were calculated as frequencies and proportions using Stata
(14.2).85 Pearson’s Chi square tests were used to compare differences in the response choice
proportions (e.g., knowledge and attitude items), by physician group. Fisher’s exact test was
used in cells with 5 or fewer counts. A p-value less than 0.05 was considered statistically
significant. A summed index score77 for the correct knowledge items was created that ranged
from 0 to 13. No partial credit was assigned for partially correct responses, rather a “1” was
assigned for identifying the correct choice.
Methodology for Aim 2b: Key Informant Interviews
Study design and sampling
The purpose of the semi-structured interviews was to explore specific domains
quantified from the questionnaires, specifically regarding screening practices, as well barriers
and recommendations to improve physician awareness. Initially a list of physicians (n= 24)
that had treated CD patients was requested by the CDC. However, the CDC did not allow
access to directly contact the physicians. Instead assistance was requested from the Texas
Chagas Taskforce to identify and recruit physicians to participate as key informants. Four of
the physicians listed were already part of the Taskforce and agreed to participate. An
additional set of physicians (n= 10) were identified by taskforce member. Only half agreed to
participate and confirmed a date and time for the call. In total, 13 physicians were identified
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and recruited to participate using purposive, convenience, and snowball sampling, four of
which indicated that they had not previously managed any type of care for a patient with CD.
Interview questions
As summarized by Padgett, the purpose of qualitative interviews is “to reveal key
domains in which the experts add a top-down insider perspective that would otherwise be
missed without their participation”.86 Physicians were asked about their practice: the number
of years in their specialty; whether they practice in a rural or urban area; type of medical
practice (i.e., hospital, private, teaching). They were asked to describe their medical
education and if they had training or medical experience in any country that is endemic to
CD. Physicians were prompted to discuss their experience(s) in managing the care to CD
patients (as defined by the continuum from screening and diagnosis, to treatment, to followup care) and elaborate on take-home messages, perceived barriers, and resources that helped
them better understand CD. The script and guiding questions are shown in Appendix C.
Recruitment
Physicians listed in the sampling frame were emailed a brief description of the study.
Once a physician agreed to participate, a follow-up email was sent to confirm the telephone
interview. The informed consent and a summary of the key questions were attached in the
email. A study identification number (Study ID) was assigned to each participant for each
corresponding group. The Study ID consisted of 4 digits. The first digit starting from the left
referred to the physician specialty: 0 if unknown at the time (i.e., if HCP provided contact
information at a workshop or from online questionnaire); 1 for infectious disease; or 2 for
cardiology. The next digit indicated whether the physician had treated for Chagas disease: 0
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if it was not known at the time the Study ID was described; 1 if they had treated CD patients;
2 if they had not treated CD patients. Finally, the two out-right digits denoted the total
sampling frame from 01 to 99.
A Study Participant List was created that linked the study ID to the names and contact
information of the participants. A copy of the KI tracking table is shown in Appendix G. The
purpose was to ensure confidentiality but be able to link physicians to their form and followup if needed. Initially, data collection was expected to conclude once saturation (i.e., “when
additional analyses of the data bring redundancy and reveal no new information”86) was
reached.87 Given the challenges in recruiting physicians especially those with no knowledge
of CD, or experience in managing the care of a CD patient the resulting domains and
sampling strategies were homogenous. Thus, saturation was reached faster than anticipated.
Interviews were conducted from late June through the end of August of 2018.
Data collection and management
Interviews ranged from 12 to 45 minutes in duration. All twelve were digitally
recorded and securely stored. The script was used to guide the discussion. Notes were written
down notes during the interview on the form, which were then scanned and securely stored
electronically and managed via NVivo for Mac, 88 which is a qualitative data analysis (QDA)
software used “to store data and facilitate coding and analysis.”86 All of the twelve KI audio
recordings were transcribed by Adept Word Management Inc.
(https://adeptwordmanagement.com/). The audio transcripts were emailed back as Word files
and stored to NVivo. Inaudible sections were reviewed by the PI to ensure the KI’s message
was accurately reflected.
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Data analysis
A grounded theory (GT) approach was used to guide the thematic analysis of the
participant’s feedback. GT is an approach that was first described by Glaser and Strauss86,89
in 1967 for qualitative research with the goal of developing “new, contextualized theories”90
that explain a “process, an action, or an interaction shaped by the views of a large number of
participants.”91 A GT approach was relevant for this research given the lack of existing
frameworks or models to explain the uptake of information among physicians regarding CD
risk factors in the U.S. and its screening and diagnostic procedures.
GT involves “inductive coding from the data, memo writing to document analytic
decisions, and weaving of theoretical ideas and concepts without permitting them to drive or
constrain the study’s emergent findings.”86 The salient feature with this approach is that the
data drives the emergence of themes (i.e. inductive) rather than relying on other research to
describe the phenomenon or use “prefigured codes or themes” from the existing literature.91
Themes or categories are “broad units of information that consist of several codes aggregated
to form a common idea.”91
Using NVivo, field notes, guides/ scripts, and the audio transcriptions were reviewed.
Cases were defined as the KI participants and coded accordingly. Descriptive themes were
developed initially as primary nodes. The nodes were reviewed and compared to identify
patterns. Axial coding was performed after the interviews were open-coded. Emerging
themes were identified to describe the experiences in participating physicians that lead to
screening and diagnosing CD and thus having an increased awareness (i.e., the identification
of the core phenomenon denoted in GT). Finally, selective coding was used to weave in the
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codes and propose hypotheses to describe the links between strategies (i.e., the actions taken
in response to the core phenomenon); the causal conditions (i.e., the factors leading to the
core phenomenon); the contextual and intervening factors (i.e., the broad and specific factors
that influenced the strategies); and the outcomes.
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LITERATURE REVIEW
Quantifying the Global Threat
Intercontinental migration (i.e., from Central and South America to North America,
Europe, and Japan) has facilitated the spread of CD into previously non-endemic
countries.47,92-94 This globalization has resulted in CD as an emerging global disease. In
countries where the vector is not present, blood transfusion, blood/ organ donations, and
vertical transmission are of concern. Through computational simulation modeling, the global
economic burden of CD is $627.5 million in health-care costs and 806,170 disability-adjusted
life-years (DALYs) annually.95 The total net costs for infected individuals $24.73 billion in
healthcare costs, which exceeds cervical cancer costs. Bern and Montgomery estimated the
possible prevalence of T. cruzi infections in Latin American- born individuals living in the
U.S. using 2005 data. They showed there to be an estimated 22.8 million immigrants from
Latin American living in the U.S. at that time and accounted for 1.31% of T. cruzi
infections.21 While Mexico accounted for the largest immigrant population, it only
represented 1.03% of infections or an estimated 174,388 cases. In contrast, Bolivia
represented the highest proportion (6.75%) but only represents about 4,149 cases. Thus, these
estimates are likely to increase as the number of immigrants from Central and South America
continue to increase.
Awareness of Chagas Disease
Among Healthcare Providers
Given the emerging global concern, HCP’s, including those in non-endemic countries
in Europe must be familiar with CD etiology, screening, management, and treatment. In a
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2013 study by Muñoz et al., physicians (pediatricians and obstetricians/gynecologists) and
nurses in Spain were surveyed regarding their knowledge on Chagas. Eight basic questions
were asked regarding the distribution, transmission in endemic countries, all routes of
transmission, clinical manifestations, diagnosis, blood donation, and treatment. Physicians
(n= 47) knew the least when it came to treatment and disease distribution (i.e., 57% and 60%
only answered correctly) but in general answered more questions correctly compared to
nursing professionals.61 When compared to findings from other HCP CD knowledge studies
from the U.S., this study suggests that HCP’s in European countries that are seeing large
waves of Latin American immigrants (i.e., Spain) are more aware than HCP’s in other
countries where screening and interventions are more limited, such as in the U.S. However, it
is important to recognize that this study was conducted in a hospital (Poniente de Almería)
that had already began screening interventions to prevent vertical transmission.
A small study done in the U.S. demonstrated a limited awareness of CD among
various sub-specialty providers. Stimpert and Montgomery showed that the knowledge,
attitudes, and practices about CD were limited among a U.S. convenience sample of
physicians in primary care, infectious disease (ID), cardiology, obstetrics/ gynecology
(OBGYN), and transplantation medicine.62 Forty-seven percent of OBGYN doctors had
never heard of CD compared to 14% in primary care, 23% in cardiology, and 19% in
infectious disease. Moreover, 68% of OBGYN physicians reported lack of confidence in CD
knowledge being up to date, compared to infectious disease specialists who had the lowest at
27%. Additionally, 33% of OBGYN physicians did not know the cause of CD, and another
big proportion (30%) of OBGYN HCP’s did not know about the clinical manifestations of
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disease. When asked how often the risk for CD in their patient population is considered: 34%
of cardiologists, 29% of ID specialists 60% of OBGYN, 43% primary care, and 39%
transplantation medicine doctors indicated that they never consider risk for CD in patients.
HCP’s were then asked to correctly identify the percentage of patients with chronic infection
for which clinical disease develops. OBGYN (56%) had the most incorrect responses and the
ID specialists the least (28%). Finally, when asked about CD symptom etiology, 48% of
OBGYN answered incorrectly while ID specialists had the least incorrect responses (14%).
All in all, OBGYN had the least amount of CD knowledge, while ID specialists had the most
awareness regarding CD.A total of 1,142 HCP’s through a national sample were surveyed.
This was one of the earlier efforts to assess and quantify differences in knowledge levels by
provider specialties.
Similar findings were observed in a 2010 Chagas awareness study from Verani et al.
Questions were related to etiology, clinical manifestations, diagnosis, and risk for congenital
transmission and represented a national sample of practicing OBGYN (n= 421). The online
questionnaire was more comprehensive and focused specifically on congenital transmission
risks and etiology. Over 68% of respondents self-reported a “very limited” level of
knowledge regarding CD and 9% had never heard of CD.75 Over a third of the participants
did not know the causative agent for CD and 32% correctly identified the clinical
manifestations for chronic CD. Next, an item was included about the proportion of patients
seen that are immigrants from Mexico, Central America or South America. About 41% of
HCP’s indicated that they see 1-10% of immigrants from Latin America. Moreover, 78% and
20% never and rarely, respectively consider a CD diagnosis for immigrant patients. This
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study helps to illustrate the differences in provider awareness and the need for tailored
messaging that is relevant to the specialty (i.e., how to mitigate or prevent congenital
transmission).
Knowledge of CD was evaluated in HCP’s in six Appalachian Ohio counties with a
higher proportion of Hispanic population compared to the rest of the state.60 HCP specialties
for this survey included cardiologists, internists, emergency department physicians, and
primary care/ family physicians. Most of the HCP’s (83%) had a very limited or limited level
of CD knowledge. Regarding the consideration for CD in diagnosis, 46% never considered
while 35% rarely did. Finally, 69% did not know the correct percentage of patients with
chronic infection for which clinical disease develops. These findings contrast somewhat to
the national results from Stimpert in that in general these Ohio HCP’s knew less than the
nationally surveyed physicians. Despite the limitations in estimating the prevalence, perhaps
the disease is not as rare as perceived, thus presenting a barrier for correctly and efficiently
diagnosing and treating patients. In the U.S., the CDC and health department have released
educational resources aimed at healthcare providers as well as the general public31. However,
the value and impact remains unseen. This study did not categorize the responses by
physician specialty, and while similar questions were asked, they were not comparable to
work from previous research.
A recent case report by Dolhoun and Antes illustrates the opportunity for missed
diagnosis from HCP with limited experience in screening and diagnosing Chagas.96 A
healthy individual with no travel history to Central or South America, in a suburban
residence in San Francisco, California presented with insect bites throughout a 6-week
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period. He initially attempted to self-treat with over the counter medication, then contacted
his primary care physician, and tried to avoid specific behaviors (i.e. not sleeping in his own
bed, using a different means of transportation). His physician prescribed him
sulfamethoxzazole-trimethoroim and naproxen. He continued to receive new bites until he
contacted a local pest management company that was able to identify triatomines in his
room. This then prompted coordination with his physician and the CDC for confirmatory
testing. It is surmised that the triatomines were found in the corrugated cardboard boxes that
were occasionally received and stored in his room.
Assessing knowledge, attitudes, and practices (KAP) is useful in identifying
“knowledge gaps and cultural barriers;”97 as well as “exploring changes in the community,”
including among “medical practicioners.”98 Unlike the latter resource, much of the KAP
guides focuses on the community-at-large in order to understand specific challenges to the
uptake of a health behavior, current needs, or any other barriers to adapting or implementing
interventions.97
Among the Population
Several recent studies have examined the level of CD awareness among Latin
American immigrants, particularly from Bolivia. A 2014 study by Sanchez et al. assessed CD
awareness among Latin American immigrants living in Los Angeles, California. Countries of
birth included Mexico, El Salvador, Guatemala, or other. A total of 62% remembered seeing
triatomines in their home country, yet 86% had never heard of CD. From those who had
heard of CD, 81% believed that it was not a serious medical condition. This presents a
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challenge in persuading high risk exposure patients to seek and follow-up with medical
treatment, assuming it is accessible and available to begin with.
Bolivian immigrants in Spain were surveyed and blood samples were screened in a
study by Salvador-Gil et al.47 Questions related to symptoms, complications, means of
transmission, and places to seek medical assistance. Out of the 96 participants, over 35%
were serological positive for T. cruzi, but nearly one quarter did not know about CD and 71%
did not know about the symptoms for CD. This suggests that not only is there high level of
knowledge deficits among high risk population, but they may not now to seek medical
assistance given that they may be already infected.
A similar study was conducted in Germany among Bolivian-origin residents.94 CD
awareness and serology was performed in 43 participants in one specific community in
Munich. Less than 10% tested positive for T. cruzi. Nearly 70% had heard about CD, 56%
were unware of the symptoms, 30% had not knowledge on CD transmission, and 93% had
never undergone testing. This research shows that even among high-risk exposure groups,
there is room to better educate and inform individuals and empower them to seek medical
resources.
Qualitative research further supports the quantitative results from surveys. Work form
Blasco-Hernández et al., highlights how Bolivian women living in Spain perceive CD with a
low-risk and may thus contribute to under diagnosis of disease.93 Through key informant
interviews and focus group sessions, women were aware of CD—the vector, the clinical
manifestations, but were indifferent to the risk of contracting the disease and getting testing.
In a different study with Bolivian women who had tested positive for CD, they
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acknowledged emotional distress when diagnosed with CD but were unable to find medical
treatment.56
A study aimed to identify barriers to access and treatment among Latin American
immigrants in Georgia revealed consistent finding through qualitative research.58 In this
sample of immigrants, the majority of participants were unaware of CD but were somewhat
familiar with the triatomes or chinches. However, they confused the vector with other
diseases not associated with Chagas. They recognized the potential to delay formal medical
care, but that they trusted these remedies, especially if they consulted with family or friends
still in their country. They also described “stoically waiting” for the illness to resolve on its
own. This research helps to frame underlying cultural barriers that may delay medical
consultation and engagement with the health system. If a patient does not have symptoms or
does not trust doctors, then they may not be as likely to seek medical attention to get
diagnosed or receive treatment.
In Honduras, a community-based surveillance pilot program that also assessed the
risk awareness among children resulted in a decline in seroprevalence from 3.4% to 0.4% and
improved awareness.99 The success of this program indicates the feasibility and rationale for
integrating vector surveillance with health education and screening.
Although, local transmission in North America is rare, specific populations who are
exposed to the outdoors more frequently than other groups has been recently studied in
Texas. For example, 36% of individuals enrolled in a Chagas study acquired the parasite
locally via a sylvatic transmission.100 Two-thirds from that proportion had reported a long
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history (10 or more years) of outdoor/ recreational rural activities, thus placing this
population of outdoor enthusiasts at an increased risk for infection.
Physiology and Biomarkers for Chagas Cardiomyopathy
One-third to 40% of CD patients will present with cardiomyopathy with various
levels of cardiac involvement.101 Biomarkers are used to assess the severity of Chagas
cardiomyopathy. Although Chagas cardiomyopathy and hear failure may have similar
pathophysiological characteristics, the former is unique in that there are frequent ventricular
arrhythmias, as well as “conduction disturbances, including sinus bradycardia, complete
atrioventricular block, and right bundle block.”101 High sensitive cardiac troponin is known
biomarker for the diagnosis of acute myocardial infarction.101 In a pilot study of T. cruzi
positive donors in southeastern Texas, 41% had ECG consistent with Chagas
cardiomyopathy and 36% were acquired through local transmission. In this study, highsensitivity troponin serum levels increased with cardiac severity. A recent from Echeverria et
al. (2017) examined the association of T. cruzi infected individuals with Chagas
cardiomyopathy and other biomarkers in a Colombian sample.101 Findings indicated that Nterminal pro B-type natriuretic peptide (NT-proBNP) was similar to high sensitivity cardiac
troponin in predicting the severity of Chagas cardiomyopathy. The clinical applications from
the results of these studies thus shows the value of biomarkers in improving screening,
particularly among the population with a high prevalence of CD. A recent literature review
by Milei et al. concludes that chagasic cardiomypathies can be misdiagnosed.102
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Surveillance
Although there is a lack of human surveillance, entomological and vector research
and estimates from blood donor screening are used to estimate the prevalence.16,29,63,74,103-107
Work from Capuani et al. demonstrated an association between seropositive status and
mortality in blood donors in Brazil using death certificates.108 A total of 159 deaths among
the seropositive donors were identified, 16% of which contained an ICD-10-CM CD cause of
death (i.e., B57.0 and B57.5). In all, deaths due to CD was 17.9 times greater in seropositive
donors compared to the seronegative donors.
United States
In the U.S., “relatively few resources have been devoted to surveillance, prevention,
and treatment”.109 Various studies throughout the last two decades have examined the
potential for T. cuzi infection from blood donors here in the U.S. One of the earlier studies
from Leiby et al., examined the prevalence of T. cruzi from blood donors in 1994 through
1998 in Los Angeles and Miami.110 One in 7,500 and 1 in 9,000 tested serologically positive
in Los Angeles and Miami donors, respectively. In a 2012 study, 41% (n=15) of the
participants in Mississippi who were blood donor eligible had serologically tested positive
for T. cruzi; out of those, 3 had reported visiting a rural area of an endemic country for less
than 2 weeks, but all had previously lived where a vector has been documented.63
Additionally, 87% reported outdoor leisure or work activity. Research on T. cruzi infections
among organ recipients from 2001 to 2011 indicated that 32 recipients received organs from
14 seropositive donors; transmission occurred in 9 recipients.111 In New York, 204 donors
tested positive out of 1.07 million donors between 2007 through 2011.112
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Texas
Public health state surveillance for CD began in 2013 in Texas. The reasons for CD
surveillance includes: 1) to identify the source of infection; 2) monitor acute and chronic
disease burden.39 Non-human (i.e., canine cases) CD data were collected and reported
between 2013 and 2016. Five locally acquired cases in southeastern Texas are described in
Garcia et al. from a pilot study of positive blood donors.28 Four were infected near their
residence; four blood donors had a moderate to high risk of transmission from birthplace. A
literature review from Garcia and colleagues indicates the first case reported of Chagas in
Texas was in 1935.23 Figure 10 shows a total of 51 confirmed of suspected cases that were
reported in the literature between 1935 and 2015 in Texas.
Figure 10: Counties in Texas with confirmed and suspected Chagas infection from
the 8literature, 1935 to 2015

8

Source: Garcia et al. (2015). Historical perspectives on the epidemiology of human Chagas Disease
in Texas and recommendations for enhanced understanding of clinical Chagas Disease in the
Southern United States. PLoS Neglected Tropical Disease, 9:11.
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Introduction
Chagas Disease (CD) is a neglected zoonotic disease1 of the Americas that can be
fatal if not diagnosed and treated in its early stages. CD accounts for the highest burden of
any parasitic disease in the 22 Latin American countries where it is endemic. T. cruzi is
endemic throughout Central and South America and is found in North America, including in
Mexico and in the Southern United States (U.S.).10 An estimated 8 million people in Latin
America have CD.11 Over 28,000 people are infected each year in Mexico, Central America
and South America, accounting for at least 12,000 deaths per year.12
Reduviids, also known as triatomines or kissing bugs, are blood-feeding insects that
transmit the parasite (mainly through their feces) that causes CD. The kissing bugs are
unaffected by T. cruzi but act as the vector for the parasite. Kissing bugs transmit the parasite
to mammals including humans,1 but can also infect reservoir hosts such as canines,
opossums, raccoons, and other domestic8,13 and sylvatic animals.14 Vectorial transmission is
most common among children and adolescents in endemic countries.8 In contrast to the lack
of compulsory screening and testing in the general population or with pregnant women, the
blood supply in the U.S. has been screened for CD antibodies since 2007.1 Blood donation
screening is the most common means by which individuals learn about their CD diagnosis in
the U.S.23
CD includes two main phases: acute and chronic.1,2 Acute infections occur up to the
first two months of the initial infection, which may manifest with mild flu-like symptoms or
febrile illness.31 Other symptoms may include: malaise, enlarged spleen, liver, and lymph
nodes; localized or generalized edema; chagomas or breaks in the skin; and result in
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abnormal electrocardiogram (ECG).8 Acute infection may manifest as early as one week after
exposure and may be self-limiting in most individuals.8 The patient may not seek medical
attention since the symptoms are mild and not unique to CD. During the chronic stage, two
presentations are possible: the indeterminate form, which is commonly asymptomatic; and
the determinate which include cardiac (e.g., cardiomyopathy, heart failure, altered heart rate
or rhythm) and intestinal complications2. The majority of infected individuals (70%-80%)2,15
will advance from the acute phase and remain in a latent or indeterminate chronic form of the
disease (mostly asymptomatic), which may persist as a lifelong infection. The danger of this
asymptomatic status is that once symptoms do manifest, eliminating the parasite becomes
more difficult or impossible and often results in death. Conversely, only 20-30% of infected
individuals will progress from the indeterminate chronic phase to a “clinically evident
disease” or chronic determinate phase, months to decades after becoming infected.15 Chronic
determinate CD often corresponds to the organ involved (heart; esophagus; and/or colon):
cardiac, digestive, or both.8 The digestive manifestation is typically found manly in South
America or in persons infected in that region.8 Heart failure occurs usually towards the latter
phase of Chagasic heart disease.8 Sudden death due to cardiac complications can occur.11
For the scope of this study, heart-related symptoms were the primary focus, given that
the digestive manifestation is a hallmark of South American infections. In the Southern Cone
of South America (i.e., Argentina, Bolivia, Chile, Paraguay, Uruguay, and parts of Brazil)
gastrointestinal CD is more common than CD cardiomyopathy, as the latter is more
commonly seen in Central America and North America.34 According to the National
Institutes of Health (NIH), cardiomyopathy, “refers to diseases of the heart muscle…as it
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becomes enlarged, thick, or rigid…the heart thus becomes weaker pumping less blood and
beating irregularly”.35 Chagasic cardiomyopathy includes “cardiac arrhythmias, heart failure,
and risk of sudden death from ventricular fibrillation or tachycardia or thromboembolic
events”8 and an estimated 5.4 million people will develop these symptoms.36 Cardiovascular
disease in CD patients is believed to be the result of “parasite persistence in cardiac tissue
and immune-mediated myocardial injury.”37 CD may present as idiopathic cardiomyopathy
and be overlooked by many or most HCPs as a diagnosis. Some estimates considering that
the Latino immigrant population is younger than the current U.S. population, suggest that, 10
– 15% of the total U.S. population (or 30,000 to 45,000 individuals) is living with
undiagnosed CD cardiomyopathy.21
This study aims to illustrate the missed diagnosis for CD in Texas using geographical
information system (GIS) mapping.
Methods
Data sources
The Inpatient Public Use Data File (IPUDF), maintained by the Texas Department of
State Health Services (TDSHS), and the number of Chagas confirmed cases data were used
to create maps for this aim. Chagas disease (CD) became reportable in 2013. Thus, the
hospital inpatient PUDF for 2013 to 2016 was requested. Census data (i.e., American Fact
Finder web application) was used to download the American Community Survey (ACS) 5year Texas population estimates for 2016.70 This included Texas demographic data on age
and Hispanic status by county. A basemap was created by downloading the shapefile for the
Texas counties from the U.S. Census Bureau (i.e., TIGER/Line Web interface).71
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Variables and case definitions
Patient demographics from the raw quarterly base inpatient data files included:
patient’s age group (i.e., <18; 18 to 44; 45 to 66; 65 to 74; and ≥75); ethnicity (Hispanic or
non-Hispanic); race (American Indian/ Eskimo; Asian or Pacific Islander; Black; White; or
Other); and sex code (male or female). All of the principle diagnostic codes (i.e., 1—24)
were coded to determine if that particular patient record contained any of the ICD-9 or 10
diagnostic codes of interest. Additional variables that were kept from the initial raw IPUDF
included: record identification number for each hospital admission; patient’s county and zip
code of residence; provider ID; and type of admission.
A cardiologist was consulted to identify and review the diagnostic codes. Dummy
variables were created using the Chagas diagnosis in the IPUDF for: ICD-9-CM (i.e., 086.0,
086.1, and 086.2) for 2013 through 2015 (third quarter); and the ICD-10-CM codes (B57.0,
B57.1, and B57.2) for the last quarter of 2015 and all of 2016. These variables were the
Chagas-related cases that were mapped. Heart-related diagnosis, a proxy for potentially
missed diagnosis, in the IPUDF included the following codes: 414.8, 422.91, 425.8, 425.4
(ICD-9); and I25.5 and I42.9 (ICD-10). Table 1 summarizes the ICD codes used to identify
the cases.
Data collection and management
Each of the quarterly IPDUF were exported as a comma separated value file (CSV) to
Excel. Stata was used to create the indicator or dummy variables (i.e., flag the case
definitions), drop variables that were not of interest for this study, denote the steps performed
and run quality checks, and merge quarterly datasets to corresponding years. “If statements”
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were used on Stata to flag each of the admitting, principal, and other diagnosis codes for any
Chagas or heart-related ICD 9/10 codes prior to merging quarterly datasets into the
corresponding yearly datasets. Patient records that did not contain the case definitions were
eliminated from the dataset. The combined raw IPUDF contained over 12 million hospital
admissions, yet 3.1% were eligible for the geospatial analysis (i.e., contained a heart related
and or Chagas disease diagnosis code).
The results from tabulations by county and case definition, and by county, case
definition, and demographic characteristic (i.e., age group, ethnicity, race, and sex) were
inputted to an Excel spreadsheet for each corresponding year. The counties were listed as
rows and the variables as numbers. An additional spreadsheet was created to summarize the
sub-totals for the corresponding ICD 9/10 Chagas disease diagnostic codes (both heart and
other organ involvement) and for the heart-related diagnostic codes for all four years. Thus,
there were multiple iterations of data management to create a final dataset and ultimately a
table with the counties by enumerating the totals for each of the cases, as shown in the
Appendix. The Federal Information Processing Standard (FIPS) code was listed for each
county in the final table to link up to the county shape file.
Demographic data for the state was downloaded using the American Fact Finder web
application as CSV files. The five year 2016 estimates were chosen for the Hispanic
population and age categories. Excel was used to import the CSV files, clean up the variables
(i.e., rename columns for ArcMap usability; remove extraneous data). An Excel workbook
was created for each variable. To calculate the Hispanic proportion, the number of Hispanics
was divide by the total population for each county. To create the table for age groups, only
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the population estimates for males, females, and all, aged 20 to 59 were summed for each
respective group (i.e., a column for each: males, females, and total).
Mapping
ArcMap GIS (Version 10.6.0), a software application used to map and analyze a
geographic information system (GIS), was used to visualize the ICD 9/10 inpatient hospital
diagnostic codes and illustrate the salience of potentially missed Chagas disease diagnoses
(e.g., cardiomyopathic diagnoses).72 GIS maps are useful in illustrating issues or particular
situations and contextualize environmental factors.73 Given that the vector is found
throughout the state as demonstrated from emerging animal and entomological surveillance74
this study aim can help visualize where the potential for missed diagnoses is the most
prevalent throughout the state and serve as exploratory for further research to map the vector
ecology with findings from this research.
Results
There frequency of each ICD code by year and by diagnostic code are described in
detail in Appendix D. In total, 101 CD diagnoses between 2013 and 2016 were identified.
The majority of CD diagnoses were identified for 2014 (n= 22, Chagas with heart
involvement) and for 2016 (n= 27, chronic Chagas with heart involvement). In contrast, only
1 acute Chagas without heart involvement was identified within the IPDF. A total of 21
occurrences of Chagas without mention of organ involvement were identified. A total of
378,592 cases of heart-related diagnoses were identified. “Cardiomyopathy, including
idiopathic” and “other chronic ischemic heart disease diagnoses” accounted for the most
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instances, 118,206 and 150,207, respectively. The least occurring diagnostic code was for
idiopathic cardiomyopathy (n= 384).
A total of 4 maps were created. First, the table of Chagas disease counts reported to
TDSHS (by local, imported, or unknown transmission). Each value was set to represent one
count. Next, the table with the heart-related ICD (9 and 10) total counts for each county was
added in order to output a choropleth map, that is as each range of values increased so did the
corresponding color intensity. The natural breaks (or Jenks) classification was initially used
in order to minimize variance within groups but maximize it between them, followed by
manual adjustments to categorize the data into 5 groups. The demographic tables from the
ACS estimates were then loaded to ArcMap. For each map, the heart-related ICD diagnoses
were represented as graduated symbols (i.e., red triangles) using the same group
classification as before (e.g., Jenks). Graduated colors were used to show the proportion of
Hispanics and the proportion of the county population aged 20 to 59, given that we expected
a larger proportion of the younger population with heart-related diagnosis could potentially
be indicative of missed CD cases All tables were linked to the county shapefile (i.e., the
basemap) using the FIPS county code. Appendix D details the frequency for each case. In
total, 366,575 heart-related diagnostic cases were created from the IPUDF and categorized
into five groups: 2 to 100; 101 to 500; 501 to 1,000; 1,001 to 20,000; and 20,001 to 60,000.
Figure 1 illustrates the number of CD cases reported to DSHS between 2013 and
2016 in Texas, by transmission type. A total of 91individual cases were reported between
that time range, with each corresponding symbol representing a case. Based on the data
presented in this figure, the largest clusters of imported cases were in Harris and Dallas.
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Individual imported cases were reported in Potter and Wilbarger in the north, El Paso in the
far west; and Shelby and Anderson towards the east. Locally-acquired cases were reported in
Bexar and some in South Texas counties of Hidalgo, Brooks and Cameron.
Figure 2, a choropleth map, shows the county unweighted burden of heart-related
diagnostic codes from the IPDUF. The lighter pink-colored counties represent fewer counts
of heart-related counts in contrast to the darker red-colored counties that represent 1,000 or
more counts of heart-related diagnosis between 2013 and 2016. Bexar, Dallas, Tarrant, and
Harris, had the highest number of heart-related codes (between 1,000 and 20,000). The
following counties were in the second highest category for heart-related codes: El Paso;
Midland, Ector, Lubbock, and Potter moving up the panhandle; Wichita, Grayson, and Lamar
along the Oklahoma border; and Zavala, Wells, Hidalgo, Cameron, and Victoria to the south.
Additionally, counties surrounding Dallas and Tarrant, counties to the north of Bexar, and
counties around Harris also had a high number of heart-related codes.
Figures 3a and 3b represent the ACS estimate of the Hispanic population and the
proportion within that county between 20 and 59 years of age, respectively. A graduated
symbology (i.e., red triangles) is shown in both maps to illustrate the potential for missed CD
disease diagnosis given that a younger population might be experiencing heart complications.
Counties with a high Hispanic population (75% to 99%) had a range of heart-related
frequency, though the highest numbers were in El Paso, Maverick, Webb, Hidalgo, and
Cameron. Counties with a lower proportion of a Hispanic population like Randall or
Montgomery had large (but not the highest) numbers of heart-related diagnostic codes. The
increase in the triangle symbology in the population map (Figure 3b) can be seen in some
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counties with a large proportion of the population aged 20 to 59. In six counties with the
largest proportion 55% to 65% in this age group (i.e., Hartley, Childress, King, Garza,
Sterling, and Concho) had 100 or less heart-related diagnostic codes.
Figure 4 shows the comparison between the CD diagnostic codes (blue) and the red
triangles for the number of heart-related codes. Harris and Dallas/ Tarrant, Travis, Bexar, and
Cameron counties show clusters of both ICD-coded CD and higher proportions of heartrelated diagnostic codes. Wilbarger had 6 CD diagnostic and only 345 heart-related codes.
Figure 5 shows the prevalence of missed diagnosis per 10,000 as adjusted by the
county population. Counties with the highest adjusted prevalence included Howard,
Wilbarger, Callahan, McMullen, Maverick, Fayette, Colorado, Burleson, Grimes, Robertson,
Leon, Wood, Camp, Red River, and Lamar.
Discussion
First and foremost, the maps demonstrate the need for statewide surveillance data in
the human population to better determine populations at risk and whom to screen. However,
in broad strokes, these maps begin to illustrate the systems-level and patient-level barriers
and challenges to accessing and receiving care for CD. The CD cases reported to TDSHS are
not homogenously dispersed throughout the state. Instead, clusters are depicted primarily in
urban areas, where presumably there is increased access to physician care. Nonetheless, even
with limited evidence, this dataset from TDSHS does show the potential for acquiring the
infection through a vector: pockets of these locally-acquired cases were reported specifically
in Bexar, Hidalgo, Brooks, and Cameron. However, no other areas, (i.e., the panhandle;
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counties bordering Mexico; western Texas including the El Paso region; and the eastern
parts) show locally-acquired infections.
Some counties with a high burden of heart-related diagnosis also are indicative areas
with CD diagnosis, as shown by the ICD codes and by the TDSHS CD-reported cases. The
reasons for the congruence in these urban hubs—Bexar, Dallas, and Harris counties—are not
only due to their respective overall populations, but also reflect the availability and ability of
physicians in those counties to recognize the screen factors and move through the continuum
of care in screening, diagnosing, and providing treatment to CD patients. However, as
indicated from the findings of an upcoming manuscript, a physician’s awareness about CD,
their inclination to consider risks in their patient population, and their knowledge on specific
screening and diagnostic processes is limited, even in these urban geographies in which CD
cases have been reported.
Collectively, the heart-related diagnosis and age demographics indicate the possibility
of missed CD diagnosis throughout the state. That is, a younger adult population with heartrelated complications is indicative various chronic conditions, including chronic Chagas
cardiomyopathy (CCC). The fact that there are potentially missed diagnoses in counties that
do not have a major Hispanic proportion of the total population—affects everyone and
should be relegated to a disease of just immigrants. It also illustrates the potential challenge
in certain populations not seeking access to medical care or having a physician available to
correctly and timely diagnose CD. It also highlights the significance of imported CD cases
that might go undiagnosed and untreated. Ultimately, the issue remains as to whether or not
the individuals with heart-related were a missed diagnosis. That is, we cannot rule out with
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any level of confidence that any of those heart-related diagnoses were due to undiagnosed
Chagas cardiomyopathy.
CD is currently found throughout Texas, and there is a potential for local
transmission.28 Five newly diagnosed CD patients are described in this 2015 case report.28
All of these patients acquired CD locally and resided in rural Southeast Texas counties and
were blood screened. This thus cements the possibility of persons currently not knowing that
they have CD because not all cases are diagnosed. Thus physicians should not only be
concerned about screening patients that come from countries where CD is endemic, but
should consider local transmission in situations in which vector exposure is possible.
Limitations
This research has several limitations. This research is the first to examine statewide
hospital records in order to qualify the potential for missed CD diagnosis in Texas. However,
this research focused on potentially missed diagnosed cases of chronic Chagas, rather than
including acute and indeterminate chronic forms of CD. Moreover, in examining chronic CD,
the scope of this research was limited to CCC, rather than looking at other sequelae (i.e.,
gastrointestinal complications). Furthermore, establishing the criteria for missed diagnoses of
CD was the greatest challenge, given the lack of research to inform specific risk factors that
account for CCC. Thus the risk of misclassification is a concern.
The data sources were another limitation. ICD-9 and ICD-10 heart-related and
Chagasic diagnostic codes were not completely comparable given differences in their
definitions. While ICD-10 denotes the disease progression (i.e., acute or chronic), there is no
code specifying the indeterminate form of CD. In ICD-9 there is a code (086.2) that alludes
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to the asymptomatic, indeterminate form (i.e., Chagas without mention or organ
involvement). Similarly, among the heart-related diagnostics, there is a cardiomyopathy,
excluding Chagas in ICD-9 code but not one for ICD-10. Between 2013 and August of 2015,
a total of 21 records indicated Chagas without mention of organ involvement.
Additionally, the Texas IPUDF was intended for administrative purposes and not
intended for clinical or population health research. That is, there may be coding errors. For
example, the difference in totals in Appendix D and E can be attributed to the hospitals not
directly collecting the patient’s county of residence or suppressing the value if a county has
fewer than five discharges for that quarter. The county of residence is assigned based on the
patient’s zip code. For 2016, 45,008 ischemic cardiomyopathies were diagnosed but only
43,597 patient records coded a county. Thus, the statewide patterns in reported and nondiagnosed cases of CD from 2013 to 2016 are difficult to illustrate.
Recommendations
Future research can further explore the patterns of missed diagnoses within specific
geographical targets (i.e., by examining and comparing urban and rural counties only in
contrast to examining patterns throughout the state; or by examining differences in census
tracts or zip codes). Furthermore, the case definitions for the missed CD diagnostic codes can
be re-evaluated. For example, additional geospatial and statistical analyses can be performed
on specific counties using only idiopathic cardiomyopathy diagnoses and comparing to other
codes that accounted for the large number of heart-related diagnoses (e.g., other ischemic
heart disease, ischemic cardiomyopathy, unspecified cardiomyopathy). Recent research, for
example, show the promise of evaluating myocardial fibrosis using cardiac magnetic
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resonance (CMR) as a predictor for CCC.113,114 As such, the ICD code for unspecified
myocarditis (e.g., I51.4) from the Texas IPDF can be mapped alongside specific age intervals
and other patient characteristics. Additional research can map the county demographics and
more specific risk factors for CCC (i.e., by narrowing the age group).
Secondly, the findings support the need for a surveillance system in the human
population that would facilitate and increase the accuracy, validity, and generalizability of
geospatial analysis. That is, maps that are created to illustrate the magnitude of CD cases in
Texas would greatly benefit from epidemiological data that is specific to CD, rather than
relying on administrative data such as the Texas PUDF.
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Figures
Results Figure 1: Reported Cases of Chagas Disease and County of Transmission, 2013
to 2016.
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Results Figure 2: ICD Codes for Heart-Related Diagnosis, 2013 to 2016*
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Results Figure 3a: Heart-Related ICD Diagnosis for 2013
to 2016, * Hispanic Population**

Results Figure 3b: Heart-Related ICD Diagnosis for 2013
to 2016*, Population Aged 20 to 59 Years of
Age
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Results Figure 4: Chagas Disease and Heart-Related ICD Diagnostics Codes for 2013 to
2016
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Results Figure 5: Heart-Related ICD Diagnostics Codes for 2013 to 2016, Adjusted by
County Population
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Introduction
Chagas Disease (CD) is a neglected zoonotic disease1 of the Americas that can be
fatal if not diagnosed and treated in its early stages. CD accounts for the highest burden of
any parasitic disease in the 22 Latin American countries where it is endemic. T. cruzi is
endemic throughout Central and South America and is found in North America, including in
Mexico and in the Southern United States (U.S.).10 An estimated 8 million people in Latin
America have CD.11 Over 28,000 people are infected each year in Mexico, Central America
and South America, accounting for at least 12,000 deaths per year.12
CD includes two main phases: acute and chronic.1,2 Acute infections occur up to the
first two months of the initial infection, which may manifest with mild flu-like symptoms or
febrile illness.31 Other symptoms may include: malaise, enlarged spleen, liver, and lymph
nodes; localized or generalized edema; chagomas or breaks in the skin; and result in
abnormal electrocardiogram (ECG).8 Acute infection may manifest as early as one week after
exposure and may be self-limiting in most individuals.8 During the chronic stage, two
presentations are possible: the indeterminate form, which is commonly asymptomatic; and
the determinate which include cardiac (e.g., cardiomyopathy, heart failure, altered heart rate
or rhythm) and intestinal complications2. The majority of infected individuals (70%-80%)2,15
will advance from the acute phase and remain in a latent or indeterminate chronic form of the
disease (mostly asymptomatic), which may persist as a lifelong infection. The danger of this
asymptomatic status is that once symptoms do manifest, eliminating the parasite becomes
more difficult or impossible and often results in death. Conversely, only 20-30% of infected
individuals will progress from the indeterminate chronic phase to a “clinically evident
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disease” or chronic determinate phase, months to decades after becoming infected.15 Chronic
determinate CD often corresponds to the organ involved (heart; esophagus; and/or colon):
cardiac, digestive, or both.8 The digestive manifestation is typically found manly in South
America or in persons infected in that region.8 Heart failure occurs usually towards the latter
phase of Chagasic heart disease.8 Sudden death due to cardiac complications can occur.11
For the scope of this study, heart-related symptoms were the primary focus, given that
the digestive manifestation is a hallmark of South American infections. Some estimates
considering that the Latino immigrant population is younger than the current U.S. population,
suggest that, 10 – 15% of the total U.S. population (or 30,000 to 45,000 individuals) is living
with undiagnosed CD cardiomyopathy.21 For the scope of this research, screening refers to
the process by which HCP’s determine if further laboratory diagnostics are required. During
the initial screening, the HCP discusses the patient’s medical history, “including questions
about travel and living conditions,” and performs a physical examination and possibly an
ECG.15,31 The diagnosing of CD represents the clinical and serological testing required to
confirm the presence of T. cruzi. In the U.S., the CDC requires confirmatory laboratory
diagnosis for T. cruzi using at least two different immunoassay procedures (i.e., enzymelinked immunosorbent assay [ELISA] and immunofluorescent antibody test) prior to
treatment.15 At least two different serological tests are required given the lack of specificity
and sensitivity obtained from one single procedure. Such laboratory assays are used to detect
IgG or IgM antibodies to the parasite are available from major commercial laboratories (e.g.,
Mayo Medical Lab, ARUP, and Quest Diagnostics).45 Nonetheless, no standardized protocol
(at the national, State, or local/county level) is available for physicians to reference when
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attempting to request the laboratory codes. Recent statistical modeling demonstrates the
value of screening Latin American immigrants in non-endemic countries.46 Women are
recognized as a target population for community screening programs in non-endemic
countries in Europe (e.g., Spain and Italy) due to the risk of transmitting the parasite to their
children.47,48 No commercially-available rapid screening kit is available for HCP’s to
routinely use that provide an immediate confirmatory results for T. cruzi. In contrast to other
chronic diseases49 (i.e., type II diabetes, heart disease, cancer, etc.), screening and diagnosing
for CD is not routinely performed.
Due to the number of cases, its asymptomatic nature, urgency for early diagnosis and
treatment and unknown prevalence in the U.S., CD should be a concern for HCP’s. Many
physicians currently practice medicine within their subspecialty and in isolation from other
HCP specialties.53 Even fewer communication exchanges occur with other scientists (i.e.,
veterinarians, entomologists, ecologists, policy scientists, etc.). The lack of collaboration and
engagement may prevent the exchange of new ideas and innovations. In turn, this is a barrier
for an accurate and timely diagnosis for a patient.53 Recent epidemiological trends in the
vector, or in zoonotic populations, for example, can shed light about the potential threat to
human health. As we move towards a healthcare model in which the patient, as the consumer,
is more informed and encouraged to participate in decision-making process, he or she may be
a stronger advocate to improve the likelihood of testing and diagnosis, rather than rely solely
on the physician as the gatekeeper for information. It is unclear how medical training and
continuing education among the various specialties and sub-specialties shape how individual
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physicians receive, synthesize, and apply information regarding emerging or rare diseases
like CD.
CD is rarely diagnosed during the acute phase of the infection.23 The latency and
asymptomatic nature of the disease may not prompt individuals to seek immediate medical
consultation or treatment. Cultural beliefs and systemic barriers may also prevent or delay a
patient from seeking medical care, particularly as documented in Central and South
American groups.55,58 For instance, an individual distrusts the medical system, while a
systemic barrier may include the lack of drugs or HCP’s.32,48,55,56 Individuals in impoverished
communities in Latin America and in the U.S. lack health insurance or the means to access
medical care, even if they wanted to get diagnosed and treated.57 These challenges are also
reflected in the Latin American immigrants in the U.S. and other non-endemic countries. In
rare occasions, individuals recognize the exposure to a kissing bug or develop clinical
manifestations (i.e., a chagoma) that may prompt medical attention. Figure 7 summarizes
some of the individual-level barriers.
Due to the rarity in reporting autochthonous cases, there is still a lack of overall
awareness among HCP’s in the U.S., including in Texas.23 HCP’s may consider CD only as a
neglected tropical disease and not recognize the risk factors for local and acquired infections
in Texas. They also may not consider their patients from Latin America or from mothers
from Latin America at risk if they have never encountered the disease before and know very
little about it.
There are few comprehensive resources targeting HCP’s that illustrate the clinical
criteria used to evaluate and diagnose CD.8,15 The TDSHS and the CDC have outlined
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general recommendations for the clinical diagnosis and treatment of CD.2,15 However, there
are no specific recommendations in Texas for HCP’s to target screening to Latin American
immigrants or women of child bearing age. A patient profile could help frame the risks of
exposure to guide HCP’s in deciding if further screening or serological testing is needed. No
patient profile currently exists that identifies populations in Texas (or the U.S.) with a higher
risk of exposure or transmission. Without such guidance, HCP’s may not perform a thorough
medical history (i.e., discuss potential exposure to the vector and parasite).60-62 For example,
the HCP’s may not ask the patient about travel history or previous place of residence. Thus,
even if a HCP is more familiar or aware of CD, s/he may have limited experience in
identifying infected individuals with the indeterminate form; performing clinical evaluations;
ordering appropriate laboratory tests; or coordinating with health officials. Consequently,
lack of awareness or experience may delay a patient from receiving adequate treatment.
Infectious disease HCP’s are hypothesized to be the most aware of CD compared to
cardiologists and family/ general practice physicians given their experience in diagnosing
related parasitic diseases. Infectious disease HCP’s were thus a focal group since other
general practice HCP’s may refer patients to them. Cardiologists were hypothesized to also
be aware and knowledgeable of CD since the chronic phase of the disease involves heartrelated complications. However, in general, cardiologists may lack the awareness to
recognize the acute or chronic asymptomatic CD cases and understand the importance or
value of screening high risk populations. Cardiologists may facilitate the communication
between other provider specialties, since they may be somewhat more familiar and aware of
CD than other general practitioners. The research aim is to identify and describe gaps related
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to knowledge, attitudes, and practices in the screening, diagnosis and treatment of CD among
practicing physicians in Texas. Specifically, though a mixed methods approach, an online
questionnaire to quantify and describe knowledge among specialists, including: cardiologists,
infectious disease specialists and family practice physician; Conduct key informant
interviews to explore the barriers to screening, diagnosis and treatment amongst physicians
who have treated CD and those who have not treated CD
Materials and Methods
Questionnaire
Study design and population
The study design was cross-sectional, in which data was collected from three online
questionnaires from July 5, 2018 through October 1, 2018. Having a baseline to quantify
general knowledge on CD, as well as specific diagnostic procedures, practices, and overall
attitudes on CD is crucial for the development of targeted HCP educational efforts and the
dissemination of resources.
Thus, similar to the recent study assessing CD awareness among Ohio HCP, the
questionnaires focused on cardiologists, infectious disease specialists, and family care
physicians. The rationale was that these providers as are more likely to provide medical care
to most patients. Although primary care physicians and other primary healthcare workers
such as physician assistant and nurse practitioners act as gate keepers in referring their
patients to specialized care, due to time constraints and limited resources the scope of this
research was only on licensed practicing physicians in Texas who were listed with a primary
specialty in cardiology, family medicine/ general practice, or infectious disease medicine. I
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expected the sample will be representative and reflect the knowledge, attitudes, and beliefs of
the targeted population, but findings may not be necessarily generalizable to all HCP’s in
Texas. However, given, the design of this research, the findings will guide future research
and outreach efforts for specific HCP populations and specific Texas geographical locations.
In turn, this target population will engage with patients seeking primary care as a result of
vector exposure, blood donation letters, or from exhibiting clinical symptoms.
Instrument development
A questionnaire was developed to describe: 1) the overall awareness of CD; 2)
screening, diagnosis, and reporting procedures; 3) and risk and exposure factors specific to
Texas. Questionnaires used to collect information related to knowledge, attitudes, and
practices (KAP) have been used by the WHO, particularly in developing countries to better
understand the community members’ perceptions about specific health concerns.76 Multiple
choice items and ordered-category items (i.e., Likert scales) are ways to objectively assess
the knowledge.77
Prior to this research, no tool was available to assess Chagas KAP among physicians
to measure specific domains (e.g., recognizing risk factors, performing screening and
diagnostic practices, frequency of CD-related resources). Thus, specific questions were
formulated to ensure physician attitudes about CD as well as their experience and selfefficacy in making a CD diagnosis were captured. The questionnaire was tailored to the three
clinically-focused specialties. Survey questions from published research62 as well as from an
online continuing education course from the CDC78 were used to create the items.
Questionnaire items included: physician demographics (i.e., practice type and years since
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graduation); clinical manifestation; risk of transmission; and whether a Latin American
immigrant population is served/ proportion served. The questionnaire will include both right/
wrong items as well as self-reported level of confidence scales.
The three instruments were piloted among Texas Chagas Taskforce members, and
practicing physicians (cardiologist, infectious disease specialist, and general practice
provider), and non-CD experts to ensure reliability, validity of questions, and address any
issues including completion time and ease of use across various platforms including smart
phones. Follow-up meetings were conducted to discuss issues and revisions to questions and
responses. For instance, after discussing with the physicians and other individuals who
piloted the questionnaire, the response choices for various knowledge items were revised to
eliminate similar or confusing answers, and thus make it easier to assess whether or not the
concept was known to the physician.
Sampling and recruitment
Sampling and recruitment were achieved through contact and coordination with local,
county, and statewide medical networks, societies and groups with access to physicians
throughout San Antonio and the state (e.g., the Texas Medical Association, Bexar County
Medical Society, Harris County Health, Metropolitan Health District, and TDSHS, the Bexar
County Health Collaborative, UT Health in San Antonio, UTHealth Tyler Population Health
at the UT System).
Sample size
In the past, TMA conducted two annual questionnaires that supported state and
legislative advocacy efforts. A 2015 Questionnaire on meaningful use program for the Center
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for Medicare and Medicaid Services (CMS) had a 4.96% (n= 543) response rate based on
10,943 eligible participants.80 However, a 2016 questionnaire on electronic health record
(EHR) usage and experiences with a sampling frame of 39,165 (Texas physicians with email
address in the TMA database) had a lower response rate of 2.77% (n=1,084).81 Initially,
response rate between 2.0 and 5.0% was expected. If the response rate within this range is
not achieved, other professional medical societies will be contacted (i.e., Texas Infectious
Disease Society; Texas Chapter of the American College of Cardiology).
Data collection and management
Qualtrics (Research Core), an online application, was used to design, manage, and
implement the questionnaire.84 The questionnaires were anonymous and self-administered.
Participants had a month to complete the questionnaire. The response rate was monitored
weekly. The recorded responses from the Qualtrics repository were exported as a CSV file
for each questionnaire. The raw dataset was managed using Microsoft Excel with each
question response that was initially coded as text numerically recoded to dichotomous or
categorical values. Individual data dictionaries were created for each questionnaire. Copies of
the original data files were saved in order to facilitate corresponding changes. A Do file
(using Stata) was created for each questionnaire to denote changes made to the original
dataset.
Among the 27 sampled ID specialists, 4 did not consent to participate and 3
additional participants were not licensed by the TMB. One participant indicated that s/he was
a cardiologist, so the responses were grouped in the cardiology group. A total of 34
physicians were sampled for the family/ general practice questionnaire. Nine did not consent,
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three additional participants were not licensed by the TMB, and one did not complete any
questionnaire items other than the specialty. Thus a total of 11 ID specialists was excluded
from the analysis. There were 11 sampled cardiologists (including the response from
captured in the ID questionnaire), 6 of which did not consent and only 4 were licensed by the
TMB. Only three were included in the analysis.
Data analysis
Descriptive statistics were calculated as frequencies and proportions using Stata
(14.2).85 Pearson’s Chi square tests were used to compare differences in the response choice
proportions (e.g., knowledge and attitude items), by physician group. Fisher’s exact test was
used in cells with 5 or fewer counts. A p-value less than 0.05 was considered statistically
significant. A summed index score77 for the correct knowledge items was created that ranged
from 0 to 13. No partial credit was assigned for partially correct responses, rather a “1” was
assigned for identifying the correct choice.
Key Informant Interviews
Study design and sampling
The purpose of the semi-structured interviews was to explore specific domains
quantified from the questionnaires. Initially a list of physicians (n= 24) that had treated CD
patients was requested by the CDC. However, the CDC did not allow access to directly
contact the physicians. Instead assistance was requested from the Texas Chagas Taskforce to
identify and recruit physicians to participate as key informants. Four of the physicians listed
were already part of the Taskforce and agreed to participate. An additional set of physicians
(n= 10) were identified by taskforce member. Only half agreed to participate and confirmed a
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date and time for the call. In total, 13 physicians were identified and recruited to participate
using purposive, convenience, and snowball sampling, four of which indicated that they had
not previously managed any type of care for a patient with CD.
Interview questions
As summarized by Padgett, the purpose of qualitative interviews is “to reveal key
domains in which the experts add a top-down insider perspective that would otherwise be
missed without their participation”.86 Physicians were asked about their practice: the number
of years in their specialty; whether they practice in a rural or urban area; type of medical
practice (i.e., hospital, private, teaching). They were asked to describe their medical
education and if they had training or medical experience in any country that is endemic to
CD. Physicians were prompted to discuss their experience(s) in managing the care to CD
patients (as defined by the continuum from screening and diagnosis, to treatment, to followup care) and elaborate on take-home messages, perceived barriers, and resources that helped
them better understand CD. The script and guiding questions are shown in Appendix C.
Recruitment
Physicians listed in the sampling frame were emailed a brief description of the study.
Once a physician agreed to participate, a follow-up email was sent to confirm the telephone
interview. The informed consent and a summary of the key questions were attached in the
email. A study identification number (Study ID) was assigned to each participant for each
corresponding group. The Study ID consisted of 4 digits. The first digit starting from the left
referred to the physician specialty: 0 if unknown at the time (i.e., if HCP provided contact
information at a workshop or from online questionnaire); 1 for infectious disease; or 2 for
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cardiology. The next digit indicated whether the physician had treated for Chagas disease: 0
if it was not known at the time the Study ID was described; 1 if they had treated CD patients;
2 if they had not treated CD patients. Finally, the two out-right digits denoted the total
sampling frame from 01 to 99.
A Study Participant List was created that linked the study ID to the names and contact
information of the participants. A copy of the KI tracking table is shown in Appendix G. The
purpose was to ensure confidentiality but be able to link physicians to their form and followup if needed. Initially, data collection was expected to conclude once saturation (i.e., “when
additional analyses of the data bring redundancy and reveal no new information”86) was
reached.87 Given the challenges in recruiting physicians especially those with no knowledge
of CD, or experience in managing the care of a CD patient the resulting domains and
sampling strategies were homogenous. Thus, saturation was reached faster than anticipated.
Interviews were conducted from late June through the end of August of 2018.
Data collection and management
Interviews ranged from 12 to 45 minutes in duration. All twelve were digitally
recorded and securely stored. The script was used to guide the discussion. Notes were written
down notes during the interview on the form, which were then scanned and securely stored
electronically and managed via NVivo for Mac, 88 which is a qualitative data analysis (QDA)
software used “to store data and facilitate coding and analysis.”86 All of the twelve key
informants (KI) audio recordings were transcribed by Adept Word Management Inc.
(https://adeptwordmanagement.com/). The audio transcripts were emailed back as Word files
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and stored in NVivo. Inaudible sections were reviewed by the PI to ensure the KI’s message
was accurately reflected.
Data analysis
A grounded theory (GT) approach was used to guide the thematic analysis of the
participant’s feedback. GT is an approach that was first described by Glaser and Strauss86,89
in 1967 for qualitative research with the goal of developing “new, contextualized theories”90
that explain a “process, an action, or an interaction shaped by the views of a large number of
participants.”91 A GT approach was relevant for this research given the lack of existing
frameworks or models to explain the uptake of information among physicians regarding CD
risk factors in the U.S. and its screening and diagnostic procedures.
GT involves “inductive coding from the data, memo writing to document analytic
decisions, and weaving of theoretical ideas and concepts without permitting them to drive or
constrain the study’s emergent findings.”86 The salient feature with this approach is that the
data drives the emergence of themes (i.e. inductive) rather than relying on other research to
describe the phenomenon or use “prefigured codes or themes” from the existing literature.91
Themes or categories are “broad units of information that consist of several codes aggregated
to form a common idea.”91
Using NVivo, field notes, guides/ scripts, and the audio transcriptions were reviewed.
Cases were defined as the KI participants and coded accordingly. Descriptive themes were
developed initially as primary nodes. The nodes were reviewed and compared to identify
patterns. Axial coding was performed after the interviews were open-coded. Emerging
themes were identified to describe the experiences in participating physicians that lead to
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screening and diagnosing CD and thus having an increased awareness (i.e., the identification
of the core phenomenon denoted in GT). Finally, selective coding was used to weave in the
codes and propose hypotheses to describe the links between strategies (i.e., the actions taken
in response to the core phenomenon); the causal conditions (i.e., the factors leading to the
core phenomenon); the contextual and intervening factors (i.e., the broad and specific factors
that influenced the strategies); and the outcomes.
Results
Knowledge, Attitudes, and Practices from Questionnaires
Participant demographics
Initially, a total of 71 physicians were sampled: 10 for cardiology; 34 for family/
general practice; and 27 infectious disease specialists. After excluding respondents who were
not eligible to participate (i.e., did not consent to participate; or not licensed by the Texas
Medical Board) and who did not respond to any other questionnaire items other than the
consent, a total of 43 individual physician responses was analyzed: 21 (48.8%) for family/
general practice; 19 (44.2%) for infectious disease; and 3 (7.0%) for cardiology. Over 37%
(n= 16) were female and the median age was 51. Over 41% (n= 18) indicated that they
primarily practiced medicine in a teaching hospital in contrast to 5 who practiced medicine in
a private setting. More than 65% (n= 28) practiced in urban areas. Almost a third of
participants (n= 14) indicated that they had 20 years of experience in their respective
specialty. The demographic characteristics by physician specialty are summarized in Table 1.
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Attitudes on Chagas disease
General attitudes: Although the majority of participants indicated that they believed
that CD is under diagnosed in Texas (a combined 76.7% of those that either strongly agreed
or somewhat agreed, n= 33), nearly 19% (n= 8) were ambivalent. Similarly, whether CD is
potentially misdiagnosed, 14% (n= 6) did not have an opinion for or against, yet the majority
agreed with the statement. More participants (nearly third, n= 14) disagreed that in Texas,
diagnosis and treatment of CD is relatively easy and with few barriers, while a quarter (n=
11) had no opinion about this statement. The difference between groups was statistically
significant in that ID specialists were more likely to have some degree of disagreement as
compared with general or family physicians. Over a third of family or general practice
physicians disagreed to some extent that their training prepared them to recognize patients
who many need to be screened. In contrast, two-thirds of ID specialists believed that their
training allowed to recognize patients. Table 2 shows the breakdown for each attitudinal and
Likert item, by physician specialty.
Confidence in screening and diagnosing skills: Collectively, nearly 70% were
confident in identifying risk factors for CD in patients. ID specialists were more confident,
compared to family/ general practice physicians and cardiologists. Nearly all of the ID
specialists surveyed (94.7%, n= 18) were confident (either somewhat or very) in being able
to recognize the vector compared to only 43% of family physicians that reported any
confidence in doing so. Overall, 23% of participants were not confident in recognizing the
vector. When asked about confidence in obtaining social history, few indicated having no
confidence at all (11%, n= 5). More than half (53%, n= 23) reported having no confidence in
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requesting the Current Procedural Terminology laboratory codes for diagnosing CD.
Moreover, less confidence was reported in coordinating with local and health departments or
contacting the CDC in managing the care of a CD patient, 42% and 40% respectively. The
complete list of agreement items is shown in Table 3.
Additional screening attitudes
Family/ general practice: Among the 21 physicians who completed the general/
family practice questionnaire, there were differences in opinion regarding the screening and
the diagnosis, in which 38% had neutral attitudes towards being able to either screen or
diagnose through their family practice. Table 4 shows the responses. These items were only
asked in this questionnaire.
Infectious disease specialists and cardiologists: Three additional items were asked
in the ID specialist and cardiologist questionnaires, as shown in Table 5. This included 1
agreement and two confidence questions. There was a total of 22 respondents but up to 7
(28%) did not provide a response. When asked if they routinely screened who present with
risk factors, 40% (n= 10) disagreed somewhat. However, 64% (n= 16) had confidence in
their skills to continue to provide follow-up medical care to CD patients. In contrast,
physicians were more likely to be less confident in using an ECG to screen and diagnose for
chronic CD—28% (n= 7) with no confidence.
Management of patients
Blood donation letter: Physicians who completed the ID and the cardiology
questionnaires were asked to rank the processes or steps in coordinating care to a potential
patient with a blood donation letter (i.e., Table 6). Both groups prioritized obtaining social
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history of patient. While ID specialists indicated that they would consult with the CDC last,
two cardiologists indicated instead that they would coordinate with local or TDSHS last.
Exposure to vector: Similarly, family/ general practice physicians were asked to
rank their priorities when managing the care of a patient who may have been exposed to a
triatomine vector. Nearly 62% indicated that they would obtain the patient’s social history
first and almost 48% reported that they would follow-up with antitrypanosomal treatment
last. Findings are shown in Table 7.
Other specialty attitudes
Risk factors: Among the ID specialists, nearly half were neutral on whether CD
patients are more likely to present with comorbidities than non-CD patients (Table 8).
Knowledge
Correct responses, common items: the correct responses for the common
knowledge questions are shown in Table 9. Appendix Table 1 details the full responses and
questions. Collectively, the least correctly answered item was regarding treatment options
(#12), in which 9% (all 4 of whom were ID specialists) indicated that benznidazole had been
approved by the FDA in children, yet nifurtimox still required CDC investigational protocol.
In contrast, nearly 70% (n= 30) were knowledgeable on the clinical manifestations of chronic
cardiomyopathy (item #8). Less than 40% (n= 17) correctly answered that the seropositive
results from two different immunoassays and/ or PCR performed at the CDC are the methods
required for confirmatory diagnosis of CD (item # 11). Moreover, nearly 40% were unsure
about the total number of reported CD cases to TDSHS (appendix results Table 1).
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Indexed scores: the descriptive statistics for the summed scores for the common
knowledge items are shown in Table 10. ID specialists scored the highest, with a mean
unadjusted score of 69 compared to 37 among family/ general practice physicians.
Screening knowledge among infectious disease specialists and cardiologists: two
additional questions on screening knowledge were asked in the ID and cardiologist
questionnaires. Less than a third (n= 6) correctly identified all of the clinical disorders that
may present in the development of chronic Chagas cardiomyopathy (table 11). Nearly 41%
(n= 9) correctly indicated that a complete physical examination, ECG, and a detailed history
are important elements of the clinical evaluation of a newly diagnosed chronic CD patient
who is asymptomatic.
Additional knowledge for infectious disease specialists: Table 12 shows the
variance in response choices, in which over a fifth (n= 4) correctly identified the typical
manifestations of chronic Chagas cardiomyopathy, although more than half (n= 10) did not
provide a response. A higher proportion of ID specialists selected all of the possible cardiac
examination findings but more than half correctly answered the reactivation concern.
Additional knowledge for cardiologists: Table 13 illustrates the responses for the 3
cardiologists regarding additional screening.
Practices
Overview: Only 7 participants indicated that they directly screened and/or confirmed
a diagnosis for Chagas in patients in their medical care in Texas in the past five years, all of
whom were ID specialists. Three indicated that they had managed the care of a CD patient
who was referred to care from a blood donation. When asked about the frequency of
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considering CD exposure risks, 23% never considered a mother or sibling with CD, 26%
never considered the history of the patient’s blood transfusions/ organ transplants, and 21%
never considered the patient’s travel history to areas where Chagas is endemic. Preferred
resources for medical information included medical websites (23% always referred to
websites such as Up to Date or Medline Plus) compared to TDSHS communiques or TMA
emails that were never used by 21% of respondents.
Practices, exposure risks consideration, all questionnaires: all participants were
asked to report the consideration of four CD exposure risks (Table 14). Non-response was a
large proportion for each item. In general, overall frequency was rare or never, but the
differences were noted when examining the ID group, in which more frequently reported
considering mother or sibling with CD, history of blood transfusions, and travel to CDendemic countries as exposure risks.
Usage of resources: When asked to indicate the frequency of resources referenced to
review information on CD, participants overall used medical website more often than any of
the other resource, including local or county health department or TDSHS websites or alerts
from TMA, which are never used by 12% of physicians.
In addition to asking about the frequency of resources, physicians were asked about
their likelihood in using other resources to learn more about CD (Table 16). Over a quarter
(n= 11) would use courses as the means to learn more about CD; nearly 28% (n= 12) would
use seminars; and 23% (n=10) would specifically use manuals. The highest proportion, 30%
(n= 13), indicated that they would use other resources. Among ID specialists, 42% (n= 8)
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identified other resources as: websites; live meetings or CME; online resources to streamline
treatment; web-based materials; webinars; and brief communications.
Direct screening and diagnosis practices: A total of 7 ID’s reported that they had
directly screened and/ or confirmed a diagnosis for CD disease in patients in their medical
care in Texas over the last 12 months. Two ID specialists reported screening and testing in 1
patient to confirm diagnosis; one indicated screening 15 to 20 patients; and one ID specialist
screened 2 patients. Two consulted with local our county health departments in the past year,
compared to 4 that coordinated with the CDC to confirm a CD disease diagnosis. Participants
who completed the family practice and cardiology questionnaires did not directly screen or
confirm a CD diagnosis in Texas in the past year; same was true for the cardiologists. From
those that did screen, we asked them to report the frequency of coordinating with the CDC:
almost half (3 out of 7) always did (compared to 3 that were not sure or that did not respond).
Three also indicated that they always coordinated with the local/ county health departments
(Q611 and 613). Comments regarding the screening and diagnosing of patients are shown in
Table 17.
Feedback regarding practices: Table 18 shows the feedback from the ID specialists
when asked to comment about their experience in confirming a CD diagnosis, obtaining and
coordinating treatment for patients, and in coordinating with local and state health
department officials. Half of the comments describe barriers in regards to the testing and
diagnostics; two allude to barriers in treatment; and one about the challenges in coordinating
care of a CD patient with local and state health department officials.
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Practices when a patient is exposed to a vector: Only 1 physician indicated that
they had at least one patient in the last five years that were exposed to the vector (Q65). Thus
it is hard to present the practices reported (e.g., Q66_1 to Q66_13), nonetheless they
indicated that they: 1) often perform physical examinations; b) rarely request laboratory
diagnostics; c) always reviewed the travel history; d) often performed other screening
differential diagnoses; e) often referred to ID; and f) sometimes consulted with TDHS to
confirm vector and presence of parasite.
Blood donation letter practices among family physicians: Among those that
completed the family practice/ general physician questionnaire, none indicated that they had
provided care to a Chagas disease patient with a blood donation letter. Thus, there are no
responses for Q64.
Blood donation letter practices, infectious disease specialists: the results are
shown in Table 19, in which only 3 had experience managing the care of a patient with a
positive CD diagnosis from a blood donation screening. All three indicated that they always
reviewed the patient’s travel history and requested the serology to confirm the CD diagnosis.
One reported to have often evaluated the patient’s cardiopulmonary function (i.e., performing
a stress test), while another reported having performed this procedure as only sometimes, and
1 never has performed it. Two always performed cardiovascular testing to assess myocardial
damage and one reported to sometimes perform this procedure. The ID specialists who have
managed patients referred from a blood screening letter were more likely to consult with
CDC than with the TDSHS to coordinate the patient’s treatment.
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Blood donation letter practices, cardiology: None of the three participants reported
that they had provided care to CD patients with a blood donation letter over the past five
years.
Screening practices for patients with idiopathic cardiomyopathy: Respondents to
the ID and the cardiologist questionnaires were asked to report the frequency of screening
procedures for patients presenting with idiopathic cardiomyopathy (Table 20). Non-responses
accounted for a large proportion in each of the four items. Physicians were more likely to
review travel history, look for signs of cardiac arrhythmias, and perform cardiovascular
testing in patients with idiopathic cardiomyopathy more frequently than they were to evaluate
cardiopulmonary function.
Feedback from Key Informants
A total of 12 physicians participated: 10 were conducted via telephone and 1
physician was interviewed in person. One physician emailed brief responses since they were
not available to participate via telephone. With the exception of one physician, the remaining
10 physicians were eager and very enthusiastic to discuss their perspectives and share their
insight. Appendix G denotes the participant’s characteristics with their names redacted.
Participant demographics
Table 21 summarizes KI demographics. Most (61%, n= 8) were infectious disease
specialists, 4 cardiologists, and 1 family provider. Seventy-seven percent had managed care
to CD patients. There were slightly more KI participants that were male, and on average had
been practicing for almost 12 years. The overall majority (84%, n= 11) practiced within an
institution and were located either in San Antonio, Houston, or Dallas. Four indicated that
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they had medical training or experience in Mexico, Central America, or South America. On
average, physicians who had managed the care of CD patients had seen six patients in Texas.
Major categories
After open and axial coding, 5 major categories emerged which included: knowledge
on CD; other perspectives on CD in Texas; physician practices on CD; barriers to care/
management of CD patients; and recommendations to improve awareness. Not surprising, the
richest data were in the knowledge among physicians, their practices, and barriers.
Attitudes, awareness and knowledge
Participants indicated that their peers had limited awareness and knowledge overall
on CD, but also regarding the need to screen and diagnose their patients. There was a
consensus that CD “might not be on their radar.” More specifically, their colleagues may not
necessarily be aware of the risk for local CD transmission in Texas. According to a
cardiologist, “we need to start thinking of this no longer just as a disease of underdeveloped
countries or—endemic areas outside of the US, but really begin to think of it as a disease
that’s more prevalent in the US, although rare.” The reasons for this lack of awareness or
limited knowledge was attributed to lack of experience and training. Some indicated that CD
was not part of their medical curriculum.
Participants reflected on their experiences that contributed to their better
understanding of CD and how it translated to their scope of practice after they had managed
the care of a patient. For ID specialists, for example, CD was either not part of their training
or had very limited emphasis. However, all of the participants that had managed the care of a
CD patient reiterated how that experience was the most helpful in considering CD diagnosis
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afterwards, and in feeling more confident in performing the screening, diagnostics, or where
to access the information needed to streamline the process. As summarized by an ID
specialist, “the more you see it, the more comfortable you’ll be.” In addition to professional
experience augmenting their knowledge and confidence in screening, diagnosing, and
treating patients, participants indicated how colleagues influenced their level of awareness
and knowledge.
Specific knowledge in screening, serology, clinical manifestations (i.e., what to look
for), and local transmission in Texas was gained after managing a CD case. One cardiologist
elaborated that:
The biggest thing that I learned is about the serology because I think we told
one of those patients that, “No, we did a confirmatory test. You actually do
have Chagas.” And then we, of course, had to go back and say, “Well, it turns
out our confirmatory test was the same one you had before. And they were
both false-positives.” I think if there’s anything that I can say that I learned
that is extremely important, it’s that about the commercial test being possibly
the same thing.
Physician practices in the management of CD patients
Several physicians cited Up to Date as a main resource to review screening and
evaluation criteria for CD. Some referenced the CDC training module. An ID specialists said
she reviewed the Mandell, Douglas and Bennett’s Principles and Practice of Infectious
Diseases. Peer-reviewed journals including The New England Journal of Medicine, The
Journal of the American College of Cardiology, and the Journal of the American Medical
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Association, which had published the 2007 systematic review on the evaluation and
treatment of Chagas disease in the United States15were additional resources. Several
recognized the value of accessing CDC staff experts to confirm diagnosis and coordinate
treatment. For one of the interviewed cardiologists, having the CDC as a resource “available
to me was critical to my being able to manage the patient.”
Through their anecdotal experiences, physicians became more aware and
knowledgeable, and thus more inclined to consider a CD diagnosis in their patients. An ID
specialist detailed the following:
So what we have done is if they have a positive screen test then we bring them
over, we do history and physical, we focus on how many lived outside of the
country, have lived in the more classic endemic areas, had mothers that were
born in those areas, had history of having received a blood donation, lived in
substandard housing, or had exposure to hunting and camping and fishing
and outdoor kinds of activities; whether they have dogs on their property,
whether they have seen reduviid bugs or whatever. So we kind of get into all
that history, and we do a basic physical exam and do an EKG with a thirtysecond rhythm strip just so we have it already, and then we—in the same visit,
we just go ahead and draw CDC-confirmatory testing and send that off. So
when we started this, that was like a later thing, and we would get RIPA first,
and if the RIPA was negative, then we were done.

101

Barriers
At the systems-level, limited access to medical care and health insurance gaps in
covering the patient’s screening and diagnostics were some of the key barriers identified by
participating physicians. Additionally, several indicated the lack of available physician
resources including screening guidelines and protocols to improve screenings in populations
at highest risk of CD. There were frequent remarks on the administrative challenges in
accessing the antitrypanosmal drugs to prescribe to their patients. There were concerns on the
specificity and sensitivity of screening and diagnostics. The limited epidemiological evidence
was another barrier. Finally, few indicated that their exposure and training on CD during
their Examples of the physicians’ feedback on barriers are shown in Table 22.
Regarding barriers at the physician level, themes emerged regarding the lack of
awareness about CD in general or about the risk for local transmission in Texas. Participants
commented on how physicians in Texas have limited knowledge on CD, which in turn
translates to a lack of confidence and expertise in screening and diagnosing patients. Finally,
given the patient demographics, physicians were asked about their proficiency in speaking
Spanish. The majority acknowledged that they could “get by” but in most cases would need
to request a translator to interpret to discuss the details of the screening procedures or the
treatment.
Finally, though not prompted, several participants provided patient-specific sociocultural barriers such as refusal of medical treatment due to lacking “respect for this
disorder”. This theme was expanded to a separate category reflecting physicians’
perspectives in which their patients did not fully understand CD. That is, their patients did
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not understand that the asymptomatic phase may progress to life-threatening complications if
left untreated. The adverse physiological complications and interactions with the treatment
were cited as a patient barrier.
Participant recommendations
Increasing education among physicians was the most detailed and frequently
discussed recommendation. Strategies to achieve that include revising the undergraduate
medical education curriculum so that students gain more depth and understand that CD is not
relegated to a tropical infectious disease that is of concern for specific patient populations in
Texas. Another approach to increasing education in providers about CD is to engage the
public, leadership within the health system, and policymakers. Concerned patients, as
described by the participants, can be the vehicle of change to prompt unaware physicians to
refer to the literature and other CD resources and become more knowledgeable. In contrast,
another physician recommended that leadership within hospital, for example, can disseminate
FAQ’s and other memos that highlight the importance of considering CD in certain
populations or remind physicians about the possibility of local transmission.
A few physicians proposed a peer-to-peer model in which CD experts within their
respective field can “take the mantle for this cause” and help raise the awareness. In turn,
specific outreach efforts include peer-review journals that are specific to those medical
specialties that are more likely to be reviewed by those physicians. The proposed
recommendations also highlighted not just the importance of educating providers, but having
materials, resources, and the research that is up to date and accessible to physicians. Many
indicated the need for epidemiological surveillance and research within the human
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population to gain a better understanding of risks and prevalence. Findings from these
research activities can be presented at focused conferences that will pique the interest of
attendees and thus leave an impression. Participation can be incentivized with continued
medical education credit.
In addition to presenting research at conferences, another approach that was discussed
was story telling:
The other way to get uptake and change people’s behavior is by story-telling
which is not evidence-based, so we tend not to gravitate to it. But if we have a
couple of big-name cases, like if there were somebody willing to put this on
television.
Two physicians indicated the value in social media and web-based approached to
education. Similar to conferences, physicians in rural or isolated communities would benefit
from webinars. Another physician proposed raising awareness about CD via Facebook ads,
that can be targeted for very specific populations. Thus, these recommendations reflect the
need to address the barriers discussed in the previous section.
Discussion
There were differences in the level of CD knowledge by physician specialty and by
domains. As hypothesized, ID specialists had a greater grasp on the nuances of CD and were
more confident than family providers. The low response rate for the cardiologist
questionnaire did not allow for meaningful comparisons across all three physician groups.
However, the qualitative data from the cardiologists interviewed suggests that their peers are
generally unaware of CD and have limited knowledge on screening and diagnostic
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procedures (i.e., “I don't know that Chagas disease has registered in the minds of my heart
failure colleagues, perhaps, the level that it should”).
In general, most questionnaire participants believed that CD is currently under
diagnosed in Texas, but no consensus was reached regarding the ease of diagnosing and
treating patients. ID specialists perceived this as a barrier, which was statistically significant,
as compared to the family/ general practice physicians. Frequent references to the
complexities in diagnosing patients from the KI feedback support this finding. Thus
physicians perceive there are challenges and barriers to being able to screen and diagnose CD
patients.
ID specialists were statistically more likely to report a higher confidence in their
training, which was further explored in the interviews, that despite the “peripheral” training
they received they had the “tools” given how “not uncommon for us to encounter a disease
for the very first time”. No surprising, ID specialists were thus confident in their skills
including in recognizing the risk factors and vectors, which was supported by the statistically
significant differences. Their knowledge scores support the increased level of knowledge
among ID specialists (i.e., a mean of 69.2% compared to 37.0% among family practice
physicians). Findings from Stimpert and Montgomery (2010) corroborate the ID specialists’
increased knowledge.62
The utilization of physician resources on CD was further described by the qualitative
data and is congruent with findings from the questionnaires. In general physicians do not
reference materials disseminated by state or county health departments, but instead prefer
websites such as Up to Date, CDC resources, and peer-reviewed articles. Moreover, there
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seems to be some reluctance in coordinating with local and state level officials, perhaps as a
result of the experiences. As one physician there was “an abundance of paperwork” that
might a barrier. Another physician indicated that the health departments should provide
“assistance in diagnosis and in obtaining drugs for treatment.” The qualitative data did not
provide additional insight into this because the key informants, even though the majority had
experience managing the care of patients, did not provide any feedback about working with
local and county health departments.
These findings, particularly the feedback from the KI, complement the work by
Forsyth (2017)56 and Manne-Goehler et al (2015)115 in contextualizing the barriers to
screening, diagnosing, treatment of CD. Although the focus was on barriers in Latin
American communities and the U.S. respectively, parallels can be drawn that explain the
possibility for missed CD diagnosis in Texas. Accessing treatment was identified as barrier
among the KI, but was considered a significant barrier by some of the questionnaire
participants. However, the questions regarding the current treatment drugs and
recommendations were the most incorrectly answered knowledge items, suggesting the need
to educate physicians on these and thus a patient receiving treatment remains a barrier.
Moreover, KI discussed socio-cultural patient barriers that are also highlighted as salient
barriers that prevent the patient from engaging in the health system, including the failure in
recognizing CD as a potentially life-threatening condition, or distrust in the system. Even if
the patient has access to a physician, and the physician recognizes the clinical manifestations
or the risk factors, and is thus willing and inclined to screen and diagnose, the patient may
eventually refuse treatment.
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Strengths and limitations
This is the first exploratory mixed methods study that examined differences in
knowledge, attitudes, and practices among physician groups. While other research has
collected KAP on CD among physicians, no studies to date have focused on examining
physicians in Texas. Through the grounded theory approach and qualitative research design,
further insights were discovered among this hard to reach population. However, sampling
and recruiting physicians represented the biggest challenge for this study. Due to the lack of a
sampling frame, the research employed snowball sampling. As such, coverage and response
bias were of concern. Physician networks were consulted to recruit our participants. Thus our
samples were in more likelihood, already physicians with some knowledge or interest in CD.
Recommendations
Future research is needed to address and describe and explore the reasons for CD
remaining under-recognized by physicians and perceptions regarding whether or not CD is a
problem in Texas. Recommendations from physicians encompass top-down and ground level
strategies to improve the awareness and education, that engage both the provider, patients,
and other key stakeholders (i.e., policymakers). One interesting specific recommendation was
that key CD experts in their respective specialties serve as “ambassadors” to raise awareness
and educate other physicians.
Implications
Follow-through on the recommendations outlined by KI will likely improve the
awareness and knowledge among Texas physicians. This study provides a rudimentary
baseline on which to continue to expand further research and documents the anecdotal
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experiences on physicians. Additional hypotheses-driven research framed with probability
sampling can better quantity differences in KAP, particularly among cardiologists and
physicians with limited experience managing the care of CD patients, and among physicians
practicing in rural counties.
Conclusion
Results from the questionnaires and feedback from key informants illustrate the
opportunity to continue to increase the level of knowledge regarding CD in Texas.
Specifically, there are knowledge gaps in understanding the screening and diagnostic
processes as well as the treatment. Physician input is also invaluable in guiding how to best
disseminate the latest clinical knowledge to physicians to ensure uptake and maintenance
(i.e., consideration of certain CD risk exposures in their patient population).
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Tables and Figures
Results Table 1: Participant Demographics, by Completion of Specialty
Questionnaire

Demographic
Characteristic
Primary physician
Specialty
Infectious Disease
General / Family
Practice
Cardiology
Secondary physician
specialty
Pediatrics
Immunology
Age,
Mean (S.D.)
Sex
Female
Male
No response
Medical setting
Teaching
Community
Private
No response
Geographical setting
Urban
Rural
No response
Years in practice
<5
5 to 10
10 to 15
15 to 20
> 20
No response

Family or
General
Practice
n= 21
(%)

Total
n= 43
(%)

18 (41.9)

0

17 (39.5)

17 (81.0)

Infectious
Disease
n= 19
(%)

18 (94.7)

Cardiology
n= 3
(%)

0

0

0

3 (7.0)

0

0

3 (100.0)

3 (7.0)
2 (4.7)

3 (14.1)
1 (4.8)

0
1 (5.3)

0
0

51.1 (16.59)

48.5 (13.30)

50.2 (16.54)

52.5 (9.19)

16 (37.2)
15 (34.9)
12 (27.9)

10 (47.6)
6 (28.6)
5 (23.8)

5 (26.3)
7 (36.8)
7 (36.8)

1 (33.3)
2 (66.7)
0

18 (41.9)
6 (14.0)
5 (11.6)
14 (32.6)

9 (42.3)
5 (23.8)
2 (9.5)
5 (23.8)

7 (36.8)
1 (5.3)
3 (15.8)
8 (42.1)

2 (66.7)
0
0
1 (33.3)

28 (65.1)
2 (4.7)
13 (30.2)

14 (66.7)
2 (9.5)
5 (23.8)

12 (63.2)
0
7 (36.9)

2 (66.7)
0
1 (33.3)

7 (16.3)
3 (7.0)
3 (7.0)
2 (4.7)
14 (32.6)
14 (32.6)

4 (19.1)
0
2 (9.5)
1 (4.8)
8 (38.1)
6 (28.6)

3 (15.8)
2 (10.5)
1 (5.3)
1 (5.3)
5 (26.3)
7 (36.8)

0
1 (33.3)
0
0
1 (33.3)
1 (33.3)
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Demographic
Characteristic
Hispanic population
served, Mean (S.D.)
Medical training
Mexico
South America
Have directly screened or
confirmed a diagnosis for
CD
Received patients via
blood donation letters

Total
n= 43
(%)

Family or
General
Practice
n= 21
(%)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

51.0 (27.19)

45.5 (27.31)

55.9 (28.9)

63.0 (4.24)

1 (2.3)
2 (4.7)

1 (4.8)
0

0
2 (10.5)

0
0

7 (16.3)

0

7 (36.8)

0

3 (7.0)

0

3 (15.8)

0

110

Results Table 2: Responses to Agreement Items, All Questionnaires
Total
Questionnaire Item
n= 43 (%)
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CD is under diagnosed in Texas
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
CD is potentially misdiagnosed
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
Process required to confirm is complex and
time consuming
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
Few barriers in order to diagnose or treat
Strongly agree

Family or
General
Practice
n= 21 (%)

Infectious
Disease
n= 19 (%)

Cardiology
n= 3 (%)

7 (33.3)
7 (33.3)
6 (28.6)
1 (4.8)
0
0

9 (47.4)
8 (42.1)
1 (5.3)
1 (5.3)
0
0

1 (33.3)
1 (33.3)
1 (33.3)
0
0
0

p-value*
0.501

17 (39.5)
16 (37.2)
8 (18.6)
2 (4.7)
0
0

0.494
16 (37.2)
19 (44.1)
6 (14.0)
2 (4.7)
0
0

7 (33.3)
9 (42.9)
5 (23.8)
0
0
0

8 (42.1)
8 (42.1)
1 (5.3)
2 (10.5)
0
0

1 (33.3)
2 (66.7)
0
0
0
0
0.237

6 (14.0)
22 (51.2)
9 (20.9)
5 (11.6)
1 (2.3)
0

2 (9.5)
10 (47.6)
7 (33.3)
2 (9.5)
0
0

1 (2.3)

1 (4.8)

4 (21.1)
11 (57.9)
1 (5.3)
2 (10.5)
1 (5.3)
0

0
1 (33.3)
1 (33.3)
1 (33.3)
0
0
<0.05

0

0

Total
Questionnaire Item
n= 43 (%)
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Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
Accessing treatment is not a barrier for their
patient population
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
Training prepared physician to recognize
patients who may need to be screened
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response

7 (16.3)
11 (25.6)
17 (39.5)
7 (16.3)
0

Family or
General
Practice
n= 21 (%)
4 (19.1)
9 (42.9)
5 (23.8)
2 (9.5)
0

Infectious
Disease
n= 19 (%)

Cardiology
n= 3 (%)

2 (10.5)
1 (5.3)
11 (57.9)
5 (26.3)
0

1 (33.3)
1 (33.3)
1 (33.3)
0
0

p-value*

0.772
4 (9.3)
12 (27.9)
10 (23.3)
13 (30.2)
3 (7.0)
1 (2.3)

1 (4.8)
6 (28.6)
6 (28.6)
7 (33.3)
1 (4.8)
0

2 (10.5)
5 (26.3)
3 (15.8)
6 (31.6)
2 (10.5)
1 (5.3)

1 (33.3)
1 (33.3)
1 (33.3)
0
0
0
<0.005

6 (14.0)
14 (32.6)
4 (9.3)
13 (30.2)
4 (9.3)
2 (4.7)

0
4 (19.1)
3 (14.3)
12 (57.1)
2 (9.5)
0

6 (31.6)
8 (42.1)
1 (5.3)
1 (5.3)
1 (5.3)
2 (10.5)

0
2 (66.7)
0
0
1 (33.3)
0

Results Table 3: Responses to Confidence Items, All Questionnaires
Total

Infectious
Disease

Cardiology

n= 43 (%)

Family or
General
Practice
n= 21 (%)

n= 19 (%)

n= 3 (%)

11 (25.6)
19 (44.2)
10 (23.3)
3 (7.0)

3 (14.3)
8 (38.1)
8 (38.1)
2 (9.5)

7 (36.8)
11 (57.9)
0
1 (5.3)

1 (33.3)
0
2 (66.7)
0

Questionnaire Item
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Confidence in identifying risk factors
Very confident
Somewhat confident
Not at all confident
No response
Confidence in recognizing the vector
Very confident
Somewhat confident
Not at all confident
No response
Confidence in obtaining social history
Very confident
Somewhat confident
Not at all confident
No response
Confidence in requesting the Current
Procedural Terminology laboratory codes for
diagnosing CD
Very confident
Somewhat confident
Not at all confident
No response

p-value*
<0.005

<0.005
16 (37.2)
14 (32.6)
10 (23.3)
3 (7.0)

3 (14.3)
6 (28.6)
10 (47.6)
2 (9.5)

11 (57.9)
7 (36.8)
0
1 (5.3)

2 (66.7)
1 (33.3)
0
0

17 (39.5)
19 (44.2)
5 (11.6)
2 (4.7)

5 (23.8)
10 (47.6)
5 (23.8)
1 (4.8)

11 (57.9)
7 (36.8)
0
1 (5.3)

1 (33.3)
2 (66.7)
0
0

0.098

0.309
2 (4.7)
13 (30.2)
23 (53.5)
4 (9.3)

1 (4.8)
5 (23.8)
14 (66.7)
1 (4.8)

3 (15.6)
7 (36.8)
7 (36.8)
2 (10.5)

0
0
2 (66.7)
1 (33.3)

Total
Questionnaire Item
n= 43 (%)
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Confidence in coordinating and following-up
with the CDC when consulting about a CD
patient
Very confident
Somewhat confident
Not at all confident
No response
Confidence in contacting and coordinating
with the local and/or state health department
when consulting about a CD patient
Very confident
Somewhat confident
Not at all confident
No response

Family or
General
Practice
n= 21 (%)

Infectious
Disease

Cardiology

n= 19 (%)

n= 3 (%)

p-value*

0.081
8 (18.6)
13 (30.2)
18 (41.9)
4 (9.3)

2 (9.5)
6 (28.6)
12 (57.1)
1 (4.8)

6 (31.6)
7 (36.8)
4 (21.1)
2 (10.5)

0
0
2 (66.7)
1 (33.3)
<0.05

8 (18.6)
14 (32.6)
17 (39.5)
4 (9.3)

2 (9.5)
6 (28.6)
12 (57.1)
1 (4.8)

6 (31.6)
8 (42.1)
3 (15.8)
2 (10.5)

0
0
2 (66.7)
1 (33.3)

Results Table 4: Attitudes of Family or General Practice Physicians Questionnaire
n= 21
(%)

Questionnaire Item
Screening for CD is possible through my general or
family practice
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
Diagnosis of CD is possible through my general or
family practice
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
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2 (9.5)
7 (33.3)
8 (38.1)
4 (19.1)
0
0

2 (9.5)
7 (33.3)
8 (38.1)
4 (19.1)
0
0

Results Table 5: Attitudes of Infectious Disease Specialists and Cardiologists
Total
Questionnaire Item
n= 22 (%)
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Routinely screen for CD in patients who present with risk
factors
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
Confidence in continuing to provide follow-up medical care to
CD patients
Very confident
Somewhat confident
Not at all confident
No response
Confidence in using electrocardiogram (ECG) to screen and
diagnose for chronic CD
Very confident
Somewhat confident
Not at all confident
No response

Infectious
Disease
n= 19 (%)

Cardiology
n= 3 (%)

p-value*
0.523

3 (12.0)
6 (24.0)
1 (4.0)
10 (40.0)
0
5 (20.0)

3 (15.8)
5 (26.3)
1 (5.3)
9 (47.4)
0
1 (5.3)

0
1 (33.3)
0
1 (33.3)
0
1 (33.3)
<0.05

6 (24.0)
10 (40.0)
2 (8.0)
7 (28.0)

6 (31.6)
10 (52.6)
1 (5.3)
2 (10.5)

0
0
2 (66.7)
1 (33.3)
0.263

3 (12.0)
10 (40.0)
7 (28.0)
5 (20.0)

2 (10.5)
10 (52.6)
6 (31.6)
1 (5.3)

1 (33.3)
0
2 (66.7)
0

Results Table 6: Priorities* for Managing Care in Blood Donation Letter Patient
Statement

Infectious Disease
n=19 (%)
4th (42.1)
5th (57.9)
2nd (42.1)

Cardiology
n= 3 (%)
5th (66.7)
4th 66.7)
2nd (66.7)

Coordinate with local or DSHS
Consult with CDC
Perform physical evaluation and additional
testing
Confirm diagnosis via commercial serology
3rd (31.6)
3rd (66.7)
st
Obtain history
1 (52.6)
1st (66.7)
*Only the largest proportion out of the total sample for each statement is shown, from most
important (#1) to least (#5)
Results Table 7: Priorities* for Managing Care for a CD Patient Potentially Exposed to a
Vector
Statement

Family
n= 21 (%)
1st (61.9)
2nd (57.7)

Obtain history
Consult with Texas DSHS for guidance on screening and diagnosis
protocol
Request serology testing from a commercial laboratory
3rd (33.3)
Perform other differential diagnosis and refer patient to infectious
4th (33.3)
disease specialist if necessary
Initiate anitrypanosomal treatment
5th (47.6)
*Only the largest proportion out of the total sample for each statement is shown, from most
important (#1) to least (#5)
Results Table 8: Attitudes among Infectious Disease Specialists
Infectious Disease
n= 19 (%)

Questionnaire Item
CD patients are more likely to present with
comorbidities than non-CD disease patients
Strongly agree
Somewhat agree
Neither
Somewhat disagree
Strongly disagree
No response
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0
4 (21.1)
9 (47.4)
5 (26.3)
0
1 (5.3)

Results Table 9: Summary of Correct Knowledge Items, All Questionnaires

Questionnaire Item

#1. Vector transmission
Feces
Incorrect or non-responses
#2. Common route of
transmission in the US
Vector exposure while
residing in Mexico, Central
or South America
Incorrect or non-responses
#3. Total number of
reported CD cases to DSHS
Between 75 and 100
Incorrect or non-responses
#4. Clinical course for CD
Acute for 1-8 weeks after
exposure, asymptomatic for
decades in most;
symptomatic in a few
Incorrect or non-responses
#5. Characteristic symptoms
for acute phase of CD
All of the above
Incorrect or non-responses
#6. Proportion of patients
with chronic CD that
develop symptoms
Between 20 and 40%
Incorrect or non-responses
#7. Symptoms that may
develop in patients with
chronic CD disease
All of the above
Incorrect or non-responses
#8. Chronic CD
cardiomyopathy possible
manifestations
Any of the above

Total
n= 43
(%)

Family or
General
Practice
n= 21
(%)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

23 (53.5)
20 (46.5)

6 (28.6)
15 (71.2)

15 (79.0)
4 (21.1)

2 (66.7)
1 (33.3)

p-value

<0.005

0.083

29 (67.4)

11 (52.4)

16 (84.2)

2 (66.7)

14 (32.6)

10 (47.6)

3 (15.8)

1 (33.3)
1.00

7 (16.3)
36 (83.7)

4 (19.1)
17 (81.0)

3 (15.8)
16 (84.2)

0
3 (100.0)
<0.005

21 (48.8)

7 (33.3)

14 (73.7)

0

22 (51.2)

14 (66.7)

5 (26.3)

3 (100.0)
0.729

23 (53.5)
20 (46.5)

10 (47.6)
11 (52.4)

11 (57.9)
8 (42.1)

2 (66.7)
1 (33.3)
<0.05

14 (32.6)
29 (67.4)

3 (14.3)
18 (85.7)

11 (57.9)
8 (42.1)

0
3 (100.0)
0.331

28 (65.1)
15 (34.9)

13 (61.9)
8 (38.1)

14 (73.7)
5 (26.3)

1 (33.3)
2 (66.7)
0.101

30 (69.8)

13 (61.9)
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16 (84.2)

1 (33.3)

Questionnaire Item

Incorrect or non-responses
#9. Screening and diagnosis
steps
All of the above
Incorrect or non-responses
#10. Social history needed to
assess potential route of
exposures
All of the above
Incorrect or non-responses
#11. Method for confirming
CD diagnosis
Seropositive results from 2
different immunoassays
and/ or PCR performed at
the CDC
Incorrect or non-responses
#12. Treatment drugs
Second and third choices
only
Incorrect or non-responses
#13. Treatment patient
recommendations
Always recommended for
patients up to age 18 and
generally recommended for
patients aged 18 to 50
Incorrect or non-responses

Family or
General
Practice
n= 21
(%)
8 (38.1)

Total
n= 43
(%)
13 (30.2)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

3 (15.8)

2 (66.7)

p-value

0.708
26 (60.5)
17 (39.5)

13 (61.9)
8 (38.1)

12 (63.2)
7 (36.8)

1 (33.3)
2 (66.7)
0.628

27 (62.8)
16 (37.2)

13 (61.9)
8 (38.1)

13 (68.4)
6 (31.6)

1 (33.3)
2 (66.7)
0.090

17 (39.5)

5 (23.8)

11 (57.9)

1 (33.3)

26 (60.4)

16 (76.2)

8 (42.1)

2 (66.7)
0.074

4 (9.3)

0

4 (21.1)

0

39 (90.7)

21 (100.0)

15 (78.9)

3 (100.0)
0.110

12 (27.9)

3 (14.3)

8 (42.1)

1 (33.3)

31 (72.1)

18 (85.7)

11 (57.9)

2 (66.7)
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Results Table 10: Summary of Correct Knowledge Items and Scores, All Questionnaires
Total

Family or
General
Practice
n= 21
(%)

Questionnaire Item
n= 43
(%)

Infectious
Disease

Cardiology

n= 19
(%)

n= 3
(%)

Total* Raw Score**
Mean
7.9
4.8
9.0
4.0
Median
8.0
6.0
10.0
4.0
S.D.
3.06
4.09
3.22
0
Total Percentile Score
Mean
60.6
37.0
69.2
30.8
Median
61.5
46.2
76.9
30.8
S.D.
23.59
31.49
24.8
0
n= 34
n= 15
n= 17
n= 2
Adjusted Raw Score
Mean
7.0
6.7
8.7
4.0
Median
6.5
7.0
9.0
4.0
S.D.
3.62
3.17
3.08
0
n= 34
n= 15
n= 17
n= 2
Adjusted Percentile Score
Mean
53.6
51.8
67.0
30.8
Median
50.0
53.8
69.2
30.8
S.D.
27.8
24.4
23.67
0
*For all questionnaire participants including those with non-responses
** Score range: 1013 (i.e., lowest to highest correct number of responses). Observations with a
total score of 0 were excluded. S.D.: Standard Deviation. Refer to Appendix for the question and
the full response options.
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Results Table 11: Knowledge on Screening for Cardiologists and Infectious Disease
Specialists

Questionnaire Item
In addition to heart failure, major
clinical disorders that manifest
frequently and concurrently to
chronic Chagas cardiomyopathy
Cardiac arrhythmias
Thromboembolism (systemic and
pulmonary)
Chest pain syndrome
**All of the above
Not sure
No response
What are the important elements of
the clinical evaluation of a newly
diagnosed chronic CD patient who is
asymptomatic?
Complete physical examination,
complete blood count, and
chemistry panel
♦Complete physical examination,
electrocardiogram (ECG) with 30
second rhythm strip, and a detailed
history
Complete physical examination,
ECG with 30 second rhythm strip,
chest radiograph, barium swallow,
and detailed history
None of the above
Not sure
No response

Infectious
Disease
n= 19 (%)

Cardiology
n= 3 (%)

10 (52.6)
0

1 (33.3)
0

0
6 (27.3)
1 (4.5)
4 (18.2)

0
5 (26.3)
1 (5.3)
3 (15.8)

0
1 (33.3)
0
1 (33.3)

0

0

0

9 (40.9)

8 (42.1)

1 (33.3)

4 (21.1)

0

0
0
7 (36.8)

0
1 (33.3)
1 (33.3)

Total
n= 22 (%)

11 (50.0)
0

4 (18.2)
0
1 (4.5)
8 (36.4)
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Results Table 12: Specific Knowledge and Indexed Scores for Infectious Disease
Specialists
n = 19
(%)

Questionnaire Item
In general, which of the following is typical of chronic CD
cardiomyopathy?
Right bundle branch block
Ventricular tachycardia
Left anterior fascicular block
♦All of the above
Not sure
No response
In patients with chronic CD cardiomyopathy, cardiac
examination typically demonstrates which of the following?
Murmurs of mitral and / or tricuspid regurgitation
Wide splitting of the second heart sound due to right bundle
branch block
A prominent diffuse apical thrust
♦All of the above
Not sure
No response
Reactivation of CD is a concern for patients who:
Are chronically infected and are receiving immune-suppressive
treatment because of organ transplantation
Are chronically infected and have HIV/AIDS
Are chronically infected and receive a live0attenuated
influenza vaccine
♦First and second responses only
Not sure
No response

122

5 (26.3)
1 (5.3)
1 (5.3)
4 (21.1)
0
10 (52.6)

0
3 (15.8)
0
5 (26.3)
4 (21.1)
10 (52.6)
0
2 (10.5)
0
10 (52.6)
0
10 (52.6)

Results Table 13: Specific Knowledge for Cardiologists
n= 3
(%)

Questionnaire Item*
Which of the following are typical of Chagas cardiomyopathy
as evaluated using electrocardiograph?
♦Right bundle branch block often associated with left anterior
hemiblock, ST-T changes, abnormal Q waves, various degrees
of AV block, sick sinus syndrome, and low QRS voltage
Mainly conduction abnormalities including first-degree AV
block, left bundle0branch block, and non0specific
interventricular conduction delays
Right bundle0branch block only
None of the above
Not sure
No response
In patients with chronic CD cardiomyopathy, cardiac
examination typically demonstrates which of the following?
Murmurs of mitral and / or tricuspid regurgitation
Wide splitting of the second heart sound due to right bundle
branch block
A prominent diffuse apical thrust
♦All of the above
Not sure
No response
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1 (33.3)

0

0
0
1 (33.3)
1 (33.3)

0
1 (33.3)
0
0
1 (33.3)
1 (33.3)

Results Table 14: Consideration of Risk Factors, Frequency by Physician Specialty

Questionnaire Item: Exposure Risk
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Mother or sibling with CD
Always
Often
Sometimes
Rarely
Never
No response
History of blood transfusions
Always
Often
Sometimes
Rarely
Never
No response
Travel to Mexico, Central, or South America
Always
Often
Sometimes
Rarely
Never
No response
Consumption of food or drinks contaminated with the
parasite
Always
Often
Sometimes
Rarely
Never

Total
n= 43 (%)

Family or
General Practice
n = 21 (%)

Infectious
Disease
n = 22 (%)

Cardiology
n= 3 (%)

3 (7.0)
2 (4.7)
3 (7.0)
8 (18.6)
10 (23.2)
16 (37.2)

1 (4.8)
0
0
5 (23.8)
7 (33.3)
8 (38.1)

3 (15.8)
2 (10.5)
3 (15.8)
3 (15.8)
1 (5.3)
7 (36.8)

0
0
0
0
2 (66.7)
1 (33.3)

3 (7.0)
1 (2.3)
6 (14.0)
7 (16.6)
11 (25.6)
15 (34.9)

0
0
1 (4.8)
5 (23.8)
8 (38.1)
7 (33.3)

3 (15.8)
1 (5.3)
5 (26.3)
2 (10.5)
1 (5.3)
7 (36.8)

0
0
0
2 (66.7)
1 (33.3)

5 (11.7)
2 (4.7)
7 (16.3)
5 (11.6)
9 (20.9)
15 (34.9)

1 (4.8)
0
1 (4.8)
4 (19.1)
8 (38.1)
7 (33.3)

4 (21.1)
2 (10.5)
5 (26.3)
1 (5.3)
0
7 (36.8)

0
0
1 (33.3)
0
1 (33.3)
1 (33.3)

1 (2.3)
1 (2.3)
4 (9.3)
5 (11.6)
17 (39.5)

1 (4.8)
0
1 (4.8)
4 (19.1)
8 (38.1)

0
1 (5.3)
2 (10.5)
1 (5.3)
8 (42.1)

0
0
1 (33.3)
0
1 (33.3)

Questionnaire Item: Exposure Risk
No response

Total
n= 43 (%)
15 (34.8)

Family or
General Practice
n = 21 (%)
7 (33.3)

Infectious
Disease
n = 22 (%)
7 (36.8)

Cardiology
n= 3 (%)
1 (33.3)
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Results Table 15: Resources Physicians Reference when Managing Care of a Patient with
CD

Usage of Resources
Medical websites (e.g., Up to
Date, Medline Plus)
Always
Often
Sometimes
Rarely
Never
No response
Official local or county
health department websites
Always
Often
Sometimes
Rarely
Never
No response
TDSHS website
Always
Often
Sometimes
Rarely
Never
No response
The CDC website
Always
Often
Sometimes
Rarely
Never
No response
Official communiques and
health alerts from TDSHS
Always
Often
Sometimes
Rarely
Never
No response

Total
n= 43
(%)

Family/
General
Practice
n= 21 (%)

Infectious
Disease
n=19
(%)

Cardiology
n= 3
(%)

10 (23.3)
9 (20.9)
5 (11.6)
0
2 (4.7)
17 (39.5)

7 (33.3)
4 (19.1)
1 (4.8)
0
2 (9.5)
7 (33.3)

2 (10.5)
5 (26.3)
4 (21.1)
0
0
8 (42.1)

1 (33.3)
0
0
0
0
2 (66.7)

1 (2.3)
3 (7.0)
13 (30.2)
3 (7.0)
5 (11.6)
17 (39.5)

1 (4.8)
2 (9.5)
6 (28.6)
1 (4.8)
4 (19.1)
7 (33.3)

0
2 (10.5)
6 (31.6)
2 (10.5)
1 (5.3)
8 (42.1)

0
0
1 (33.3)
0
0
2 (66.7)

1 (2.3)
1 (2.3)
8 (18.6)
6 (14.0)
5 (11.6)
17 (39.5)

1 (4.8)
5 (23.8)
3 (14.3)
2 (9.5)
3 (14.3)
7 (33.3)

0
1 (5.3)
5 (26.3)
3 (15.8)
2 (10.5)
8 (42.1)

0
0
0
1 (33.3)
0
2 (66.7)

8 (18.6)
9 (20.9)
5 (11.6)
0
2 (4.6)
17 (39.5)

4 (19.1)
4 (19.1)
2 (19.1)
0
2 (9.5)
7 (33.3)

3 (15.8)
5 (26.3)
3 (15.8)
0
0
8 (42.1)

1 (33.3)
0
0
0
0
2 (66.7)

2 (4.7)
1 (2.3)
11 (25.6)
5 (11.6)
9 (20.9)
15 (34.9)

1 (4.8)
0
5 (23.8)
2 (9.5)
6 (28.6)
7 (33.3)

1 (5.3)
1 (5.3)
6 (31.6)
2 (10.5)
1 (5.3)
8 (42.1)

0
0
0
1 (33.3)
2 (66.7)
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Usage of Resources
Email alerts from TMA
Always
Often
Sometimes
Rarely
Never
No response
MMWR
Always
Often
Sometimes
Rarely
Never
No response

Total
n= 43
(%)

Family/
General
Practice
n= 21 (%)

Infectious
Disease
n=19
(%)

Cardiology
n= 3
(%)

1 (2.3)
2 (4.7)
6 (14.0)
8 (18.6)
9 (20.9)
17 (39.5)

1 (4.8)
1 (4.8)
3 (14.3)
4 (19.1)
5 (23.8)
7 (33.3)

0
1 (5.3)
2 (10.6)
4 (21.1)
4 (21.1)
8 (42.1)

0
0
1 (33.3)
0
0
2 (66.7)

0
2 (4.7)
7 (16.3)
9 (20.9)
8 (18.6)
18 (41.9)

0
0
1 (4.8)
6 (28.6)
7 (33.3)
7 (33.3)

0
2 (10.5)
6 (31.6)
3 (15.8)
0
9 (42.1)

0
0
0
0
1 (33.3)
2 (66.7)

Results Table 16: Likelihood of Resources Used to Learn More about Chagas Disease

Resources

Total
n= 43 (%)

Courses
Seminars
Manuals
Other

11 (25.6)
12 (27.9)
10 (23.3)
13 (30.2)
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Family/
General
Practice
n= 21 (%)
6 (28.6)
6 (28.6)
6 (28.6)
5 (23.8)

Infectious
Disease
n=19 (%)

Cardiology
n= 3 (%)

4 (21.1)
4 (21.1)
4 (21.1)
8 (42.1)

1 (33.3)
2 (66.7)
0
0

Results Table 17: Screening and Diagnosis Practices among Infectious Disease
Specialists
Screening and Diagnosing Practices
Method(s) used to screen for CD
Physical assessment
12-lead electrocardiogram
Patient’s medical and social history
Lab method(s) used to confirm CD diagnosis
PCR performed at the CDC
Commercial antibody testing using ARUP
Commercial antibody testing using Mayo Medical Lab
Commercial antibody testing using Quest Diagnostics
Commercial antibody testing using Labcorp
Not sure
Consultation and coordination with:
Local/ county health department
The CDC
Classification of cases
Acute
Chronic indeterminate
Chronic cardiomyopathy
Chronic gastrointestinal
Other
Not sure
Source of transmission
Locally0acquired
Imported
Not sure
Missing
Referred to other specialties
Yes (all to cardiology)
No
Missing
Referred by other specialties
Yes (family med; internal; cardiology)
No
Not applicable—did not screen or diagnose
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n= 19
(%)
3 (15.8)
2 (10.5)
5 (26.3)
3 (15.8)
2 (9.1)
0
1 (5.3)
1 (5.3)
2 (10.5)
2 (10.5)
4 (21.1)
0
3 (15.8)
2 (10.5)
0
0
2 (10.5)
1 (5.3)
2 (10.5)
3 (15.8)
1 (5.3)
3 (15.8)
3 (15.8)
1 (5.3)
4 (21.1)
2 (10.5)
13 (68.4)

Results Table 18: Additional Comments Regarding Screening Practices
Additional Comments (#) Comment
Experience in confirming a “More than one serological test type, PCR, not finding
CD diagnosis (Q6.6)
circulating typomastigotes, not finding cardiac amstigotes
(biopsy)”
Experience obtaining and
“I have found many patients with evidence of some form of CD
coordinating treatment for disease in Central America (a project)”
patients (Q6.12)
Experience in coordinating “Abundant paperwork”
with local and state health
department
“Assistance in diagnosis and in obtaining drugs for treatment”
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Results Table 19: Frequency of Procedures in Patients Referred from a Blood Donation
Letter
Questionnaire Item: Procedure
Review the patient’s travel history
Always
Often
Sometimes
Rarely
Never
Did not provide care to a patient with blood donation latter
Request serology to confirm diagnosis
Always
Often
Sometimes
Rarely
Never
No response
Evaluate patient’s cardiopulmonary function (i.e., exercise stress
test)
Always
Often
Sometimes
Rarely
Never
No response
Perform cardiovascular testing to assess myocardial damage
Always
Often
Sometimes
Rarely
Never
No response
Consult with TDSHS to manage treatment
Always
Often
Sometimes
Rarely
Never
No response
Consult with the CDC to manage treatment
Always
Often
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Infectious Disease
n= 19 (%)
3 (15.8)
0
0
0
0
16 (84.2)
3 (15.8)
0
0
0
0
16 (84.2)

0
1 (5.2)
1 (5.2)
0
1 (5.2)
16 (84.2)
2 (10.5)
0
1 (5.2)
0
0
16 (84.2)
1 (5.2)
0
1 (5.2)
1 (5.2)
0
16 (84.2)
2 (10.5)
1 (5.2)

Questionnaire Item: Procedure
Sometimes
Rarely
Never
No response
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Infectious Disease
n= 19 (%)
0
0
0
16 (84.2)

Results Table 20: Frequency of Procedures when Presenting with Idiopathic
Cardiomyopathy among Cardiologists and Infectious Disease Specialists
Total
n= 22
(%)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

4 (18.2)
4 (18.2)
3 (13.6)
1 (4.5)
1 (4.5)
9 (40.9)

4 (21.1)
4 (21.1)
2 (10.5)
1 (5.3)
0
8 (42.1)

0
0
1 (33.3)
0
1 (33.3)
1 (33.3)

4 (18.2)
4 (18.2)
3 (13.6)
1 (4.5)
2 (9.1)
8 (36.4)

3 (15.8)
4 (21.1)
3 (15.8)
1 (5.3)
1 (5.3)
7 (36.8)

1 (33.3)
0
0
0
1 (33.3)
1 (33.3)

1 (4.5)
1 (4.5)
8 (36.4)
2 (9.1)
1 (4.5)
10 (45.5)

0
1 (5.3)
7 (31.6)
2 (10.5)
1 (5.3)
9 (47.4)

1 (33.3)
0
1 (33.3)
0
0
1 (33.3)

5 (22.7)
2 (9.1)
6 (27.3)
1 (4.5)
0
8 (36.4)

3 (15.8)
2 (10.5)
6 (31.6)
1 (5.3)
0
7 (36.8)

2 (66.7)
0
0
0
0
1 (33.3)

Questionnaire Item: Procedure
Review the patient’s travel history
Always
Often
Sometimes
Rarely
Never
No response
Look for signs of cardiac arrhythmias
that may arise due to chronic Chagas
cardiomyopathy
Always
Often
Sometimes
Rarely
Never
No response
Evaluate patient’s cardiopulmonary
function (i.e., exercise stress test)
Always
Often
Sometimes
Rarely
Never
No response
Perform cardiovascular testing to assess
myocardial damage
Always
Often
Sometimes
Rarely
Never
No response
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Results Table 21: Key Informant Demographics

Characteristic

Specialty
Infectious disease
Cardiology
Family practice
Sex
Male
Female
Years in specialty
Mean, (S.D.)
Practice setting
Institution
Community clinic
City
San Antonio
Houston
Dallas
Training in endemic
countries
Mexico
Central America
South America
Number of CD patients
Mean, (S.D.)

Managed
CD Care
n= 10
(%)

Total
n= 13
(%)

Had Not
Managed CD
Care
n= 3
(%)

p-value

0.245
8 (61.5)
4 (30.8)
1 (7.7)

7 (70.0)
3 (30.0)
0

1 (33.3)
1 (33.3)
1 (33.3)
0.563

7 (53.9)
6 (46.2)

5 (50.0)
5 (50.0)

2 (66.7)
1 (33.3)
-

11.8 (9.52)

11.9 (10.73)

11.3 (5.03)
0.577

11 (84.6)
2 (15.4)

8 (80.0)
2 (20.0)

3 (100.0)
0

6 (45.2)
5 (38.5)
2 (15.4)

5 (50.0)
3 (30.0)
2 (20.0)

1 (33.3)
2 (66.7)
0

0.738

1 (7.7)
2 (15.4)
1 (7.7)

1 (10.0)
0
1 (10.0)

0
2 (66.7)
0
-

6.4 (8.04)
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Results Table 22: Perceived Barriers Preventing the Management of Care for Patients with Chagas Disease
Level

Theme

System

Limited access to medical
care

Lack of insurance to cover
diagnostic or screening tests

Example(s) of Participant Feedback
He doesn’t even live in a place with an ID doctor. He lives in the middle of nowhere in
rural west Texas.
Not every Texan is going to be able to receive—just due to, I think, maybe insurance
approvals
In other areas where people don’t have access to that insurance, and you can’t get an EKG
or an echo or even see a provider—like you were saying, in rural areas
When rare stuff comes up that they’re not used to looking at when they’re doing blood
donor screening or something, there are guidelines about what to do with HIV testing,
Hepatitis B testing, and Hepatitis C testing. You can look this up, but it’s kind of hard to
figure out if you don’t know where to look. Like, what am I supposed to do with this?
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I think the most important message is that although you may not have seen Chagas Disease
in your practice before, there are patients out there walking around with indeterminate
Chagas Disease, and it’s not a false-positive necessarily
No clear and up to date
guidelines, protocols, and
patient risk profile resources

Well, I think that the biggest that I faced in regards to diagnosis is—determining which
children should be screened for Chagas disease. There are certain high-risk situations that I
think—definitely weren’t testing.
I think the biggest challenges for us were—on accessing the medications.
It would be optimal for me, being in a teaching hospital, if it were on a formulary so that I
could just say, “Give me some benznidazole.”

Physician access to
pharmaceutical drugs
Lack specificity and
sensitivity in screening and
diagnostic tools

Well, I guess I would say that the only real problem—getting the drug was the biggest
challenge
What I’m amazed is sort of the screening tests and how neither sensitive nor specific they
are.

Level

Theme

Lack of epidemiological
evidence

Outdated education during
undergraduate medical
education suggesting that CD
should not be considered in
the U.S.
Limited knowledge or
expertise to screen and/ or
Physician diagnose
135
General unawareness

Example(s) of Participant Feedback
Now barriers in screening are a—I guess are a concern is the right word regarding the
sensitivity and specificity of commercially available test
EPI surveillance is pricey and not available—not systematically available with Chagas
The education that I had about Chagas disease as limited in medical school—medical
school training—was that Chagas disease was not generally a disease present in the United
States and if it were present, the cardiac manifestations are not likely to be present before
adulthood, therefore on those two bases, that most of my patients are, in fact, from the U.S.
and virtually none of them are in the twenty plus age range, that it's simply not a
consideration. So, that—that was my attitude and opinion before I became sensitized to
Chagas.
Sort of—not neglected only in the sense of a tropical disease being neglected, but also
neglected by physicians in the difference of diagnosis, it’s kind of funny. So with that, I
don’t think there’s a huge expertise.
I don't know that Chagas disease has registered in the minds of my heart failure colleagues,
perhaps, the level that it should.
But I would still say of people and most physicians—they would—be unaware of some of
it. I’m just—the more I learn with <<researcher name redacted>>, the more intrigued I am
of the lack of awareness of the disease.
They were not from an endemic area but were hunters between me and you and San
Antonio—from Aliceville, from some other rural areas—who had tested positive but had
not traveled outside the country. But then people were kind of interested in that component
of it. And I think that they were not aware—of a potential local-acquisition disease.
Most doctors know of Chagas disease, but especially because we don’t see it a whole lot in
Texas, some people might not—that might not be on their radar.

Not knowing CD is in Texas
and local transmission

I don't know that Chagas disease has registered in the minds of my heart failure colleagues,
perhaps, the level that it should.

Level

Patient

Theme

Example(s) of Participant Feedback
Definitely language barriers—absolutely—would be difficulties in patients, you know,
Language as a communication receiving additional care, additional imaging I think, from a cardiovascular perspective, as
barrier
well.
I think barriers, with respect to patients not having a respect for this disorder and this
disease—

Patient refusing treatment

Patient fearing to engage in
the health system
136
Patient not understanding or
“respecting” the disease
Patient complications from
treatment

So this one—the patient who had early cardiomyopathy, he might’ve still been a candidate
for treatment because it was really super mild, but he lived in the middle of nowhere in the
Valley. He was getting out of the Air Force. He was not all that motivated anyway to get
treated with months of non-FDA-approved drugs
definitely like racial barriers, they’re definitely just like social barriers or just, I think—I
think the fear of patients who may be not appropriately documented, you know, seeking
out care and that, you know, them limiting the chance of them being screened and
diagnosed
them thinking that it is truly a disease that still only exists in Central and South America,
not within the United States, so they may think that they’re immune because they’re here
This is a really, really big problem, you know because—my case, my eighteen-year-old
male, he isn’t dying, you know, he’s—he overall feels good right now
Yeah, I mean, it’s a big challenge, you know, with the toxicity to the medication
And then the second aspect that’s always difficult is the medication itself. You know, the
benznidazole and the nifurtimox. It’s a two-to-three-month treatment duration. And there’s
a lot of nausea and vomiting with a lot of patients. And actually, the older the patient is—
which—I deal with adults. I don’t see kids. But the older the patient is, the more likely
they’re probably going to have the side effects. And on top of that—I’ve never seen the
neurotoxicity or the photosensitivity or any of that, but one thing we always check for is
liver inflammation from the medication, and also effects on their white blood cell count,
hemoglobin and platelets also. The medication can alter those.
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CONCLUSION
Main Findings
The maps illustrate the barriers and challenges to accessing and receiving care for CD
in Texas. Particularly, they demonstrate the potential for increased CD diagnosis in urban
counties. Nonetheless, CD diagnosis are possible in rural areas, as indicated by TDSHS
reported CD cases data. Moreover, the maps indicate the overall likelihood of currently
missed CD diagnosis throughout the state. The mapped data also visualize the potential risk
of local transmission throughout the state. Thus, this begins to shed light into physicians
under recognizing CD as a potential threat. The maps also stress the importance that missed
CD diagnosis are due not just due to limited physician access, but maybe also due a lack of
access to knowledgeable physicians who may be trained and willing to recognize the risks
and follow-through with screening and diagnosis.
The findings from the questionnaires are consistent with the literature60,62,75,116 and
reinforce CD knowledge gaps by physician specialties, particularly among general or family
practitioners. The lack or limited knowledge, as a physician or systems-level barrier, prevents
or delays CD diagnosis. More than half of the participants did not answer the correct
response in 6 of the 13 knowledge items. This included: the prevalence of total reported CD
cases to TDSHS; the clinical course for CD; the proportion of patients with chronic CD that
develop symptoms; methods for confirming CD diagnosis; pharmaceutical drugs for
treatment; and treatment recommendations for patients. The questionnaire responses from the
screening and diagnosis practice items indicate that only one-fifth of surveyed physicians
were frequently assessing CD exposure risks among their patient populations. This is
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congruent in a recent study by Edwards et al (2018). A national population of pediatric ID
specialists were sampled and specific items on screening practices and knowledge in their
pediatric Latino immigrant population were assessed. There was a low level of knowledge
regarding congenital transmission prevalence and risk factors and rarely or ever considered a
diagnosis of congenital CD in a newborn infant born to immigrants from Mexico or Central
America or South America.116
This thus demonstrates the need to improve outreach and education among physicians
so that more of them recognize the need to assess CD exposure risks more frequently.
Interestingly, the majority perceived that CD is under diagnosed in Texas and potentially
misdiagnosed. Moreover, in general, questionnaire participants believed that the process to
confirm CD is complex. Access to treatment by their patient population was not seen as a
barrier, yet medical training was: ID specialists believed that they are trained to recognize
patients who may need to be screened as compared to family or general practice physicians.
Training and experience, according to the KI, were essential in shaping physicians’
understanding of CD in Texas. Findings from a study in Spain support this, in which
physicians who worked in a community clinic in which immigrant patients were screened for
CD were more knowledgeable about CD than physicians who practiced in a clinic where no
screening was performed.61 Unpublished participant data from a 2017 Texas Chagas
Taskforce workshop on CD further illustrate the value in training and educating physicians.
Knowledge scores increased from 69% prior to the session to 90% after the materials were
presented.
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Ultimately, the emerging themes from the KI further solidify the framework for
existing barriers that are congruent with other proposed frameworks115,117. Specific physician
recommendations to enhance awareness and improve knowledge on CD in Texas include: 1)
engage patients and physician leadership; 2) increase surveillance to better understand
prevalence; 3) improve access to physician resources and how materials on CD are
disseminated; and 4) improving and updating physician resources.
Study Strengths
This is the first study aimed to examine CD knowledge among three specialties
(infectious disease, cardiology, general/ family practice) throughout Texas. The findings
build on the seminal work Stimpert and Montgomery (2010).62 This study is also unique in
that incorporates ICD-9 and ICD-10 coding to illustrate the potential for missed CD
diagnosis. Principles of community engagement were applied to ensure to validate the tools
and recruit participants. Finally, this research employed a mixed methodology that will help
inform and guide future research on CD and other neglected diseases. The findings and
recommendations will be disseminated through the appropriate means (e.g., Texas Chagas
Taskforce meetings; updates to collaborators; and peer-reviewed articles).
Study Limitations
Nonetheless, given the nested, explanatory mixed methodology design, the results do
not statistically support a hypothesis or association. The generalizability of the results is
limited given the non-probability sampling. Coverage error was a limitation for Aim 2a in
that not all eligible physicians (i.e., within cardiology, family practice, or ID specialists) were
affiliated or were members of the physician network(s) that sent out the email invitation(s) to
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participate in the questionnaires (i.e., not all eligible physicians had a nonzero chance of
being included in the sample). This was also a concern for the key informants, in which a
new sampling frame was developed that relied on the Texas Chagas Taskforce contacts and
collaborators, rather than on the CDC list of physicians who had treated for CD in Texas.
Sampling error occurred as a failure to open or read the email invitations to participate in the
questionnaire or KI interview. Not surprisingly, the majority of questionnaire participants
practiced in urban areas, while most of the KI’s were in Houston or San Antonio. Thus,
physicians practicing in rural counties had very limited representation. The contextual
barriers, as perceived by physicals in these rural communities, were not identified by this
research, the challenge remains in the application of translating the proposed
recommendations into these settings without identifying feedback from these stakeholders.
Furthermore, the recruited questionnaire participants might reflect those HCP’s who
might be more interested in CD, and thus be more aware or biased, and therefore more
willing to participate. Furthermore, there may be response bias in answering the questions.
The missing data was another limitation, that could be attributed to measurement error. Nonresponse bias was another limitation illustrated in the low participation from cardiologists for
the questionnaires and their unwillingness to answer all the questions.
There were limitations for using administrative data for Aim 1 (i.e., the Texas
PUDF). The hospital inpatient dataset does not reflect all the missed CD cardiomyopathy
cases since it includes only discharge data for inpatients only (e.g., outpatient hospital data is
excluded). Moreover, county names are suppressed so the enumeration of all CD diagnostics
is incomplete. Although a cardiologist was consulted, a focused literature review, including
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the most recent guidelines published by the American Heart Association regarding Chagas
cardiomyopathy,118 other recent findings on the clinical evaluation of CCC113,114, can be used
to improve the definition of missed diagnosed CD cases. Finally, the implication of
participant under-representation from rural counties limits the
Recommendations
The impetus to continue to raise awareness and education amongst physicians in
Texas remains a priority at the systems and physician levels. A multi-level approach to
reducing the number of missed CD diagnosis in Texas is needed that does not rely uniquely
on individual uptake of CD knowledge. Table 3 summarizes the recommendations framed at
the systems, physician, and patient levels. These recommendations can be framed as
responses to the barriers identified in Figure 9.
At the systems-level, curricula that discuss the specific context to CD in Texas are
needed. As such, policymakers must be engaged so that they recognize the value in revising
the undergraduate medical curriculum on CD. More time must be allotted to this topic to
ensure physicians in training recognize the risk factors in their patient populations in Texas.
Nonetheless, improved surveillance and data are needed for physicians to recognize the
problem that CD is not just likely from patients who lived in endemic countries, rather that
local transmission is possible and has been reported in Texas.
At the physician level, there are various opportunities to engage with physicians
through the continuum of CD care, as first demonstrated in Figure 8. A physician managing
the medical care potential CD patient (i.e., before performing screening or requesting
diagnostics), must be able to synthesize the information received form the patient. To do that,
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however, they must first recognize the potential for CD (i.e., be inclined to consider CD),
have access to the latest clinical guidelines and diagnostic procedures, collaborate with other
physicians (or non-physician CD experts; work outside their medical “silo”), and be able to
communicate the results of the screening or diagnostics and discuss treatment options, side
effects, and follow-up management. One recommendation is to have Spanish resources
readily accessible for the patient in situations in which translating services are not costly or
timely.
Access to resources and educational opportunities that inform or guide physician
screening practices must be targeted. For example, many of the KI’s cited the pivotal JAMA
article15 alongside CDC materials, and Up to Date 9 as helpful resources. None of the
questionnaire participants reported frequent usage of local, county, or health department
resources. Instead, efforts, as framed by the findings, must focus on continuing medical
education (CME) workshops and webinars, and conferences.
Web-based outreach is particularly beneficial for physicians in rural or remote areas.
The potential for a Chagas webinar has been demonstrated in the continuing efforts from the
Texas Chagas Taskforce. That is, in February 2, 2018, a total of 17 physicians participated in
a CD webinar. Targeted physician recruitment through existing physician networks can
further improve participation and ultimately knowledge on CD.
Additionally, experts in the field (i.e., cardiologists or IDs) must recognize the
opportunity to educate physicians in other specialties about their case studies and other CD

9

Marin-Neto et al (2018). Chagas Heart Disease: https://www.uptodate.com/contents/chagas-heartdisease-clinical-manifestations-and-diagnosis
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research. Peer-to-peer models are way to improve uptake and maximize the impact of
physician awareness and education. Engaged medical leadership is a recommendation that
has also been discussed elsewhere.116
Other specific outreach strategies to improve the uptake of information at the
individual physician level includes the usage of peer-reviewed journals that are specific to
physician specialties. For example, a recent update to the clinical management of Chagas
cardiomyopathy was published by the American Heart Association and endorsed by the
Inter-American Society of Cardiology summarizes and lists the current.118
The patient engagement framework (Figure 8) further demonstrates the potential
impact of improving physician awareness and education. For example, a recent kissing bug
and CD field guide was developed and released by the Texas Chagas Taskforce. The kissing
bug field guide is available online through the TDSHS and various statewide web resources
with the purpose of engaging the community at large that may be at risk of exposure to
infected triatomines, and educating them about the long-term adverse health outcomes of
delaying screening and diagnosing if exposed. This outreach effort had gathered statewide
awareness and has empowered community members to discuss with their provider the risk of
CD and be their own health advocate.
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Table 3: Recommendations to Improve Chagas Disease Education at the System,
Physician and Patient Levels
Level

Systems

Recommendation

Strategy/ Example
Ensure that specialty journals provide updates to
CD clinical care (e.g., America Heart
Association)

Improve/ facilitate access to
resources for physicians
Improve undergraduate medical
education
Improve awareness within
medical systems

Encourage usage of Up to Date among other
physicians
Engage policymakers so that more time can be
spent to contextualize CD in the U.S.
Engage physician leadership so that briefs and
alerts are disseminated throughout hospital
Pilot studies to better understand prevalence in
specific communities

Continue research and
surveillance to improve
prevalence estimates and ensure
physicians can access data
Promote collaboration between
physicians/ Increase awareness/

Conduct routine surveillance at local/ regional
blood banks (i.e., not just first time donors)
Disseminate updates from TDSHS in specialty
journals or TMA
Encourage dissemination of CD case studies/
research by physicians at local/ society
conferences
Use story telling
Use social media including Facebook to target
physicians

Use conferences to share knowledge, including
Increase awareness
available CME
Target rural or physicians in
Use webinars and other streaming educational
Physician remote locations
opportunities
Increase awareness and improve Educate community members (e.g., Kissing Bug
Patient
education
Field Guide)
Next Steps and Implications
Physicians who may not consider CD as current or potential threat in Texas believe
that epidemiological research and disease surveillance are needed to estimate the human
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prevalence of CD and better quantify the need to screen and diagnose to guide their practices.
Public health CD surveillance in Texas is needed to monitor incident cases and assess the
risk of local transmission.39 Texas, like the other states where CD is reportable, publish a
report and update their website as the means to disseminate surveillance data. Additional
dissemination methods employed by other states like Tennessee include peer-reviewed
literature and targeted reports to healthcare providers. These additional strategies might help
increase awareness. Interestingly, Texas is the only state out the six that currently utilized the
Taskforce to increase physicians awareness.39 Texas Chagas Taskforce activities are in line
with the proposed recommendations, including the development and publication of a
healthcare provider protocol and a testing algorithm. 10 However as indicated through the
findings, one of the main barriers lies in the reluctance or unwillingness to access or utilize
CD resources from local or county, or state health departments. Further research can explain
the underlying reasons for this. The findings also support the need for improved diagnostic
tools and updated physician guidelines. The uptake and impact of the recently published
AHA statement and guidelines to raise the recognition of Chagas cardiomyopathy remains to
be seen. Understanding the experiences and attitudes of rural-based physicians is also critical
to improve the understanding of KAP of CD among these physicians and thus increase
screening, diagnosis, and management of care to high-risk patients. Furthermore, additional
research must explore the patient’s perspectives.

10

Texas Department of State Health Services (2018). Chagas disease for healthcare providers:
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Chagas Disease Questionnaire for Cardiologists
SURVEY FLOW
Consent and Eligibility
Definitions
Attitudes (5 Questions)
Knowledge (14 Questions)
Knowledge for Cardiologists (3 Questions)
Practices: Actual Chagas (20 Questions)
Practices: Other Activities- Rated (7 Questions)
Participant Demographics (10 Questions)
Questionnaire Conclusion and Follow-up
Q1.2 Thank you for your interest in completing the following online questionnaire. The purpose of this
brief 20-minute questionnaire is to gain a better understanding of Chagas disease awareness, and
practices among cardiologists, infectious disease specialists and family physicians licensed by the Texas
Medical Board.
If you would like to participate in the questionnaire, please continue to the next page.
If you do not wish to participate in the questionnaire, we thank you for your time and interest. You
can close this page now.
Q1.3
INFORMED CONSENT

INVITATION TO TAKE PART
You are invited to take part in a research project called, Chagas Disease Awareness among Physicians in
Texas, conducted by doctoral candidate Gerardo J. Pacheco of the University of Texas Health Science
Center at Houston (UTHealth) School of Public Health. For this research project, he will be called the
Principal Investigator or PI.
Your decision to take part is voluntary. This research project has been reviewed by the Committee for the
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston as
HSC-SPH-17-1039. Although we appreciate your valuable input in this questionnaire, please be advised
that you may refuse to take part or choose to stop taking part, at any time. Additionally, you may also
refuse to answer any question(s).
PROCEDURES
If you agree to take part in this study, you will first confirm your consent by answering the question below.
Once you consent, you will be directed to the questionnaire. It contains sections regarding your attitudes
and perspectives, knowledge, and current practices about Chagas disease in Texas. At the completion of
the questionnaire, you will be prompted to respond whether or not you would like to participate in a 15-
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minute key informant phone interview. You will then be prompted to provide your email address if you
agree to participate. Conversely, if you decline, you will be directed to a page with the answer key to the
Chagas disease knowledge questions.
PURPOSE
The purpose of this research study is to examine the level of knowledge, awareness, and
practices among licensed physicians in Texas regarding screening, diagnosis, and treatment of Chagas
as well as to illustrate the potential for missed cases for Chagas disease diagnosis in Texas.
TIME COMMITMENT
The questionnaire will require 20-25 minutes to complete and will be available for up to two weeks.
BENEFITS
The potential benefits to participating in this study include the self-assessment of Chagas disease, which
will allow you as a physician to understand where your current knowledge deficits might be and if further
resources should be reviewed to be up to date. In more general terms, the results from this study can
help point towards statewide knowledge deficits and gaps that might be present and push towards
recommendations for targeted outreach and workshops (e.g., by specialty, location, etc.).
You may receive no direct benefit from being in the study; however, you taking part may help patients
receive better in the future.
An answer key is provided at the end of the questionnaire for you to review the Chagas disease
knowledge section.
RISKS AND/OR DISCOMFORTS
The risks and discomfort associated with participation in this study are no greater than those ordinarily
encountered in daily life or during the performance of routine exams. The experience is expected to be
informative and interesting and thus a generally positive experience.
Confidentiality: Although every measure will be taken to properly safeguard all data pertaining to this
study, there is a possible risk of breach of confidentiality.
Questionnaire: You may get tired when we are asking you questions or you are completing
questionnaires. You do not have to answer any questions you do not want to answer.
STUDY WITHDRAWAL
Your decision to take part is voluntary. Although we appreciate your valuable input in this questionnaire,
please be advised that you may refuse to take part or choose to stop taking part, at any time. You may
decide to stop taking part in the study at any time, but you must submit in writing to the PI if you choose to
have your responses excluded from the analysis.
COSTS, REIMBURSEMENT AND COMPENSATION
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If you decide to take part in this research study, you will not incur any additional costs.
You will not be paid for taking part in this study.
CONFIDENTIALITY
Identifying information will not appear on records retained by the sponsor, with the exception of your birth
year and your email address if you choose to provide that information for participation in follow-up
interviews. You will not be personally identified in any reports or publications that may result from this
study.
QUESTIONS
If you have questions at any time about this research study, please feel free to contact the PI at (915)
240-2821 as he will be glad to answer your questions. You can contact the PI to discuss problems, voice
concerns, obtain information, and offer input in addition to asking questions about the research.
If you have any questions or concerns about your rights as a research subject, call the Committee for the
Protection of Human Subjects at (713) 500-7943. You may also call the Committee if you wish to discuss
problems, concerns, and questions; obtain information about the research; and offer input about current
or past participation in a research study.
SIGNATURES
Submit your consent below to participate in this research only if you understand the information given to
you about the research and you choose to take part. No signature is required to proceed if you confirm
your consent below. Make sure that any questions have been answered and that you understand the
study.
CPHS STATEMENT: This study (HSC-SPH-17-1039) has been reviewed by the Committee for the
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston. For
any questions about research subject's rights, or to report a research-related injury, call the CPHS at
(713) 500-7943.
Q1.5 If you wish to participate, please indicate below:

o
o

Yes, I agree to participate. (1)
No, I do not wish to participate. (2)

Skip To: End of Survey If Q1.5 = 2

IRB NUMBER: HSC-SPH-17-1039
Page 3 of 29
IRB APPROVAL DATE: 07/02/2018

Q1.6 Are you an MD or DO licensed by the Texas Medical Board to practice in the state of Texas?

o
o

Yes (1)
No (2)

Display This Question:
If Q1.6 = 2
Q1.7
Thank you for your interest. However, this questionnaire is intended for physicians.
You may close this page now.
Skip To: End of Survey If Q1.7(1) Is Displayed
Q1.8 Please indicate your primary medical specialty. If it is not listed below, select “Other”:

o
o
o
o

General Practice/ Family Medicine (1)
Infectious Disease (2)
Cardiology (3)
Other (4)

Display This Question:
If Q1.8 = 4
Q1.9 If Other, please describe:
________________________________________________________________
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Q2.1 DEFINITIONS
Definitions used for the purpose of this questionnaire:
Screening: clinical decision-making process or differential diagnosis to determine if further laboratory
diagnostics are required.
Diagnosis: the clinical and serological testing required to confirm Chagas disease.
Vector: Triatomine or Reduviid insect that is able to transmit the parasite T cruzi that causes Chagas
disease.
Q3.1
ATTITUDES ON CHAGAS DISEASE
The following sections are about your opinions and attitudes regarding Chagas disease.
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Q3.2 To what extent do you agree or disagree with the following statements?
Strongly
agree (1)
a. Chagas
disease is under
diagnosed in
Texas (i.e.,
failure to
recognize or
correctly
diagnose a
disease or
condition in a
significant
proportion of the
population). (1)
b. Chagas
disease is
potentially
misdiagnosed
in patients (e.g.,
incorrectly
diagnosed cases
of chronic
Chagas
cardiomyopathy
for idiopathic
cardiomyopathy).
(2)
c.The process
required to
confirm Chagas
disease is
complex and
thus time
consuming. (4)
d. In Texas,
diagnosis and
treatment of
Chagas disease
is a relatively
easy process
with few barriers.
(9)

Somewhat
agree (2)

Neither agree
nor disagree
(3)

Somewhat
disagree (4)

Strongly
disagree (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q3.3 As a cardiologist, to what extent do you agree or disagree with the following statements?
Strongly
agree (1)
a. My medical
training prepared
me to recognize
patients who may
need to be
screened for
Chagas disease.
(8)
b. I routinely
screen for
Chagas disease
in patients who
present with risk
factors. (11)
c. Accessing
Chagas disease
treatment is not a
barrier for the
population I
serve. (12)
d. I have access
to a 12-lead
electrocardiogram
with a 30 second
lead to screen for
Chagas
cardimyopathy
within my
practice. (14)
e. I have access
to cardiac
ultrasound
equipment to
perform
echocardiograms
to screen for
Chagas disease
within my
practice. (16)

Somewhat
agree (2)

Neither agree
or disagree
(3)

Somewhat
disagree (4)

Strongly
disagree (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q3.4 How confident are you in performing the following when screening for Chagas disease in your
patient population?
Very confident (1)

Somewhat confident
(2)

Not at all confident (3)

a. Identifying risk
factors for Chagas
disease in patients. (1)

o

o

o

b. Recognizing the
vector that transmits
Chagas disease. (11)

o

o

o

c. Obtaining a patient's
social history to identify
potential risk factors for
Chagas disease. (13)

o

o

o

o

o

o

o

o

o

d. Using
electrocardiogram
(ECG) to screen and
diagnose for chronic
Chagas disease. (12)
e. Using a stress test to
evaluate clinical
manifestations to
screen and diagnose
for chronic Chagas
cardiomyopathy. (16)
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Q3.5 How confident are you in performing the following in patients with Chagas disease?
Very confident (1)
a. Contacting and
coordinating with the
local and/or state
health department
when consulting about
a Chagas patient. (1)
b. Contacting,
coordinating, and
following-up with the
Centers for Disease
Control and Prevention
(CDC) when consulting
about a Chagas
patient. (2)
c. Requesting the
Current Procedural
Terminology laboratory
codes for diagnosing
Chagas disease. (4)
d. Continuing to provide
follow-up medical care
to Chagas patients. (5)

Somewhat confident
(2)

Not at all confident (3)

o

o

o

o

o

o

o

o

o

o

o

o

Q3.6 What would be the recommended sequence when managing care of a Chagas patient who has a
blood donation letter? Please rank from 1 to 5 on how you would prioritize (drag and drop).
______ Coordinate with local health department and Texas Department of State Health Services (DSHS)
to confirm diagnosis. (1)
______ Consult with the CDC to manage patient's treatment protocol. (2)
______ Perform baseline clinical workup that includes physical exam, 12-lead ECG, and additional
testing if warranted. (5)
______ Confirm diagnosis via commercial serology testing. (3)
______ Obtain thorough history to evaluate potential routes of exposure. (4)
Q4.1 KNOWLEDGE The following sections are to help us asses Texas physicians' knowledge about
the cause, transmission, and clinical aspects of Chagas disease.
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Q4.2 How does the vector with the parasite transmit Chagas disease to humans?

o

The infected vector penetrates the human host skin during bloodmeal, transmitting parasite
through saliva. (1)

o

Through infected feces of the vector, that is deposited during the bloodmeal, most commonly
when the person rubs the infected feces into the bite wound while scratching the area. (2)

o
o
o

The infected vector regurgitates after bloodmeal, transmitting parasite to the human. (3)
None of the above. (4)
Not sure. (5)

Q4.3 How do the majority of people with Chagas disease living in the United States acquire the infection?

o
o
o
o
o

From drinking unpasteurized juices. (1)
From exposure to vectors while residing in Mexico, Central, or South America. (2)
From their mothers (i.e., congenital transmission). (3)
From another infected person. (4)
Not sure. (5)

Q4.4 Since becoming a reportable condition in the state of Texas in 2013, approximately how many total
Chagas confirmed cases (local and imported) have been reported to the Texas DSHS, between 2013 and
2016?

o
o
o
o
o

Less than 5. (1)
Between 20 and 30. (2)
Between 75 and 100. (3)
More than 1,000. (4)
Not sure. (5)
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Q4.5 Which of the following best describes the clinical course of Chagas disease?

o

Acute for 10 to 30 days following exposure to parasite, is self-limiting in most persons within 2
months, and rarely progresses into the chronic phase. (1)

o

Acute for a week following exposure to parasite. If left untreated, it is a chronic lifelong infection 24 weeks following exposure to parasite. (2)

o

Acute for 1-8 weeks following exposure to parasite; asymptomatic for years to decades in the
majority of infected persons; but becoming symptomatic in a portion of persons infected with parasite.
(3)

o
o

None of the above. (4)
Not sure. (5)

Q4.6 The acute phase of Chagas disease may be characterized by which of the following:

o
o
o
o
o

Fever (1)
Swelling at the site of inoculation (2)
No symptoms (3)
All of the above (4)
Not sure (5)

Q4.7 In addition to heart failure, what major clinical disorders manifest frequently and concurrently that
lead to chronic Chagas cardiomyopathy?

o
o
o
o
o

Cardiac arrhythmias (1)
Thromboembolism (systemic and pulmonary) (2)
Chest pain syndrome (3)
All of the above (4)
Not sure (5)
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Q4.8 Approximately what percentage of patients worldwide with chronic Chagas disease eventually
develop the clinical (symptomatic) form of the disease?

o
o
o
o
o

Less than 1%. (1)
Between 20 and 40%. (2)
More than 50%. (3)
None of the above. (4)
Not sure. (5)

Q4.9 Persons infected with chronic Chagas disease may develop which of the following?

o
o
o
o
o

Cardiac conduction abnormalities and/ or cardiomyopathy. (1)
Megaesophagus and/or megacolon. (2)
Co-clinical manifestations. (3)
All of the above. (4)
Not sure. (5)

Q4.10 Which of the following may occur in patients with chronic Chagas cardiomyopathy?

o
o
o
o
o

None- can present without clinical manifestations and be asymptomatic. (1)
Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, and edema. (2)
Sudden death. (3)
Any of the above. (4)
Not sure. (5)
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Q4.11 You should request commercial laboratory diagnostic serology tests, initiate a clinical evaluation of
the patient, and conduct a thorough history in a patient who:

o

Has tested positive for T cruzi during a blood donation or has a sibling or mother who is Chagaspositive. (1)

o
o

Was exposed or potentially exposed to a vector in a period longer than 8 weeks. (2)

Presents with onset of cardiac disease manifestations that are compatible with chronic Chagas
cardiomyopathy. (3)

o
o

All of the above. (4)
Not sure (5)

Q4.12 In patients who test positive for Chagas disease after a blood donation or from a laboratory
diagnostics, obtaining a social history is needed to assess potential routes of exposure, including:

o
o
o
o
o

Travel to or residence in areas endemic for Chagas disease. (1)
Previous history of blood transfusions or organ/ tissue transplants. (2)
Possibility of congenital Chagas disease transmission. (3)
All of the above. (4)
Not sure. (5)

Q4.13 Which of the following best describes the method(s) for a confirmatory diagnosis of Chagas
disease?

o
o
o
o
o

Seropostive results from 2 different immunoassays and/or PCR performed at the CDC. (1)
Positive serology from blood screening donations. (2)
Detection of apolipoprotein A-1 (APOA1) upregulation in human serum. (3)
All of the above. (4)
Not sure. (5)

IRB NUMBER: HSC-SPH-17-1039
Page 13 of 29
IRB APPROVAL DATE: 07/02/2018

Q4.14 Which of the following describes the current treatment options for Chagas disease?

o

Benzindazole and nifurtimox are available only under current investigational protocol by the CDC
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic
infection who have no indication of advanced cardiomyopathy. (1)

o

Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 212 years of age and is available commercially. (4)

o
o
o

Nifurtimox is only available by the CDC under investigational protocol. (5)
Second and third choices only. (8)
Not sure. (7)

Q4.15 Should patients with chronic Chagas disease be treated with antitrypanosomal drugs?

o

No, there is no evidence that antitrypanosomal treatment for chronic Chagas disease can be
effective. (1)

o
o

Yes, only patients younger than 5 years of age should be treated for chronic Chagas disease. (2)

Treatment is always recommended for patients up to age 18 years of age and generally
recommended for patients aged 18 to 50. (3)

o
o

Only Chagas disease patients manifesting with moderate to severe cardiomyopathy. (4)
Not sure. (5)

Q5.1 SPECIFIC KNOWLEDGE ON CHAGAS DISEASE SCREENING & DIAGNOSTICS The following
questions are specific to you as a cardiologist in identifying the clinical manifestations of Chagas disease
and screening the patient.
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Q5.2 What are the important elements of the clinical evaluation of a newly diagnosed chronic Chagas
patient who is asymptomatic?

o
o

Complete physical examination, complete blood count (CBC), and chemistry panel. (1)

Complete physical examination, electrocardiogram (ECG) with 30 second rhythm strip, and
detailed history. (7)

o

Complete physical examination, ECG with 30 second rhythm strip, chest radiograph, barium
swallow, and detailed history. (8)

o
o

None of the above. (9)
Not sure. (10)

Q5.3 Which of the following are typical of Chagas cardiomyopathy as evaluated using
electrocardiograph?

o

Right bundle branch block often associated with left anterior hemiblock, ST-T changes, abnormal
Q waves, various degrees of AV block, sick sinus syndrome, and low QRS voltage. (1)

o

Mainly conduction abnormalities including first-degree AV block, left bundle-branch block, and
nonspecific interventricular conduction delays. (6)

o
o
o

Right bundle-branch block only. (7)
None of the above. (8)
Not sure. (9)

Q5.4 In patients with chronic Chagas cardiomyopathy, cardiac examination typically demonstrates which
of the following?

o
o
o
o
o

Murmurs of mitral and/ or tricuspid regurgitation. (1)
Wide splitting of the second heart sound due to right bundle branch block. (6)
A prominent diffuse apical thrust. (7)
All of the above. (8)
Not sure. (9)
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Q6.1 PRACTICES RELATED TO SCREENING, DIAGNOSING, AND TREATING CHAGAS DISEASE
The following are about your practices related to the identification, screening, and treatment of actual
Chagas disease case(s).
Q6.2 Over the past five years since becoming a reportable condition in Texas, have you directly screened
and/ or confirmed a diagnosis for Chagas in patients in your medical care in Texas?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.2 = 1
Q6.3 In the past year, how many patients that you suspected for Chagas disease did you screen and test
to confirm diagnosis?
________________________________________________________________

Display This Question:
If Q6.2 = 1
Q6.4 In the past year, out of those patients that you screened and/ or diagnosed, did any of them receive
a positive confirmatory diagnosis?

o
o

Yes (8)
No (9)

Display This Question:
If Q6.4 = 8
Q6.5 In the past year, if you screened suspected Chagas patients, how many that were positive were
confirmed by the CDC?
________________________________________________________________
Display This Question:
If Q6.4 = 8
Q6.6 Please provide additional comments regarding your experience in confirming a Chagas disease
diagnosis:
________________________________________________________________
________________________________________________________________
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________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q6.2 = 1
Q6.7 In the past year, if you have screened suspected Chagas patients, what method(s) did you use to
screen for Chagas disease? Select all that apply.

▢
▢
▢

Physical assessment. (2)
12 lead strip electrocardiogram. (3)
Patient's medical and social history. (4)

Display This Question:
If Q6.2 = 1
Q6.8 If you screened patients for Chagas disease in the past year, did you consult with local/ county
health departments to coordinate treatment?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.2 = 1
Q6.9 If you screened patients for Chagas disease in the past year, did you coordinate with the CDC to
confirm diagnosis?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.2 = 1
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Q6.10 If you screened and/ or diagnosed patients for Chagas disease in the past year, what method(s)
did you use to confirm diagnosis for Chagas disease? Select all that apply.

▢
▢
▢
▢
▢
▢

PCR performed at the CDC. (1)
Commercial antibody testing- ARUP Lab. (2)
Commercial antibody testing- Mayo Medical Lab. (3)
Commercial antibody testing- Quest Diagnostics. (4)
Commercial antibody testing- Labcorp. (5)
Not sure. (6)

Display This Question:
If Q6.2 = 1
Q6.11 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you
coordinate with the CDC for treatment?

o
o
o
o

Always (1)
Sometimes (2)
Never (4)
Not sure (3)

Display This Question:
If Q6.2 = 1
Q6.12 Please provide additional comments regarding your experience obtaining and coordinating
treatment for patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Display This Question:
If Q6.2 = 1
Q6.13 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you
coordinate with the local health department and/ or Texas DSHS to confirm diagnosis?

o
o
o
o

Always (1)
Sometimes (2)
Never (4)
Not sure (3)

Display This Question:
If Q6.2 = 1
Q6.14 Please provide additional comments regarding your experience in coordinating with local and state
health department officials when diagnosing a Chagas patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________

Display This Question:
If Q6.2 = 1
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Q6.15 If you screened patients in the past year and diagnosis was confirmed, please indicate the
classification of the case(s):

▢
▢
▢
▢
▢
▢

Acute (1)
Chronic-indeterminate (2)
Chronic-cardiomyopathy (3)
Chronic-gastrointestinal (4)
Other (6)
Not sure (5)

Display This Question:
If Q6.15 = 6
Q6.16 Please describe the classification of the Chagas case(s) if "other" was selected:
________________________________________________________________

Display This Question:
If Q6.2 = 1
Q6.17 Please indicate the source(s) of transmission:

▢
▢
▢

Locally-acquired (1)
Imported (2)
Not sure (3)

Display This Question:
If Q6.2 = 1
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Q6.18 Did you refer out the patient to any other specialist?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.18 = 1
Q6.19 If you did refer out, please indicate to what other physician specialty:
________________________________________________________________
Display This Question:
If Q6.2 = 1
Q6.20 Was the patient referred to you by another physician?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.20 = 1
Q6.21 What was the physician specialty/ies that referred the Chagas patient(s) to you?
________________________________________________________________
Q7.1 PHYSICIAN PRACTICES
The following are Chagas disease screening and diagnosing practices related to your medical specialty.
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Q7.2 In general, how often do you consider each of the following as exposure risks for Chagas disease in
your patients?
Never (1)
a. Mother or
sibling with
Chagas
disease. (2)
b. History of
blood
transfusions
or organ/
tissue
transplants.
(3)
c. Travel to
Mexico,
Central, or
South
America. (4)
d.
Consumption
foods or
drinks
contaminated
with the
parasite. (5)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q7.3 In general, how often do you perform the following in patients under your medical care who present
with idiopathic cardiomyopathy?
Never (1)
a. Review the
patient's travel
history. (3)
b. Look for signs
of cardiac
arrhythmias that
may arise due to
chronic Chagas
cardiomyopathy.
(5)
c. Evaluate
patient's
cardiopulmonary
function (i.e.,
exercise stress
test). (17)
d. Perform
cardiovascular
testing (chest xray,
echocardiogram,
etc.) to asses
myocardial
damage. (2)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Q7.4 In the past 5 years while practicing medicine in Texas, have you provided care to a Chagas disease
patient with a blood donation letter?

o
o

Yes (1)
No (2)

Display This Question:
If Q7.4 = 1
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Q7.5 In the past 5 years while practicing in Texas, how often did you perform the following in patients
under your medical care who received a positive Chagas diagnosis (i.e., letter) from a blood donation
screening?
Never (1)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

a. Review the
patient's travel
history. (6)

o

o

o

o

o

o

b. Request
serology to
confirm Chagas
diagnosis. (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

e. Consult with
the Texas DSHS
to manage
treatment. (9)

o

o

o

o

o

o

f. Consult with
the CDC to
manage
treatment. (21)

o

o

o

o

o

o

c. Evaluate
patient's
cardiopulmonary
function (i.e.,
exercise stress
test). (7)
d. Perform
cardiovascular
testing (chest xray,
echocardiogram,
etc.) to asses
myocardial
damage. (20)
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Q7.6 In thinking about resources you reference when managing the care of a patient who may potentially
have Chagas disease, how often do you access:
Never (1)
a. Medical
websites
(e.g.,
UpToDate,
MedlinePlus,
etc.) (1)
b. Official
local or
county health
department
websites. (2)
c. The Texas
DSHS
website. (3)
d. The CDC
website. (4)
e. Official
communiques
and health
alerts from
Texas DSHS.
(5)
f. Email alerts
from the
Texas
Medical
Association.
(6)
g. Morbidity
and Mortality
Weekly
Report
(MMWR)
email updates
from the
CDC. (7)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q7.7 Which of the following would you be interested in accessing in order to strengthen your ability to
help patients with Chagas disease? Select all that apply.

▢
▢
▢
▢

Courses (1)
Seminars (2)
Manuals (3)
Other resources (4)

Display This Question:
If Q7.7 = 4
Q7.8 If you indicated other, please describe:
________________________________________________________________
Q8.1 DEMOGRAPHICS

The following section is about demographics and your medical practice.

Q8.2 How many years have you been practicing in family or general practice?

o
o
o
o
o

Less than 5 years. (1)
5 to 10 years. (2)
10 to 15 years. (3)
15 to 20 years. (4)
More than 20 years. (5)

Q8.3 Which of the following best describes the current type of medical setting you currently practice in?

o
o
o
o

Private (1)
Teaching (2)
Community (3)
Other (4)
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Display This Question:
If Q8.3 = 4
Q8.4 If other, please describe:
________________________________________________________________
Q8.5 Which of the following best describes the setting where you practice at?

o
o
o

Urbanized area (i.e., 50,000 or more people). (1)
Rural area (i.e., at least 2,500 people but than 50,000). (2)
None of the above. (3)

Q8.6 In your current medical practice, what proportion of total patients you see on average that are
Hispanics/ Latinos?
0 10 20 30 40 50 60 70 80 90 100
Click to write Choice 1 ()

Q8.7 PARTICIPANT DEMOGRAPHICS- PART 2
Q8.8 Are you male or female?

o
o

Male (1)
Female (2)

Q8.9 What is your year of birth? (YYYY)
________________________________________________________________
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Q8.10 Please indicate if you received medical training in any of the following places:

o
o
o
o
o

Mexico (1)
Central America (2)
South America (3)
None of the above (4)
Prefer not to answer (5)

Display This Question:
If Q8.10 = 2
Q8.11 If you received medical training in Central America, indicate the country:
________________________________________________________________
Display This Question:
If Q8.10 = 3
Q8.12 If you received medical training in South America, indicate the country:
________________________________________________________________
Q9.1
CONCLUSION
Q9.2 Thank you for participating in this questionnaire. We know your time is valuable. Your responses will
remain anonymous and will be used to identify a baseline of knowledge and awareness of Chagas
disease throughout the state. In addition to the questionnaire, we are conducting additional research
via phone interviews with practicing physicians to identify and explore additional barriers related to
screening and diagnosing of Chagas disease in Texas. The goal is to understand the challenges that lead
to missed Chagas diagnosis and frame recommendations to improve awareness and education among
practicing physicians in Texas. Questionnaire responses will be kept separate and confidential if you do
decide to provide your contact information to participate in the phone interviews.
Q9.3 Would you like participate in a 15-minute phone interview?

o
o

Yes, I would like to participate. (1)
No, I decline. (2)
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Display This Question:
If Q9.3 = 1

Q9.4 Please provide your email:
________________________________________________________________
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Chagas Disease Questionnaire for Family or General Practice
Physicians
Survey Flow
Consent and Eligibility
Definitions
Attitudes (4 Questions)
Knowledge (13 Questions)
Practices: Actual Chagas (20 Questions)
Practices: Common, Other Activities- Rated (8 Questions)
Participant Demographics (11 Questions)
Questionnaire Conclusion and Follow-up
Q1.2 Thank you for your interest in completing the following online questionnaire. The purpose of this
brief 20-minute questionnaire is to gain a better understanding of Chagas disease awareness, and
practices among cardiologists, infectious disease specialists and family physicians licensed by the Texas
Medical Board.
If you would like to participate in the questionnaire, please continue to the next page.
If you do not wish to participate in the questionnaire, we thank you for your time and interest. You
can close this page now.
Q1.3
INFORMED CONSENT

You are invited to take part in a research project called, Chagas Disease Awareness among Physicians in
Texas, conducted by doctoral candidate Gerardo J. Pacheco of the University of Texas Health Science
Center at Houston (UTHealth) School of Public Health. For this research project, he will be called the
Principal Investigator or PI.
Your decision to take part is voluntary. This research project has been reviewed by the Committee for the
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston as
HSC-SPH-17-1039. Although we appreciate your valuable input in this questionnaire, please be advised
that you may refuse to take part or choose to stop taking part, at any time. Additionally, you may also
refuse to answer any question(s).
PROCEDURES
If you agree to take part in this study, you will first confirm your consent by answering the question below.
Once you consent, you will be directed to the questionnaire. It contains sections regarding your attitudes
and perspectives, knowledge, and current practices about Chagas disease in Texas. At the completion of
the questionnaire, you will be prompted to respond whether or not you would like to participate in a 15minute key informant phone interview. You will then be prompted to provide your email address if you
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agree to participate. Conversely, if you decline, you will be directed to a page with the answer key to the
Chagas disease knowledge questions.
PURPOSE
The purpose of this research study is to examine the level of knowledge, awareness, and
practices among licensed physicians in Texas regarding screening, diagnosis, and treatment of Chagas
as well as to illustrate the potential for missed cases for Chagas disease diagnosis in Texas.
TIME COMMITMENT
The questionnaire will require 20-25 minutes to complete and will be available for up to two weeks.
BENEFITS
The potential benefits to participating in this study include the self-assessment of Chagas disease, which
will allow you as a physician to understand where your current knowledge deficits might be and if further
resources should be reviewed to be up to date. In more general terms, the results from this study can
help point towards statewide knowledge deficits and gaps that might be present and push towards
recommendations for targeted outreach and workshops (e.g., by specialty, location, etc.).
You may receive no direct benefit from being in the study; however, you taking part may help patients
receive better in the future.
An answer key is provided at the end of the questionnaire for you to review the Chagas disease
knowledge section.
RISKS AND/OR DISCOMFORTS
The risks and discomfort associated with participation in this study are no greater than those ordinarily
encountered in daily life or during the performance of routine exams. The experience is expected to be
informative and interesting and thus a generally positive experience.
Confidentiality: Although every measure will be taken to properly safeguard all data pertaining to this
study, there is a possible risk of breach of confidentiality.
Questionnaire: You may get tired when we are asking you questions or you are completing
questionnaires. You do not have to answer any questions you do not want to answer.
STUDY WITHDRAWAL
Your decision to take part is voluntary. Although we appreciate your valuable input in this questionnaire,
please be advised that you may refuse to take part or choose to stop taking part, at any time. You may
decide to stop taking part in the study at any time, but you must submit in writing to the PI if you choose to
have your responses excluded from the analysis.
COSTS, REIMBURSEMENT AND COMPENSATION
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If you decide to take part in this research study, you will not incur any additional costs.
You will not be paid for taking part in this study.
CONFIDENTIALITY
Identifying information will not appear on records retained by the sponsor, with the exception of your birth
year and your email address if you choose to provide that information for participation in follow-up
interviews. You will not be personally identified in any reports or publications that may result from this
study.
QUESTIONS
If you have questions at any time about this research study, please feel free to contact the PI at (915)
240-2821 as he will be glad to answer your questions. You can contact the PI to discuss problems, voice
concerns, obtain information, and offer input in addition to asking questions about the research.
If you have any questions or concerns about your rights as a research subject, call the Committee for the
Protection of Human Subjects at (713) 500-7943. You may also call the Committee if you wish to discuss
problems, concerns, and questions; obtain information about the research; and offer input about current
or past participation in a research study.
SIGNATURES
Submit your consent below to participate in this research only if you understand the information given to
you about the research and you choose to take part. No signature is required to proceed if you confirm
your consent below. Make sure that any questions have been answered and that you understand the
study.
CPHS STATEMENT: This study (HSC-SPH-17-1039) has been reviewed by the Committee for the
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston. For
any questions about research subject's rights, or to report a research-related injury, call the CPHS at
(713) 500-7943.

Q1.5 If you wish to participate, please indicate below:

o
o

Yes, I agree to participate. (1)
No, I do not wish to participate. (2)

Skip To: End of Survey If Q1.5 = No, I do not wish to participate.
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Q1.6 Are you an MD or DO licensed by the Texas Medical Board to practice in the state of Texas?

o
o

Yes (1)
No (2)

Display This Question:
If Q1.6 = No
Q1.7
Thank you for your interest. However, this questionnaire is intended for physicians.
You may close this page now.
Skip To: End of Survey If Q1.7() Is Displayed
Q1.8 Please indicate your primary medical specialty. If it is not listed below, select “Other”:

o
o
o
o

General Practice/ Family Medicine (1)
Infectious Disease (2)
Cardiology (3)
Other (4)

Display This Question:
If Q1.8 = Other
Q1.9 If Other, please describe:
________________________________________________________________
Q2.1 DEFINITIONS
Definitions used for the purpose of this questionnaire:
Screening: clinical decision-making process or differential diagnosis to determine if further laboratory
diagnostics are required.
Diagnosis: the clinical and serological testing required to confirm Chagas disease.
Vector: Triatomine or Reduviid insect that is able to transmit the parasite T cruzi that causes Chagas
disease.
Q3.1
ATTITUDES ON CHAGAS DISEASE
The following sections are about your opinions and attitudes regarding Chagas disease.
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Q3.2 To what extent do you agree or disagree with the following statements?
Strongly
agree (1)
a. Chagas
disease is under
diagnosed in
Texas (i.e.,
failure to
recognize or
correctly
diagnose a
disease or
condition in a
significant
proportion of the
population). (1)
b. Chagas
disease is
potentially
misdiagnosed
in patients (e.g.,
incorrectly
diagnosed cases
of chronic
Chagas
cardiomyopathy
for idiopathic
cardiomyopathy).
(2)
c.The process
required to
confirm Chagas
disease is
complex and
thus time
consuming. (4)
d. In Texas,
diagnosis and
treatment of
Chagas disease
is a relatively
easy process
with few barriers.
(9)

Somewhat
agree (2)

Neither agree
nor disagree
(3)

Somewhat
disagree (4)

Strongly
disagree (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q3.3 As a general practice or family physician, to what extent do you agree or disagree with the following
statements?
Strongly agree
(1)
a. My medical
training
prepared me
to recognize
patients who
may need to
be screened
for Chagas
disease. (8)
b. Screening
for Chagas
disease is
possible
through my
general or
family practice.
(11)
c. Diagnosis
for Chagas
disease is
possible
through my
general or
family practice.
(13)
d. Accessing
Chagas
disease
treatment is
not a barrier
for the
population I
serve. (12)

Somewhat
agree (2)

Neither agree
or disagree (3)

Somewhat
disagree (4)

Strongly
disagree (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q3.4 How confident are you in performing the following when screening and diagnosing Chagas disease
in your patient population?
Very confident (1)

Somewhat confident
(2)

Not at all confident (3)

a. Identifying risk
factors for Chagas
disease in patients. (1)

o

o

o

b. Recognizing the
vector that transmits
Chagas disease. (11)

o

o

o

c. Obtaining a patient's
social history to identify
potential risk factors for
Chagas disease. (12)

o

o

o

o

o

o

o

o

o

o

o

o

d. Requesting the
Current Procedural
Terminology laboratory
codes for diagnosing
Chagas disease. (5)
e. Contacting and
coordinating with the
local health department
and/or the Texas
Department of State
Health Services
(DSHS) when
consulting about a
Chagas patient. (6)
f. Contacting,
coordinating, and
following-up with the
Centers for Disease
Control and Prevention
(CDC) when consulting
about a Chagas
patient. (7)

Q3.5 What would be the recommended sequence when managing care of a patient who may have
been exposed to parasite (i.e., exposure to vector in Texas or in endemic areas) within an 8-week period
and presents with acute symptoms? Please rank from 1 to 5 on how you would prioritize (drag and drop).
______ Initiate antitrypanosomal treatment. (1)
______ Request serology testing from a commercial laboratory. (5)
______ Perform other tests for differential diagnosis and refer patient to infectious disease specialist if
necessary. (3)
______ Obtain thorough history to evaluate potential routes of exposure. (4)
______ Consult with the Texas DSHS for guidance on screening and diagnosis protocol. (2)
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Q4.1 KNOWLEDGE The following sections are to help us asses Texas physicians' knowledge about
the cause, transmission, and clinical aspects of Chagas disease.
Q4.2 How does the vector with the parasite transmit Chagas disease to humans?

o

The infected vector penetrates the human host skin during bloodmeal, transmitting parasite
through saliva. (1)

o

Through infected feces of the vector, that is deposited during the bloodmeal, most commonly
when the person rubs the infected feces into the bite wound while scratching the area. (2)

o
o
o

The infected vector regurgitates after bloodmeal, transmitting parasite to the human. (3)
None of the above. (4)
Not sure. (5)

Q4.3 How do the majority of people with Chagas disease living in the United States acquire the infection?

o
o
o
o
o

From drinking unpasteurized juices. (1)
From exposure to vectors while residing in Mexico, Central, or South America. (2)
From their mothers (i.e., congenital transmission). (3)
From another infected person. (4)
Not sure. (5)

Q4.4 Since becoming a reportable condition in the state of Texas in 2013, approximately how many total
Chagas confirmed cases (local and imported) have been reported to the Texas DSHS, between 2013 and
2016?

o
o
o
o
o

Less than 5. (1)
Between 20 and 30. (2)
Between 75 and 100. (3)
More than 1,000. (4)
Not sure. (5)
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Q4.5 Which of the following best describes the clinical course of Chagas disease?

o

Acute for 10 to 30 days following exposure to parasite, is self-limiting in most persons within 2
months, and rarely progresses into the chronic phase. (1)

o

Acute for a week following exposure to parasite. If left untreated, it is a chronic lifelong infection 24 weeks following exposure to parasite. (2)

o

Acute for 1-8 weeks following exposure to parasite; asymptomatic for years to decades in the
majority of infected persons; but becoming symptomatic in a portion of persons infected with parasite.
(3)

o
o

None of the above. (4)
Not sure. (5)

Q4.6 The acute phase of Chagas disease may be characterized by which of the following:

o
o
o
o
o

Fever (1)
Swelling at the site of inoculation (2)
No symptoms (3)
All of the above (4)
Not sure (5)

Q4.7 Approximately what percentage of patients worldwide with chronic Chagas disease eventually
develop the clinical (symptomatic) form of the disease?

o
o
o
o
o

Less than 1%. (1)
Between 20 and 40%. (2)
More than 50%. (3)
None of the above. (4)
Not sure. (5)
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Q4.8 Persons infected with chronic Chagas disease may develop which of the following?

o
o
o
o
o

Cardiac conduction abnormalities and/ or cardiomyopathy. (1)
Megaesophagus and/or megacolon. (2)
Co-clinical manifestations. (3)
All of the above. (4)
Not sure. (5)

Q4.9 Which of the following may occur in patients with chronic Chagas cardiomyopathy?

o
o
o
o
o

None- can present without clinical manifestations and be asymptomatic. (1)
Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, and edema. (2)
Sudden death. (3)
Any of the above. (4)
Not sure. (5)

Q4.10 You should request commercial laboratory diagnostic serology tests, initiate a clinical evaluation of
the patient, and conduct a thorough history in a patient who:

o

Has tested positive for T cruzi during a blood donation or has a sibling or mother who is Chagaspositive. (1)

o
o

Was exposed or potentially exposed to a vector in a period longer than 8 weeks. (2)

Presents with onset of cardiac disease manifestations that are compatible with chronic Chagas
cardiomyopathy. (3)

o
o

All of the above. (4)
Not sure. (5)
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Q4.11 In patients who test positive for Chagas disease after a blood donation or from a laboratory
diagnostics, obtaining a social history is needed to assess potential routes of exposure, including:

o
o
o
o
o

Travel to or residence in areas endemic for Chagas disease. (1)
Previous history of blood transfusions or organ/ tissue transplants. (2)
Possibility of congenital Chagas disease transmission. (3)
All of the above. (4)
Not sure. (5)

Q4.12 Which of the following best describes the method(s) for a confirmatory diagnosis of Chagas
disease?

o
o
o
o
o

Seropostive results from 2 different immunoassays and/or PCR performed at the CDC. (1)
Positive serology from blood screening donations. (2)
Detection of apolipoprotein A-1 (APOA1) upregulation in human serum. (3)
All of the above. (4)
Not sure. (5)
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Q4.13 Which of the following describes the current treatment options for Chagas disease?

o

Benzindazole and nifurtimox are available only under current investigational protocol by the CDC
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic
infection who have no indication of advanced cardiomyopathy. (1)

o

Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 212 years of age and is available commercially. (4)

o
o
o

Nifurtimox is only available by the CDC under investigational protocol. (5)
Second and third choices only. (8)
Not sure. (7)

Q4.14 Should patients with chronic Chagas disease be treated with antitrypanosomal drugs?

o

No, there is no evidence that antitrypanosomal treatment for chronic Chagas disease can be
effective. (1)

o
o

Yes, only patients younger than 5 years of age should be treated for chronic Chagas disease. (2)

Treatment is always recommended for patients up to age 18 years of age and generally
recommended for patients aged 18 to 50. (3)

o
o

Only Chagas disease patients manifesting with moderate to severe cardiomyopathy. (4)
Not sure. (5)

Q5.1 PRACTICES RELATED TO SCREENING, DIAGNOSING, AND TREATING CHAGAS DISEASE
The following are about your practices related to the identification, screening, and treatment of actual
Chagas disease case(s).
Q5.2 Over the past five years since becoming a reportable condition in Texas, have you directly screened
and/ or confirmed a diagnosis for Chagas in patients in your medical care in Texas?

o
o

Yes (1)
No (2)

Display This Question:
If Q5.2 = Yes
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Q5.3 In the past year, how many patients that you suspected for Chagas disease did you screen and test
to confirm diagnosis?
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.4 In the past year, out of those patients that you screened and/ or diagnosed, did any of them receive
a positive confirmatory diagnosis?

o
o

Yes (8)
No (9)

Display This Question:
If Q5.4 = Yes
Q5.5 In the past year, if you screened suspected Chagas patients, how many that were positive were
confirmed by the CDC?
________________________________________________________________

Display This Question:
If Q5.4 = Yes
Q5.6 Please provide additional comments regarding your experience in confirming a Chagas disease
diagnosis:
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q5.2 = Yes
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Q5.7 In the past year, if you have screened suspected Chagas patients, what method(s) did you use to
screen for Chagas disease? Select all that apply.

▢
▢
▢

Physical assessment. (2)
12 lead strip electrocardiogram. (3)
Patient's medical and social history. (4)

Display This Question:
If Q5.2 = Yes
Q5.8 If you screened patients for Chagas disease in the past year, did you consult with local/ county
health departments to coordinate treatment?

o
o

Yes (1)
No (2)

Display This Question:
If Q5.2 = Yes
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Q5.9 If you screened for patients for Chagas disease in the past year, did you coordinate with the CDC to
confirm diagnosis?

o
o

Yes (1)
No (2)

Display This Question:
If Q5.2 = Yes
Q5.10 If you screened and/ or diagnosed patients for Chagas disease in the past year, what method(s)
did you use to confirm diagnosis for Chagas disease? Select all that apply.

▢
▢
▢
▢
▢
▢

PCR performed at the CDC. (1)
Commercial antibody testing- ARUP Lab. (2)
Commercial antibody testing- Mayo Medical Lab. (3)
Commercial antibody testing- Quest Diagnostics. (4)
Commercial antibody testing- Labcorp. (5)
Not sure. (6)

Display This Question:
If Q5.2 = Yes
Q5.11 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you
coordinate with the CDC for treatment?

o
o
o
o

Always (1)
Sometimes (2)
Never (4)
Not sure (3)

Display This Question:
If Q5.2 = Yes
Q5.12 Please provide additional comments regarding your experience obtaining and coordinating
treatment for patient(s):
________________________________________________________________
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________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________

Display This Question:
If Q5.2 = Yes
Q5.13 If you screened and/ or diagnosed patients for Chagas in the past year, how often did you
coordinate with the local health department and/ or Texas DSHS to confirm diagnosis?

o
o
o
o

Always (1)
Sometimes (2)
Never (4)
Not sure (3)

Display This Question:
If Q5.2 = Yes
Q5.14 Please provide additional comments regarding your experience in coordinating with local and state
health department officials when diagnosing a Chagas patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q5.2 = Yes
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Q5.15 If you screened and/ or diagnosed patients for Chagas disease in the past year and diagnosis was
confirmed, please indicate the classification of the case(s):

▢
▢
▢
▢
▢
▢

Acute (1)
Chronic-indeterminate (2)
Chronic-cardiomyopathy (3)
Chronic-gastrointestinal (4)
Other (6)
Not sure (5)

Display This Question:
If Q5.15 = Other
Q5.16 Please describe the classification of the Chagas case(s) if "other" was selected:
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.17 Please indicate the source(s) of transmission:

▢
▢
▢

Locally-acquired (1)
Imported (2)
Not sure (3)

Display This Question:
If Q5.2 = Yes
Q5.18 Did you refer out the patient to any other specialist?

o
o

Yes (1)
No (2)

Display This Question:
If Q5.18 = Yes
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Q5.19 If you did refer out, please indicate to what other physician specialty:
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.20 Was the patient referred to you by another physician?

o
o

Yes (1)
No (2)

Display This Question:
If Q5.20 = Yes
Q5.21 What was the physician specialty/ies that referred the Chagas patient(s) to you?
________________________________________________________________
Q6.1 PHYSICIAN PRACTICES
The following are Chagas disease screening and diagnosing practices related to your medical specialty.
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Q6.2 In general, how often do you consider each of the following as exposure risks for Chagas disease in
your patients?
Never (1)
a. Mother or
sibling with
Chagas
disease. (2)
b. History of
blood
transfusions
or organ/
tissue
transplants.
(3)
c. History of
travel to
Mexico,
Central, and
South
America. (4)
d.
Consumption
of foods or
drinks
contaminated
with the
parasite. (5)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Q6.3 In the past 5 years while practicing medicine in Texas, have provided care to a Chagas disease
patient with a blood donation letter?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.3 = Yes
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Q6.4 How often did you perform the following in patients under your medical care who receive a positive
Chagas diagnosis (i.e., letter) from a blood donation screening?
Never (1)
a. Perform a
physical
examination.
(1)
b. Request
commercial
laboratory
diagnostics.
(5)
c. Review
the patient's
travel
history. (6)
d. Perform
other
screening
tests for
differential
diagnosis
(e.g., ECG).
(7)
e. Refer to a
cardiologist.
(9)
f. Refer to
an infectious
disease
specialist.
(15)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q6.5 In the past 5 years while practicing medicine in Texas, have you had a patient that was exposed to
the vector seek medical care from you?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.5 = Yes
Q6.6 How often did you perform the following in patients under your medical care who were exposed to
a vector?
Never (1)
a. Perform a
physical
examination.
(1)
b. Request
commercial
laboratory
diagnostics.
(2)
c. Review
the patient's
travel
history. (3)
d. Perform
other
screening
tests for
differential
diagnosis
(e.g., ECG).
(4)
e. Refer to
an infectious
disease
specialist.
(11)
f. Consult
with Texas
DSHS to
confirm
vector and/
or presence
of parasite.
(13)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q6.7 In thinking about resources you reference when managing the care of a patient who may potentially
have Chagas disease, how often do you access:
Never (1)
a. Medical
websites
(e.g.,
UpToDate,
MedlinePlus,
etc.) (1)
b. Official
local or
county health
department
websites. (2)
c. The Texas
DSHS
website. (3)
d. The CDC
website. (4)
e. Official
communiques
and health
alerts from
Texas DSHS.
(5)
f. Email alerts
from the
Texas
Medical
Association.
(6)
g. Morbidity
and Mortality
Weekly
Report
(MMWR)
email updates
from the
CDC. (7)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q6.8 Which of the following would you be interested in accessing in order to strengthen your ability to
help patients with Chagas disease? Select all that apply.

▢
▢
▢
▢

Courses (1)
Seminars (2)
Manuals (3)
Other resources (4)

Display This Question:
If Q6.8 = Other resources
Q6.9 If you indicated other, please describe:
________________________________________________________________
Q7.1 DEMOGRAPHICS

The following section is about demographics and your medical practice.

Q7.2 How many years have you been practicing in family or general practice?

o
o
o
o
o

Less than 5 years. (1)
5 to 10 years. (2)
10 to 15 years. (3)
15 to 20 years. (4)
More than 20 years. (5)

Q7.3 Which of the following best describes the current type of medical setting you currently practice in?

o
o
o
o

Private (1)
Teaching (2)
Community (3)
Other (4)

Display This Question:
If Q7.3 = Other
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Q7.4 If other, please describe:
________________________________________________________________
Q7.5 Which of the following best describes the setting where you practice at?

o
o
o

Urbanized area (i.e., 50,000 or more people). (1)
Rural area (i.e., at least 2,500 people but than 50,000). (2)
None of the above. (3)

Q7.6 In your current medical practice, what proportion of total patients you see on average that are
Hispanics/ Latinos?
0 10 20 30 40 50 60 70 80 90 100
Click to write Choice 1 ()

Q7.7 PARTICIPANT DEMOGRAPHICS- PART 2
Q7.8 Are you male or female?

o
o

Male (1)
Female (2)

Q7.9 What is your year of birth? (YYYY)
________________________________________________________________
Q7.10 Please indicate if you received medical training in any of the following places:

o
o
o
o
o

Mexico (1)
Central America (2)
South America (3)
None of the above (4)
Prefer not to answer (5)
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Display This Question:
If Q7.10 = Central America
Q7.11 If you received medical training in Central America, indicate the country:
________________________________________________________________
Display This Question:
If Q7.10 = South America
Q7.12 If you received medical training in South America, indicate the country:
________________________________________________________________
Q8.1
CONCLUSION
Q8.2 Thank you for participating in this questionnaire. We know your time is valuable. Your responses will
remain anonymous and will be used to identify a baseline of knowledge and awareness of Chagas
disease throughout the state. In addition to the questionnaire, we are conducting additional research
via phone interviews with practicing physicians to identify and explore additional barriers related to
screening and diagnosing of Chagas disease in Texas. The goal is to understand the challenges that lead
to missed Chagas diagnosis and frame recommendations to improve awareness and education among
practicing physicians in Texas. Questionnaire responses will be kept separate and confidential if you do
decide to provide your contact information to participate in the phone interviews.
Q8.3 Would you like participate in a 15-minute phone interview?

o
o

Yes, I would like to participate. (1)
No, I decline. (2)

Display This Question:
If Q8.3 = Yes, I would like to participate.

Q8.4 Please provide your email:
________________________________________________________________
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Chagas Disease Questionnaire for Infectious Disease Specialists
SURVEY FLOW
Consent and Eligibility
Definitions
Attitudes (5 Questions)
Knowledge (14 Questions)
Knowledge for Infectious Disease Specialists (5 Questions)
Practices: Actual Chagas (20 Questions)
Practices: Other Activities- Rated (7 Questions)
Participant Demographics (10 Questions)
Questionnaire Conclusion
Q1.2 Thank you for your interest in completing the following online questionnaire. The purpose of this
brief 20-minute questionnaire is to gain a better understanding of Chagas disease awareness, and
practices among cardiologists, infectious disease specialists and family physicians licensed by the Texas
Medical Board.
If you would like to participate in the questionnaire, please continue to the next page.
If you do not wish to participate in the questionnaire, we thank you for your time and interest. You
can close this page now.

Q1.3
INFORMED CONSENT
INVITATION TO TAKE PART
You are invited to take part in a research project called, Chagas Disease Awareness among Physicians in
Texas, conducted by doctoral candidate Gerardo J. Pacheco of the University of Texas Health Science
Center at Houston (UTHealth) School of Public Health. For this research project, he will be called the
Principal Investigator or PI.
Your decision to take part is voluntary. This research project has been reviewed by the Committee for the
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston as
HSC-SPH-17-1039. Although we appreciate your valuable input in this questionnaire, please be advised
that you may refuse to take part or choose to stop taking part, at any time. Additionally, you may also
refuse to answer any question(s).
PROCEDURES
If you agree to take part in this study, you will first confirm your consent by answering the question below.
Once you consent, you will be directed to the questionnaire. It contains sections regarding your attitudes
and perspectives, knowledge, and current practices about Chagas disease in Texas. At the completion of
the questionnaire, you will be prompted to respond whether or not you would like to participate in a 15-
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minute key informant phone interview. You will then be prompted to provide your email address if you
agree to participate. Conversely, if you decline, you will be directed to a page with the answer key to the
Chagas disease knowledge questions.
PURPOSE
The purpose of this research study is to examine the level of knowledge, awareness, and
practices among licensed physicians in Texas regarding screening, diagnosis, and treatment of Chagas
as well as to illustrate the potential for missed cases for Chagas disease diagnosis in Texas.
TIME COMMITMENT
The questionnaire will require 20-25 minutes to complete and will be available for up to two weeks.
BENEFITS
The potential benefits to participating in this study include the self-assessment of Chagas disease, which
will allow you as a physician to understand where your current knowledge deficits might be and if further
resources should be reviewed to be up to date. In more general terms, the results from this study can
help point towards statewide knowledge deficits and gaps that might be present and push towards
recommendations for targeted outreach and workshops (e.g., by specialty, location, etc.).
You may receive no direct benefit from being in the study; however, you taking part may help patients
receive better in the future.
An answer key is provided at the end of the questionnaire for you to review the Chagas disease
knowledge section.
RISKS AND/OR DISCOMFORTS
The risks and discomfort associated with participation in this study are no greater than those ordinarily
encountered in daily life or during the performance of routine exams. The experience is expected to be
informative and interesting and thus a generally positive experience.
Confidentiality: Although every measure will be taken to properly safeguard all data pertaining to this
study, there is a possible risk of breach of confidentiality.
Questionnaire: You may get tired when we are asking you questions or you are completing
questionnaires. You do not have to answer any questions you do not want to answer.
STUDY WITHDRAWAL
Your decision to take part is voluntary. Although we appreciate your valuable input in this questionnaire,
please be advised that you may refuse to take part or choose to stop taking part, at any time. You may
decide to stop taking part in the study at any time, but you must submit in writing to the PI if you choose to
have your responses excluded from the analysis.
COSTS, REIMBURSEMENT AND COMPENSATION
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If you decide to take part in this research study, you will not incur any additional costs.
You will not be paid for taking part in this study.
CONFIDENTIALITY
Identifying information will not appear on records retained by the sponsor, with the exception of your birth
year and your email address if you choose to provide that information for participation in follow-up
interviews. You will not be personally identified in any reports or publications that may result from this
study.
QUESTIONS
If you have questions at any time about this research study, please feel free to contact the PI at (915)
240-2821 as he will be glad to answer your questions. You can contact the PI to discuss problems, voice
concerns, obtain information, and offer input in addition to asking questions about the research.
If you have any questions or concerns about your rights as a research subject, call the Committee for the
Protection of Human Subjects at (713) 500-7943. You may also call the Committee if you wish to discuss
problems, concerns, and questions; obtain information about the research; and offer input about current
or past participation in a research study.
SIGNATURES
Submit your consent below to participate in this research only if you understand the information given to
you about the research and you choose to take part. No signature is required to proceed if you confirm
your consent below. Make sure that any questions have been answered and that you understand the
study.
CPHS STATEMENT: This study (HSC-SPH-17-1039) has been reviewed by the Committee for the
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston. For
any questions about research subject's rights, or to report a research-related injury, call the CPHS at
(713) 500-7943.
Q1.5 If you wish to participate, please indicate below:

o
o

Yes, I agree to participate. (1)
No, I do not wish to participate. (2)

Skip To: End of Survey If Q1.5 = No, I do not wish to participate.
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Q1.6 Are you and MD or DO licensed by the Texas Medical Board to practice in the state of Texas?

o
o

Yes (1)
No (2)

Display This Question:
If Q1.6 = No
Q1.7
Thank you for your interest. However, this questionnaire is intended for physicians.
You may close this page now.
Skip To: End of Survey If Q1.7() Is Displayed

Q1.8 Please indicate your primary medical specialty. If it is not listed below, select “Other”:

o
o
o
o

General Practice/ Family Medicine (1)
Infectious Disease (2)
Cardiology (3)
Other (4)

Display This Question:
If Q1.8 = Other
Q1.9 If Other, please describe:
________________________________________________________________
Q2.1 DEFINITIONS
Definitions used for the purpose of this questionnaire:
Screening: clinical decision-making process or differential diagnosis to determine if further laboratory
diagnostics are required.
Diagnosis: the clinical and serological testing required to confirm Chagas disease.
Vector: Triatomine or Reduviid insect that is able to transmit the parasite T cruzi that causes Chagas
disease.
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Q3.1
ATTITUDES ON CHAGAS DISEASE
The following sections are about your opinions and attitudes regarding Chagas disease.
Q3.2 To what extent do you agree or disagree with the following statements?
Strongly
agree (1)
a. Chagas
disease is under
diagnosed in
Texas (i.e.,
failure to
recognize or
correctly
diagnose a
disease or
condition in a
significant
proportion of the
population). (1)
b. Chagas
disease is
potentially
misdiagnosed
in patients (e.g.,
incorrectly
diagnosed cases
of chronic
Chagas
cardiomyopathy
for idiopathic
cardiomyopathy).
(2)
c. The process
required to
confirm Chagas
disease is
complex and
thus time
consuming. (4)
d. In Texas,
diagnosis and
treatment of
Chagas disease
is a relatively
easy process
with few barriers.
(9)

Somewhat
agree (2)

Neither agree
nor disagree
(3)

Somewhat
disagree (4)

Strongly
disagree (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q3.3 As an infectious disease specialist, to what extent do you agree or disagree with the following
statements?
Strongly agree
(1)
a. My medical
training
prepared me
to recognize
patients who
may need to
be screened
for Chagas
disease. (8)
b. I routinely
screen for
Chagas
disease in
patients who
present with
risk factors.
(11)
c. Accessing
Chagas
disease
treatment is
not a barrier
for the
population I
serve. (12)
d. Chagas
disease
patients are
more likely to
present with
comorbidities
than nonChagas
disease
patients. (14)

Somewhat
agree (2)

Neither agree
or disagree (3)

Somewhat
disagree (4)

Strongly
disagree (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q3.4 How confident are you in performing the following when screening for Chagas disease in your
patient population?
Very confident (1)

Somewhat confident
(2)

Not at all confident (3)

a. Identifying risk
factors for Chagas
disease in patients. (1)

o

o

o

b. Recognizing the
vector that transmits
Chagas disease. (11)

o

o

o

c. Obtaining a patient's
social history to identify
potential risk factors for
Chagas disease. (13)

o

o

o

o

o

o

d. Using
electrocardiogram
(ECG) to screen and
diagnose for chronic
Chagas disease. (12)

Q3.5 How confident are you in performing the following in patients with Chagas disease?
Very confident (1)
a. Contacting and
coordinating with the
local and/or state
health department
when consulting about
a Chagas patient. (1)
b. Contacting,
coordinating, and
following-up with the
Centers for Disease
Control and Prevention
(CDC) when consulting
about a Chagas
patient. (2)
c. Requesting the
Current Procedural
Terminology laboratory
codes for diagnosing
Chagas disease. (4)
d. Continuing to provide
follow-up medical care
to Chagas patients. (5)

Somewhat confident
(2)

Not at all confident (3)

o

o

o

o

o

o

o

o

o

o

o

o

Q3.6 What would be the recommended sequence when managing care of a Chagas patient who has a
blood donation letter? Please rank from 1 to 5 on how you would prioritize (drag and drop).

IRB NUMBER: HSC-SPH-17-1039
Page 7 of 28
IRB APPROVAL DATE: 07/02/2018

______ Coordinate with local health department and Texas Department of State Health Services (DSHS)
to confirm diagnosis. (1)
______ Consult with the CDC to manage patient's treatment protocol. (2)
______ Perform baseline clinical workup that includes physical exam, 12-lead ECG, and additional
testing if warranted. (5)
______ Confirm diagnosis via commercial serology testing. (3)
______ Obtain thorough history to evaluate potential routes of exposure. (4)
Q4.1 KNOWLEDGE The following sections are to help us asses Texas physicians' knowledge about
the cause, transmission, and clinical aspects of Chagas disease.
Q4.2 How does the vector with the parasite transmit Chagas disease to humans?

o

The infected vector penetrates the human host skin during bloodmeal, transmitting parasite
through saliva. (1)

o

Through infected feces of the vector, that is deposited during the bloodmeal, most commonly
when the person rubs the infected feces into the bite wound while scratching the area. (2)

o
o
o

The infected vector regurgitates after bloodmeal, transmitting parasite to the human. (3)
None of the above. (4)
Not sure. (5)

Q4.3 How do the majority of people with Chagas disease living in the United States acquire the infection?

o
o
o
o
o

From drinking unpasteurized juices. (1)
From exposure to vectors while residing in Mexico, Central, or South America. (2)
From their mothers (i.e., congenital transmission). (3)
From another infected person. (4)
Not sure. (5)
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Q4.4 Since becoming a reportable condition in the state of Texas in 2013, approximately how many total
Chagas confirmed cases (local and imported) have been reported to the Texas DSHS, between 2013 and
2016?

o
o
o
o
o

Less than 5. (1)
Between 20 and 30. (2)
Between 75 and 100. (3)
More than 1,000. (4)
Not sure. (5)

Q4.5 Which of the following best describes the clinical course of Chagas disease?

o

Acute for 10 to 30 days following exposure to parasite, is self-limiting in most persons within 2
months, and rarely progresses into the chronic phase. (1)

o

Acute for a week following exposure to parasite. If left untreated, it is a chronic lifelong infection 24 weeks following exposure to parasite. (2)

o

Acute for 1-8 weeks following exposure to parasite; asymptomatic for years to decades in the
majority of infected persons; but becoming symptomatic in a portion of persons infected with parasite.
(3)

o
o

None of the above. (4)
Not sure. (5)

Q4.6 The acute phase of Chagas disease may be characterized by which of the following:

o
o
o
o
o

Fever (1)
Swelling at the site of inoculation (2)
No symptoms (3)
All of the above (4)
Not sure (5)
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Q4.7 In addition to heart failure, what major clinical disorders manifest frequently and concurrently that
lead to chronic Chagas cardiomyopathy?

o
o
o
o
o

Cardiac arrhythmias (1)
Thromboembolism (systemic and pulmonary) (2)
Chest pain syndrome (3)
All of the above (4)
Not sure (5)

Q4.8 Approximately what percentage of patients worldwide with chronic Chagas disease eventually
develop the clinical (symptomatic) form of the disease?

o
o
o
o
o

Less than 1%. (1)
Between 20 and 40%. (2)
More than 50%. (3)
None of the above. (4)
Not sure. (5)

Q4.9 Persons infected with chronic Chagas disease may develop which of the following?

o
o
o
o
o

Cardiac conduction abnormalities and/ or cardiomyopathy. (1)
Megaesophagus and/or megacolon. (2)
Co-clinical manifestations. (3)
All of the above. (4)
Not sure. (5)
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Q4.10 Which of the following may occur in patients with chronic Chagas cardiomyopathy?

o
o
o
o
o

None- can present without clinical manifestations and be asymptomatic. (1)
Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, and edema. (2)
Sudden death. (3)
Any of the above. (4)
Not sure. (5)

Q4.11 You should request commercial laboratory diagnostic serology tests, initiate a clinical evaluation of
the patient, and conduct a thorough history in a patient who:

o

Has tested positive for T cruzi during a blood donation or has a sibling or mother who is Chagaspositive. (1)

o
o

Was exposed or potentially exposed to a vector in a period longer than 8 weeks. (2)

Presents with onset of cardiac disease manifestations that are compatible with chronic Chagas
cardiomyopathy. (3)

o
o

All of the above. (4)
Not sure (5)

Q4.12 In patients who test positive for Chagas disease after a blood donation or from a laboratory
diagnostics, obtaining a social history is needed to assess potential routes of exposure, including:

o
o
o
o
o

Travel to or residence in areas endemic for Chagas disease. (1)
Previous history of blood transfusions or organ/ tissue transplants. (2)
Possibility of congenital Chagas disease transmission. (3)
All of the above. (4)
Not sure. (5)
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Q4.13 Which of the following best describes the method(s) for a confirmatory diagnosis of Chagas
disease?

o
o
o
o
o

Seropostive results from 2 different immunoassays and/or PCR performed at the CDC. (1)
Positive serology from blood screening donations. (2)
Detection of apolipoprotein A-1 (APOA1) upregulation in human serum. (3)
All of the above. (4)
Not sure. (5)

Q4.14 Which of the following describes the current treatment options for Chagas disease?

o

Benzindazole and nifurtimox are available only under current investigational protocol by the CDC
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic
infection who have no indication of advanced cardiomyopathy. (1)

o

Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 212 years of age and is available commercially. (4)

o
o
o

Nifurtimox is only available by the CDC under investigational protocol. (5)
Second and third choices only. (8)
Not sure. (7)

Q4.15 Should patients with chronic Chagas disease be treated with antitrypanosomal drugs?

o

No, there is no evidence that antitrypanosomal treatment for chronic Chagas disease can be
effective. (1)

o
o

Yes, only patients younger than 5 years of age should be treated for chronic Chagas disease. (2)

Treatment is always recommended for patients up to age 18 years of age and generally
recommended for patients aged 18 to 50. (3)

o
o

Only Chagas disease patients manifesting with moderate to severe cardiomyopathy. (4)
Not sure. (5)

Q5.1 SPECIFIC KNOWLEDGE ON CHAGAS DISEASE SCREENING & DIAGNOSTICS The following
questions are specific to you as an infectious disease specialist in identifying the clinical manifestations of
Chagas disease and screening the patient.
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Q5.2 What are the important elements of the clinical evaluation of a newly diagnosed chronic Chagas
patient who is asymptomatic?

o
o

Complete physical examination, complete blood count (CBC), and chemistry panel. (1)

Complete physical examination, electrocardiogram (ECG) with 30 second rhythm strip, and
detailed history. (7)

o

Complete physical examination, ECG with 30 second rhythm strip, chest radiograph, barium
swallow, and detailed history. (8)

o
o

None of the above. (9)
Not sure. (10)

Q5.3 In general, which of the following is typical of chronic Chagas cardiomyopathy?

o
o
o
o
o

Right bundle branch block. (1)
Ventricular tachycardia. (6)
Left anterior fascicular block. (7)
All of the above. (8)
Not sure. (9)

Q5.4 In patients with chronic Chagas cardiomyopathy, cardiac examination typically demonstrates which
of the following?

o
o
o
o
o

Murmurs of mitral and/ or tricuspid regurgitation. (1)
Wide splitting of the second heart sound due to right bundle branch block. (6)
A prominent diffuse apical thrust. (7)
All of the above. (8)
Not sure. (9)
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Q5.5 Reactivation of Chagas disease is a concern for patients who:

o

Are chronically infected and are receiving immuno-suppressive treatment because of organ
transplantation. (1)

o
o
o
o

Are chronically infected and have HIV/AIDS. (2)
Are chronically infected and receive a live-attenuated influenza vaccine. (3)
First and second responses only. (4)
Not sure. (5)

Q5.6 Which of the following describes the current treatment options for Chagas disease?

o

Benzindazole and nifurtimox are available only under current investigational protocol by the CDC
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic
infection who have no indication of advanced cardiomyopathy. (1)

o

Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 212 years of age and is available commercially. (4)

o
o
o

Nifurtimox is only available by the CDC under investigational protocol. (5)
Second and third responses only. (6)
Not sure. (7)

Q6.1 PRACTICES RELATED TO SCREENING, DIAGNOSING, AND TREATING CHAGAS DISEASE
The following are about your practices related to the identification, screening, and treatment of actual
Chagas disease case(s).
Q6.2 Over the past five years since becoming a reportable condition in Texas, have you directly screened
and/ or confirmed a diagnosis for Chagas in patients in your medical care in Texas?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.2 = Yes
Q6.3 In the past year, how many patients that you suspected for Chagas disease did you screen and test
to confirm diagnosis?
________________________________________________________________
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Display This Question:
If Q6.2 = Yes
Q6.4 In the past year, out of those patients that you screened and/ or diagnosed, did any of them receive
a positive confirmatory diagnosis?

o
o

Yes (8)
No (9)

Display This Question:
If Q6.4 = Yes
Q6.5 In the past year, if you screened suspected Chagas patients, how many that were positive were
confirmed by the CDC?
________________________________________________________________
Display This Question:
If Q6.4 = Yes
Q6.6 Please provide additional comments regarding your experience in confirming a Chagas disease
diagnosis:
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Display This Question:
If Q6.2 = Yes
Q6.7 In the past year, if you have screened suspected Chagas patients, what method(s) did you use to
screen for Chagas disease? Select all that apply.

▢
▢
▢

Physical assessment. (2)
12 lead strip electrocardiogram. (3)
Patient's medical and social history. (4)

Display This Question:
If Q6.2 = Yes
Q6.8 If you screened patients for Chagas disease in the past year, did you consult with local/ county
health departments to coordinate treatment?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.2 = Yes
Q6.9 If you screened patients for Chagas disease in the past year, did you coordinate with the CDC to
confirm diagnosis?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.2 = Yes
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Q6.10 If you screened and/ or diagnosed patients for Chagas disease in the past year, what method(s)
did you use to confirm diagnosis for Chagas disease? Select all that apply.

▢
▢
▢
▢
▢
▢

PCR performed at the CDC. (1)
Commercial antibody testing- ARUP Lab. (2)
Commercial antibody testing- Mayo Medical Lab. (3)
Commercial antibody testing- Quest Diagnostics. (4)
Commercial antibody testing- Labcorp. (5)
Not sure. (6)

Display This Question:
If Q6.2 = Yes
Q6.11 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you
coordinate with the CDC for treatment?

o
o
o
o

Always (1)
Sometimes (2)
Never (4)
Not sure (3)

Display This Question:
If Q6.2 = Yes
Q6.12 Please provide additional comments regarding your experience obtaining and coordinating
treatment for patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Display This Question:
If Q6.2 = Yes
Q6.13 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you
coordinate with the local health department and/ or Texas DSHS to confirm diagnosis?

o
o
o
o

Always (1)
Sometimes (2)
Never (4)
Not sure (3)

Display This Question:
If Q6.2 = Yes
Q6.14 Please provide additional comments regarding your experience in coordinating with local and state
health department officials when diagnosing a Chagas patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q6.2 = Yes
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Q6.15 If you screened patients in the past year and diagnosis was confirmed, please indicate the
classification of the case(s):

▢
▢
▢
▢
▢
▢

Acute (1)
Chronic-indeterminate (2)
Chronic-cardiomyopathy (3)
Chronic-gastrointestinal (4)
Other (6)
Not sure (5)

Display This Question:
If Q6.15 = Other
Q6.16 Please describe the classification of the Chagas case(s) if "other" was selected:
________________________________________________________________
Display This Question:
If Q6.2 = Yes
Q6.17 Please indicate the source(s) of transmission:

▢
▢
▢

Locally-acquired (1)
Imported (2)
Not sure (3)

Display This Question:
If Q6.2 = Yes
Q6.18 Did you refer out the patient to any other specialist?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.18 = Yes
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Q6.19 If you did refer out, please indicate to what other physician specialty:
________________________________________________________________
Display This Question:
If Q6.2 = Yes
Q6.20 Was the patient referred to you by another physician?

o
o

Yes (1)
No (2)

Display This Question:
If Q6.20 = Yes
Q6.21 What was the physician specialty/ies that referred the Chagas patient(s) to you?
________________________________________________________________
Q7.1 PHYSICIAN PRACTICES
The following are Chagas disease screening and diagnosing practices related to your medical specialty.
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Q7.2 In general, how often do you consider each of the following as exposure risks for Chagas disease in
your patients?
Never (1)
a. Mother or
sibling with
Chagas
disease. (2)
b. History of
blood
transfusions
or organ/
tissue
transplants.
(3)
c. Travel to
Mexico,
Central, or
South
America. (4)
d.
Consumption
foods or
drinks
contaminated
with the
parasite. (5)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q7.3 In general, how often do you perform the following in patients under your medical care who present
with idiopathic cardiomyopathy?
Never (1)
a. Review the
patient's travel
history. (3)
b. Look for signs
of cardiac
arrhythmias that
may arise due to
chronic Chagas
cardiomyopathy.
(5)
c. Evaluate
patient's
cardiopulmonary
function (i.e.,
exercise stress
test). (17)
d. Perform
cardiovascular
testing (chest xray,
echocardiogram,
etc.) to asses
myocardial
damage. (2)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

Q7.4 In the past 5 years while practicing medicine in Texas, have you provided care to a Chagas disease
patient with a blood donation letter?

o
o

Yes (1)
No (2)

Display This Question:
If Q7.4 = Yes
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Q7.5 In the past 5 years while practicing in Texas, how often did you perform the following in patients
under your medical care who received a positive Chagas diagnosis (i.e., letter) from a blood donation
screening?
Never (1)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

a. Review the
patient's travel
history. (6)

o

o

o

o

o

o

b. Request
serology to
confirm Chagas
diagnosis. (5)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

e. Consult with
the Texas DSHS
to manage
treatment. (9)

o

o

o

o

o

o

f. Consult with
the CDC to
manage
treatment. (21)

o

o

o

o

o

o

c. Evaluate
patient's
cardiopulmonary
function (i.e.,
exercise stress
test). (7)
d. Perform
cardiovascular
testing (chest xray,
echocardiogram,
etc.) to asses
myocardial
damage. (20)
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Q7.6 In thinking about resources you reference when managing the care of a patient who may potentially
have Chagas disease, how often do you access:
Never (1)
a. Medical
websites
(e.g.,
UpToDate,
MedlinePlus,
etc.) (1)
b. Official
local or
county health
department
websites. (2)
c. The Texas
DSHS
website. (3)
d. The CDC
website. (4)
e. Official
communiques
and health
alerts from
Texas DSHS.
(5)
f. Email alerts
from the
Texas
Medical
Association.
(6)
g. Morbidity
and Mortality
Weekly
Report
(MMWR)
email updates
from the
CDC. (7)

Rarely (2)

Sometimes
(3)

Often (4)

Always (5)

N/A (6)

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o

o
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Q7.7 Which of the following would you be interested in accessing in order to strengthen your ability to
help patients with Chagas disease? Select all that apply.

▢
▢
▢
▢

Courses (1)
Seminars (2)
Manuals (3)
Other resources (4)

Display This Question:
If Q7.7 = Other resources
Q7.8 If you indicated other, please describe:
________________________________________________________________
Q8.1 DEMOGRAPHICS

The following section is about demographics and your medical practice.

Q8.2 How many years have you been practicing in family or general practice?

o
o
o
o
o

Less than 5 years. (1)
5 to 10 years. (2)
10 to 15 years. (3)
15 to 20 years. (4)
More than 20 years. (5)

Q8.3 Which of the following best describes the current type of medical setting you currently practice in?

o
o
o
o

Private (1)
Teaching (2)
Community (3)
Other (4)
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Display This Question:
If Q8.3 = Other
Q8.4 If other, please describe:
________________________________________________________________
Q8.5 Which of the following best describes the setting where you practice at?

o
o
o

Urbanized area (i.e., 50,000 or more people). (1)
Rural area (i.e., at least 2,500 people but than 50,000). (2)
None of the above. (3)

Q8.6 In your current medical practice, what proportion of total patients you see on average that are
Hispanics/ Latinos?
0 10 20 30 40 50 60 70 80 90 100
Click to write Choice 1 ()

Q8.7 PARTICIPANT DEMOGRAPHICS- PART 2
Q8.8 Are you male or female?

o
o

Male (1)
Female (2)

Q8.9 What is your year of birth? (YYYY)
________________________________________________________________
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Q8.10 Please indicate if you received medical training in any of the following places:

o
o
o
o
o

Mexico (1)
Central America (2)
South America (3)
None of the above (4)
Prefer not to answer (5)

Display This Question:
If Q8.10 = Central America
Q8.11 If you received medical training in Central America, indicate the country:
________________________________________________________________
Display This Question:
If Q8.10 = South America
Q8.12 If you received medical training in South America, indicate the country:
________________________________________________________________
Q9.1
CONCLUSION
Q9.2 Thank you for participating in this questionnaire. We know your time is valuable. Your responses will
remain anonymous and will be used to identify a baseline of knowledge and awareness of Chagas
disease throughout the state. In addition to the questionnaire, we are conducting additional research
via phone interviews with practicing physicians to identify and explore additional barriers related to
screening and diagnosing of Chagas disease in Texas. The goal is to understand the challenges that lead
to missed Chagas diagnosis and frame recommendations to improve awareness and education among
practicing physicians in Texas. Questionnaire responses will be kept separate and confidential if you do
decide to provide your contact information to participate in the phone interviews.
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Q9.3 Would you like participate in a 15-minute phone interview?

o
o

Yes, I would like to participate. (1)
No, I decline. (2)

Display This Question:
If Q9.3 = Yes, I would like to participate.

Q9.4 Please provide your email:
________________________________________________________________
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Appendix C: Semi-Structured Interview Scripts and Forms
Date: _____ / ______ / _______

Time: ______________

Study ID: ___ ___ ____ ____

Semi-structured Interview Script for Physicians: Managed Care of Chagas Patients
Introduction
•

Good morning/ afternoon. Thank you for your time. My name is Jerry Pacheco. I’m a doctoral
candidate at the UT School of Public Health.

•

As part of my doctoral dissertation, I will focus on Chagas disease in Texas and the level of
awareness among healthcare providers. I will be collecting primary data for my research, as part of
my aims, I am collecting quantitative data (that is data from online questionnaires) as well as
qualitative data—that is the data I hope to collect today through this interview.

•

We hope that through this interview, we can dive further and explore challenges and barriers that
physicians have experienced that way we can frame recommendations for improving outreach,
education, and resources to physicians in Texas about Chagas disease so that the disease is
diagnosed and managed on time.

•

Thank you for agreeing to participate.

Informed consent
Explain the risks/ benefits and confidentiality and how results will be used (refer them to form)
• I emailed a copy of the consent. Please review and keep for your records. The risks and discomfort

associated with participation in this study are no greater than those ordinarily encountered in daily
life or during the performance of routine exams. The experience is expected to be informative and
interesting and thus a generally positive experience.

•

Your decision to take part is voluntary. You may decide to stop taking part in the study at any time.

•

I would like to make am audio recording of our discussion, so that I can have an accurate record of
the information that you provide to me.

•

This study (HSC-SPH-17-1039) has been reviewed by the Committee for the Protection of Human
Subjects of the University of Texas Health Science Center at Houston.

•

If you have any questions refer to the Informed Consent Form I email you for the university research
office’s contact information..

Confirm provider specialty and/ or treatment of CD patients
•

Can you confirm your specialty?

Provider Specialty:

241

 Infectious Disease
 Cardiology
 Other: ____________________
Demographics and type of practice
1.

How many years of have you been in your primary specialization? _________________________________

2.

How would you describe your current medical practice?
a.

3.

b.

institution, community clinic, private

rural or urban

Did you receive any medical training or practice in Mexico, Central or South America? Please
describe:
______________________________________________________________________________________
______________________________________________________________________________________

Guiding Questions
I will be asking questions regarding the continuum of care, which includes screening, diagnosis, treatment,
and follow-up of care. For the purpose of my research and this interview:
Screening: is the clinical, decision-making process or differential diagnosis to determine if further
laboratory diagnosis are required.
Diagnosis: the clinical and serological testing required to confirm Chagas disease.
1.

Can you describe your experience in managing the care of a Chagas disease patient?
a.

How many cases have you managed? Screened: ____ Diagnosed: ____ Treated:____ Total: ____
i. Were they in Texas? Mexico? Central America? South America?

ii. When? ______________________________________________________________
b.

How did that patient(s) come to your care? ____________________________________________
_______________________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________

c.

Can you provide a brief summary, from your recollection, of the case study/ studies?
i. Local:

ii. Acute:

Imported:

Indeterminate:

Chronic:

iii. Patient demographics (age, sex, Ethnicity/ race)
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________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
d.

________________________________________________________________________

What resources did you review or whom did you consult with to better understand the
process to screen, diagnose, or treat a Chagas disease patient?
_____________________________________
______________________________________________________________________________

e.

______________________________________________________________________________

What was the most important lesson(s) learned from your experience(s)?
_______________________________________________________________________________
_______________________________________________________________________________

f.

What were the most challenging aspects or barriers in delivering care to your patient with
Chagas disease? ________________________________________________________________________
_______________________________________________________________________________

_______________________________________________________________________________

i. Screening specific: ________________________________________________________

ii. Diagnosis specific: _________________________________________________________

2.

iii. Treatment specific: ________________________________________________________

Did you ever consider a Chagas disease diagnosis prior to your first experience in managing a
Chagas patient?
a.

b.

Why? Why not? _________________________________________________________________
_______________________________________________________________________________
______________________________________________________________________________

What was your level of knowledge and skills in diagnosing patients with Chagas disease
before your experience(s) managing your first Chagas disease patient(s)?
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_______________________________________________________________________________
_______________________________________________________________________________
c.

What was your level of knowledge and skills in diagnosing patients with Chagas disease
after your experience(s) managing your first Chagas disease patient(s)?
_______________________________________________________________________________
______________________________________________________________________________

d.

Looking back, what are some considerations or resources that you now know of that could
have been helpful during your first experience managing the care of a Chagas disease
patient?
_______________________________________________________________________________
_______________________________________________________________________________

e.

Did you have sufficient education/ training to be able to screen, diagnose, and/ or treat
Chagas disease patients? ________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________

3.

Do you think that Chagas disease is a bigger problem in Texas than other states in the U.S.?
a.

Why? Why not? __________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________

b.

Do we need to increase the level of outreach and education that we provide to physicians in
Texas? _______________________________________________________________________________
_______________________________________________________________________________

c.

How can we increase communication to physicians in Texas for them to better understand
Chagas disease? _______________________________________________________________________
______________________________________________________________________________
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4.

What proportion of Hispanic/ Latino population do you serve in your medical practice?
_______________
a.

What is your Spanish fluency in terms of managing Hispanic/Latino patients with Chagas
disease?
______________________________________________________________________________
______________________________________________________________________________

b.

How do you handle patients with limited English fluency? ________________________________
_______________________________________________________________________________
_______________________________________________________________________________

5.

Are there any additional comments, suggestions, or feedback you would like to share?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

6.

Lastly, are there any colleagues, within your specialty (cardiology or ID) in Texas that I may reach
out and interview about their experiences managing the care of Chagas disease patients?
a.

Name: _________________________________________________________________________

c.

Phone Number: __________________________________________________________________

b.

Summary

d.

Email: __________________________________________________________________________

Physician Specialty: _______________________________________________________________

Recap what was discussed.
Conclusion

Thank the participant for their time and remind them about confidentiality and how important this
qualitative data will be in framing the results from the survey and framing recommendations.

Thank you for your time. I know your time is valuable and your responses will help frame recommendations
to address current barriers and challenges that might prevent or delay the diagnosis of Chagas disease.

.
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Date: _____ / ______ / _______

Time: ______________

Study ID: ___ ___ ____ ____

Semi-structured Interview Script for Physicians: Not Managed Care of Chagas Patients
Introduction
•

Good morning/ afternoon. Thank you for your time. My name is Jerry Pacheco. I’m a doctoral
candidate at the UT School of Public Health.

•

As part of my doctoral dissertation, I will focus on Chagas disease in Texas and the level of
awareness among healthcare providers. I will be collecting primary data for my research, as part of
my aims, I am collecting quantitative data (that is data from online questionnaires) as well as
qualitative data—that is the data I hope to collect today through this interview.

•

We hope that through this interview, we can dive further and explore challenges and barriers that
physicians have experienced that way we can frame recommendations for improving outreach,
education, and resources to physicians in Texas about Chagas disease so that the disease is
diagnosed and managed on time.

•

Thank you for agreeing to participate.

Informed consent
Explain the risks/ benefits and confidentiality and how results will be used (refer them to form)
• I emailed a copy of the consent. Please review and keep for your records. The risks and discomfort

associated with participation in this study are no greater than those ordinarily encountered in daily
life or during the performance of routine exams. The experience is expected to be informative and
interesting and thus a generally positive experience.

•

Your decision to take part is voluntary. You may decide to stop taking part in the study at any time.

•

I would like to make am audio recording of our discussion, so that I can have an accurate record of
the information that you provide to me.

•

This study (HSC-SPH-17-1039) has been reviewed by the Committee for the Protection of Human
Subjects of the University of Texas Health Science Center at Houston.

•

If you have any questions refer to the Informed Consent Form I email you for the university research
office’s contact information.

Confirm provider specialty and/ or treatment of CD patients
•

Can you confirm your specialty?

Provider Specialty:
 Infectious Disease
 Cardiology
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 Other: ____________________
Demographics and type of practice
4.

How many years of have you been in your primary specialization? _________________________________

5.

How would you describe your current medical practice?
a.

6.

b.

institution, community clinic, private, other: ________________

rural or urban

Did you receive any medical training or practice in Mexico, Central or South America? Please
describe:
______________________________________________________________________________________
______________________________________________________________________________________

Guiding Questions
I will be asking questions regarding the continuum of care, which includes screening, diagnosis, treatment,
and follow-up of care. For the purpose of my research and this interview:
Screening: is the clinical, decision-making process or differential diagnosis to determine if further
laboratory diagnosis are required.
Diagnosis: the clinical and serological testing required to confirm Chagas disease.
7.

Can you confirm whether you have directly managed the care of a Chagas disease patient?
a.

Can you please describe your experience(s) with Chagas disease? __________________________
______________________________________________________________________________
______________________________________________________________________________

b.

What resources would you use, or whom did you consult with to better understand the
process to screen, diagnose, or treat a Chagas disease patient?
_____________________________________
______________________________________________________________________________

c.

______________________________________________________________________________

What do you think are the most challenging aspects or barriers in delivering care to a
patient with Chagas disease in Texas?
________________________________________________________________________
_______________________________________________________________________________
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_______________________________________________________________________________

i. Screening specific: ________________________________________________________

ii. Diagnosis specific: _________________________________________________________

8.

iii. Treatment specific: ________________________________________________________

Have you ever considered a Chagas disease diagnosis?
a.

b.

Why? Why not? _________________________________________________________________
_______________________________________________________________________________
______________________________________________________________________________

What is your current level of knowledge and skills in screening and diagnosing patients
with Chagas disease?
_______________________________________________________________________________
_______________________________________________________________________________

c.

Do you have sufficient education/ training to be able to screen, diagnose, and/ or treat
Chagas disease patients? ________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________

9.

Do you think that Chagas disease is a bigger problem in Texas than other states in the U.S.?
a.

Why? Why not? __________________________________________________________________
_______________________________________________________________________________
_______________________________________________________________________________

b.

Do we need to increase the level of outreach and education that we provide to physicians in
Texas? _______________________________________________________________________________
_______________________________________________________________________________

c.

How can we increase communication to physicians in Texas for them to better understand
Chagas disease? _______________________________________________________________________
______________________________________________________________________________
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10. What proportion of Hispanic/ Latino population do you serve in your medical practice?
_______________
a.

What is your Spanish fluency in terms of managing Hispanic/Latino patients with Chagas
disease?
______________________________________________________________________________
______________________________________________________________________________

b.

How do you handle patients with limited English fluency? ________________________________
_______________________________________________________________________________
_______________________________________________________________________________

11. Are there any additional comments, suggestions, or feedback you would like to share?
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
12. Lastly, are there any colleagues, within your specialty (cardiology or ID) in Texas that I may reach
out and interview about their experiences managing the care of Chagas disease patients?
a.

Name: _________________________________________________________________________

c.

Phone Number: __________________________________________________________________

b.

Summary

d.

Email: __________________________________________________________________________

Physician Specialty: _______________________________________________________________

Recap what was discussed.
Conclusion

Thank the participant for their time and remind them about confidentiality and how important this
qualitative data will be in framing the results from the survey and framing recommendations.

Thank you for your time. I know your time is valuable and your responses will help frame recommendations
to address current barriers and challenges that might prevent or delay the diagnosis of Chagas disease.
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Appendix D: Table of ICD-9 CM and ICD-10 CM Chagas and Cardiomyopathy
Codes
ICD

ICD
Code

Code Description

ICD-9
ICD-10

0860
B570

ICD-10

B572

ICD-10

B571

ICD-9

0861

ICD-10

B575

ICD-9

0862

ICD-9

4148

ICD-10
ICD-9
ICD-9

I255
42291
4254

ICD-10
ICD-10
ICD-9

I425
I428
4258

ICD-10

I429

Chagas with heart involvement
Acute Chagas with heart
involvement
Chronic Chagas with heart
involvement
Acute Chagas without heart
involvement
Chagas with other organ
involvement
Chagas disease (chronic) with
other organ involvement
Chagas without mention of
organ involvement
Other chronic ischemic heart
disease
Ischemic cardiomyopathy
Idiopathic myocarditis
Cardiomyopathy, includes
idiopathic
Other restrictive cardiomyopathy
Other cardiomyopathies
Cardiomyopathy, excluding
Chagas
Cardiomyopathy, unspecified
Combined Chagas DX
Combined Heart-Related DX
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Total

2013

2014

2015

2016

42

12

22

8

-

0

-

-

0

0

37

-

-

10

27

1

-

-

1

0

0

0

0

0

-

0

-

-

0

0

21

4

11

6

-

118,206

42,172

42,757

33,277

-

55,668
384

127

141

10,660
116

45,008
-

150,207

52,970

54,302

42,935

-

0
0

-

-

0
0

0
0

5,666

2,092

1,956

1,618

-

48,461

-

-

9,553

38,908

101
378,592

Appendix E: Table of Mapped ICD Counts, by County

Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Anderson

0

0

0

978

Andrews

0

0

0

157

Angelina

0

0

0

1,704

Aransas

0

0

0

366

Archer

0

0

0

129

Armstrong

0

0

0

10

Atascosa

0

0

0

849

Austin

0

0

0

609

Bailey

0

0

0

96

Bandera

0

0

0

417

Bastrop

0

0

0

1,483

Baylor

0

0

0

73

Bee

0

0

0

521

Bell

0

0

0

3,762

Bexar

7

1

8

21,195

Blanco

0

1

1

205

Borden

0

0

0

2

Bosque

0

1

1

168

Bowie

0

0

0

2,066

Brazoria

1

0

1

3,954

Brazos

0

0

0

2,705

Brewster

0

0

0

99

Briscoe

0

0

0

7

Brooks

0

0

0

136

Brown

0

0

0

820

Burleson

0

0

0

652

Burnet

0

0

0

736

Caldwell

0

0

0

777

Calhoun

0

0

0

355

Callahan

0

0

0

347

Cameron

3

0

3

8,567

Camp

0

0

0

420

Carson

0

0

0

90

Cass

0

0

0

705

Castro

0

0

0

53

County Name
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Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Chambers

0

0

0

408

Cherokee

0

0

0

1,153

Childress

0

0

0

65

Clay

0

0

0

214

Cochran

0

0

0

50

Coke

0

0

0

62

Coleman

0

0

0

170

Collin

2

0

2

7,913

Collingsworth

0

0

0

38

Colorado

0

0

0

561

Comal

0

0

0

1,397

Comanche

0

0

0

216

Concho

0

0

0

44

Cooke

0

0

0

586

Coryell

0

0

0

759

Cottle

0

0

0

24

Crane

0

0

0

28

Crockett

0

0

0

57

Crosby

0

0

0

56

Culberson

0

0

0

46

Dallam

0

0

0

100

Dallas

21

5

26

34,526

Dawson

0

0

0

97

Deaf Smith

0

0

0

149

Delta

0

0

0

112

Denton

7

1

8

7,218

DeWitt

0

0

0

335

Dickens

0

0

0

29

Dimmit

0

0

0

223

Donley

0

0

0

59

Duval

0

0

0

219

Eastland

0

0

0

337

Ector

0

0

0

2,177

Edwards

0

0

0

35

Ellis

0

0

0

2,482

El Paso

0

0

0

7,777

Erath

0

0

0

451

County Name
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Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Falls

0

0

0

195

Fannin

0

0

0

704

Fayette

0

0

0

651

Fisher

0

0

0

58

Floyd

0

0

0

61

Foard

0

0

0

28

Fort Bend

0

0

0

6,064

Franklin

0

0

0

131

Freestone

0

0

0

219

Frio

0

0

0

276

Gaines

0

0

0

110

Galveston

0

0

0

7,049

Garza

0

0

0

79

Gillespie

0

0

0

404

Glasscock

0

0

0

7

Goliad

0

0

0

166

Gonzales

0

0

0

268

Gray

0

0

0

565

Grayson

0

0

0

2,578

Gregg

0

0

0

2,233

Grimes

0

0

0

833

Guadalupe

0

0

0

1,070

Hale

0

0

0

369

Hall

0

0

0

63

Hamilton

0

0

0

72

Hansford

0

0

0

51

Hardeman

0

0

0

92

Hardin

0

0

0

962

Harris

21

4

25

59,118

Harrison

0

0

0

769

Hartley

0

0

0

8

Haskell

0

0

0

111

Hays

0

0

0

2,068

Hemphill

0

0

0

35

Henderson

0

0

0

1,882

Hidalgo

0

0

0

11,020

Hill

0

0

0

447

County Name
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Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Hockley

0

0

0

266

Hood

0

0

0

907

Hopkins

0

0

0

553

Houston

0

0

0

448

Howard

0

0

0

951

Hudspeth

0

0

0

46

Hunt

0

0

0

1,624

Hutchinson

0

0

0

351

Irion

0

0

0

20

Jack

0

0

0

150

Jackson

0

0

0

271

Jasper

0

0

0

589

Jeff Davis

0

0

0

17

Jefferson

0

2

2

4,664

Jim Hogg

0

0

0

70

Jim Wells

0

0

0

653

Johnson

5

3

8

3,836

Jones

0

0

0

272

Karnes

0

0

0

179

Kaufman

0

0

0

1,505

Kendall

0

0

0

544

Kenedy

0

0

0

5

Kent

0

0

0

7

Kerr

0

0

0

899

Kimble

0

0

0

49

King

0

0

0

2

Kinney

0

0

0

50

Kleberg

0

0

0

433

Knox

0

0

0

66

Lamar

0

0

0

1,416

Lamb

0

0

0

126

Lampasas

0

0

0

459

La Salle

0

0

0

127

Lavaca

0

0

0

420

Lee

0

0

0

380

Leon

0

0

0

502

Liberty

0

0

0

1,846

County Name
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Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Limestone

0

0

0

234

Lipscomb

0

0

0

38

Live Oak

0

0

0

159

Llano

0

0

0

440

Loving

0

0

0

-

Lubbock

0

0

0

2,781

Lynn

0

0

0

58

McCulloch

0

0

0

191

McLennan

0

0

0

1,734

McMullen

0

0

0

18

Madison

0

0

0

344

Marion

0

0

0

220

Martin

0

0

0

70

Mason

0

0

0

54

Matagorda

0

0

0

705

Maverick

0

0

0

1,802

Medina

0

0

0

729

Menard

0

0

0

35

Midland

0

0

0

1,629

Milam

0

0

0

444

Mills

0

0

0

41

Mitchell

0

0

0

116

Montague

0

0

0

431

Montgomery

2

0

2

7,536

Moore

0

0

0

152

Morris

0

0

0

263

Motley

0

0

0

19

Nacogdoches

0

0

0

903

Navarro

0

0

0

855

Newton

0

0

0

157

Nolan

0

0

0

336

Nueces

0

0

0

4,300

Ochiltree

0

0

0

85

Oldham

0

0

0

15

Orange

0

0

0

1,586

Palo Pinto

0

0

0

612

Panola

0

0

0

405

County Name
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Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Parker

0

0

0

1,795

Parmer

0

0

0

73

Pecos

0

0

0

119

Polk

0

0

0

944

Potter

0

0

0

1,764

Presidio

0

0

0

59

Rains

0

0

0

258

Randall

0

0

0

1,337

Reagan

0

0

0

39

Real

0

0

0

74

Red River

0

0

0

372

Reeves

0

0

0

123

Refugio

0

0

0

129

Roberts

0

0

0

13

Robertson

0

0

0

522

Rockwall

0

0

0

840

Runnels

0

0

0

179

Rusk

0

0

0

812

Sabine

0

0

0

193

San Augustine

0

0

0

200

San Jacinto

0

0

0

451

San Patricio

0

0

0

897

San Saba

0

0

0

105

Schleicher

0

0

0

33

Scurry

0

0

0

177

Shackelford

0

0

0

65

Shelby

0

0

0

405

Sherman

0

0

0

26

Smith

0

0

0

4,176

Somervell

0

0

0

92

Starr

0

0

0

850

Stephens

0

0

0

197

Sterling

0

0

0

10

Stonewall

0

0

0

25

Sutton

0

0

0

67

Swisher

0

0

0

119

Tarrant

2

0

2

28,002

County Name

256

Chagas, Heart

Chagas,
Other

Chagas, Total

Non-Chagas Heart- Related
Total

Taylor

0

0

0

2,711

Terrell

0

0

0

13

Terry

0

0

0

158

Throckmorton

0

0

0

36

Titus

0

0

0

337

Tom Green

0

0

0

1,760

Travis

2

1

3

11,941

Trinity

0

0

0

360

Tyler

0

0

0

360

Upshur

0

0

0

595

Upton

0

0

0

31

Uvalde

0

0

0

573

Val Verde

0

0

0

700

Van Zandt

0

0

0

1,118

Victoria

0

0

0

2,038

Walker

0

0

0

1,735

Waller

0

0

0

619

Ward

0

0

0

123

Washington

0

0

0

676

Webb

0

0

0

2,365

Wharton

0

0

0

847

Wheeler

0

0

0

74

Wichita

0

0

0

3,035

Wilbarger

5

1

6

345

Willacy

0

0

0

458

Williamson

0

0

0

3,806

Wilson

0

0

0

402

Winkler

0

0

0

90

Wise

0

0

0

1,325

Wood

0

0

0

1,126

Yoakum

0

0

0

54

Young

0

0

0

366

Zapata

0

0

0

175

Zavala

0

0

0

279

County Name

78

20

257

98

366,575

Appendix F: Raw Responses for Knowledge Questions, All Questionnaires

Questionnaire Item

258

Q1. How does the vector with the parasite transmit CD to
humans?
Infected vector penetrates the human host skin during
bloodmeal, transmitting parasite through saliva
♦Through infected feces of the vector, that is deposited during
bloodmeal, most commonly when the person rubs the infected
feces into the bite wound while scratching the area
The infected vector regurgitates after bloodmeal, transmitting
parasite to human
None of the above
Not sure
No response
Q2. How do the majority of people with CD living in the U.S.
acquire the infection?
From drinking unpasteurized juices
♦From exposure to vectors while residing in Mexico, Central,
or South America
From their mothers
From another infected person
Not sure
No response
Q3. Total number of reported CD cases to DSHS
Less than 5

Total
n= 43
(%)

Family or
General
Practice
n= 21 (%)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

5 (11.6)

4 (19.1)

1 (5.3)

-

23 (53.5)

6 (28.6)

15 (79.0)

2 (66.7)

2 (4.7)

1 (4.8)

1 (5.3)

-

4 (9.3)
9 (20.9)

4 (8.0)
6 (28.6)

2 (10.5)

1 (33.3)

-

-

-

-

29 (67.4)

11 (52.4)

16 (84.2)

2 (66.7)

5 (11.6)
9 (20.9)

4 (19.1)
6 (28.6)

1 (5.3)
2 (10.5)

1 (33.3)

-

-

-

-

Questionnaire Item

259

Between 20 and 30
♦Between 75 and 100
More than 1,000
Not sure
No response
Q4. Clinical course for CD
Acute for 10-30 days following exposure to parasite, is selflimiting in most persons within 2 months, and rarely progresses
into the chronic phase
Acute for a week following exposure to parasite. If left
untreated, it is a chronic lifelong infection 2-4 weeks following
exposure to parasite.
♦Acute 1-8 weeks following exposure to parasite;
asymptomatic for years to decades in the majority of infected
persons; but becoming symptomatic in a portion of persons
infected with parasite
None of the above
Not sure
No response
Q5. Characteristic symptoms for acute phase of CD
Fever
Swelling at the site of inoculation
No symptoms
♦All of the above

4 (9.3)
7 (16.3)
6 (14.0)
17 (39.5)
9 (20.9)

Family or
General
Practice
n= 21 (%)
1 (4.0)
4 (19.1)
2 (9.5)
8 (38.1)
6 (28.6)

Infectious
Disease
n= 19
(%)
3 (15.8)
3 (15.8)
3 (15.8)
8 (42.1)
2 (10.5)

3 (7.0)

2 (9.5)

-

1 (33.3)

1 (2.3)

-

-

1 (33.3)

21 (48.8)

7 (33.3)

14 (73.7)

-

8 (18.6)
14 (32.6)

6 (28.6)
10 (40.0)

2 (10.5)
3 (15.8)

1 (33.3)

1 (2.3)
5 (11.6)

1 (4.8)
1 (4.8)

-

-

-

23 (53.5)

10 (47.6)

4 (21.1)
11 (57.9)

Total
n= 43
(%)

Cardiology
n= 3
(%)
1 (33.3)
1 (33.3)
1 (33.3)

2 (66.7)

Questionnaire Item

260

Not sure
No response
Q6. Proportion of patients with chronic CD that develop
symptoms
Less than 1%
♦Between 20% and 40%
More than 50%
None of the above
Not sure
No response
Q7. Symptoms that may develop in patients with chronic CD
Cardiac conduction abnormalities and/ or cardiomyopathy
Megaesophagus and/ or megacolon
Co-clinical manifestations
♦All of the above
Not sure
No response
Q8. Chronic CD cardiomyopathy possible manifestations
None- can present without clinical manifestations and be
asymptomatic
Dyspnea on exertion, fatigue, palpitations, dizziness, syncope,
and edema
Sudden death
♦Any of the above
Not sure

4 (9.3)
10 (23.3)

Family or
General
Practice
n= 21 (%)
3 (14.3)
6 (28.6)

Infectious
Disease
n= 19
(%)
1 (5.3)
3 (15.8)

7 (16.3)
14 (32.6)
2 (4.7)
10 (23.3)
10 (23.3)

5 (23.8)
3 (14.3)
1 (4.8)
6 (28.6)
6 (28.6)

1 (5.3)
11 (57.9)
1 (5.3)
3 (15.8)
3 (15.8)

1 (33.3)
1 (33.3)
1 (33.3)

2 (4.7)
1 (2.3)
28 (65.1)
2 (4.7)
10 (23.3)

13 (61.9)
2 (9.5)
6 (28.6)

1 (5.3)
1 (5.3)
14 (73.7)
3 (15.8)

1 (33.3)
1 (33.3)
1 (33.3)

-

-

-

-

1 (2.3)

-

-

1 (33.3)

30 (69.8)
2 (4.7)

13 (52.0)
2 (8.0)

16 (84.2)
-

1 (33.3)
-

Total
n= 43
(%)

Cardiology
n= 3
(%)
1 (33.3)

Questionnaire Item

261

No response
Q9. Request commercial lab diagnostic serology tests, initiate a
clinical evaluation of the patient, and conduct a thorough
history in a patient who:
Has tested positive for parasite during blood donation or has a
sibling or mother who is CD-positive
Was exposed or potentially exposed to a vector in a period
longer than 8 weeks
Presents with onset of cardiac disease manifestations that are
compatible with chronic CD cardiomyopathy
♦All of the above
Not sure
No response
Q10. In patients who test positive for CD disease after blood
donation or from a lab diagnostic, obtaining social history is
needed to assess potential routes of exposure, including;
Travel to residence in areas endemic for CD disease
Previous history of blood transfusions or organ/ tissue
transplants
Possibility of congenital CD disease transmission
♦All of the above
Not sure
Not response
Q11. Which of the following best describes the method(s) for
confirmatory diagnosis of CD?

14 (32.6)

Family or
General
Practice
n= 21 (%)
10 (40.0)

Infectious
Disease
n= 19
(%)
3 (15.8)

1 (2.3)

-

-

1 (33.3)

-

-

-

-

-

-

-

-

26 (60.5)
3 (7.0)
13 (30.2)

13 (61.9)
2 (9.5)
6 (28.6)

12 (63.2)
1 (5.3)
6 (31.6)

1 (33.3)
1 (33.3)

1 (2.3)

-

-

1 (33.3)

-

-

-

-

27 (62.8)
2 (4.7)
13 (30.2)

13 (61.9)
2 (9.5)
6 (28.6)

13 (68.4)
6 (31.6)

1 (33.3)
1 (33.3)

Total
n= 43
(%)

Cardiology
n= 3
(%)
1 (33.3)

Questionnaire Item

262

♦Seropositive results from 2 different immunoasays and/ or
PCR performed at the CDC
Positive serology from blood screening donations
Detection of apolipoprotein A-1 upregulation in human serum
All of the above
Not sure
No response
Q12. Which of the following describes the current treatment
options for Chagas disease?
Benznidazole and nifurtimox are available only under current
investigational protocol by the CDC in children up to 18 years
of age with chronic infections, and in adults up to age 50 with
chronic infection who have no indication of advanced
cardiomyopathy
Benznidazole has been approved by the U.S. FDA for patients
2-12 years of age and is available commercially
Nifurtimox is only available by the CDC under investigational
protocol
♦Second and third choices only
Not sure
No response
Q13. Should patients with chronic CD be treated with
anitrypanosomal drugs?
No, there is no evidence that antitrypanosomal treatment for
Chronic CD can be effective

Total
n= 43
(%)

Family or
General
Practice
n= 21 (%)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

17 (39.5)

5 (23.8)

11 (57.9)

1 (33.3)

2 (4.7)
11 (25.6)
13 (30.2)

2 (9.5)
8 (38.1)
6 (28.6)

2 (10.5)
6 (31.6)

1 (33.3)
1 (33.3)

10 (23.3)

2 (9.5)

7 (36.8)

1 (33.3)

1 (2.3)

-

1 (5.3)

-

2 (4.7)

2 (9.5)

-

-

4 (9.3)
13 (30.2)
13 (30.2)

11 (52.4)
6 (28.6)

4 (21.1)
1 (5.3)
6 (31.6)

1 (33.3)
1 (33.3)

5 (11.6)

2 (9.5)

3 (15.8)

-

Questionnaire Item

Total
n= 43
(%)

Family or
General
Practice
n= 21 (%)
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Yes, only patients younger than 5 years of age should be
treated for chronic CD
♦Treatment is always recommended for patients up to age 18
12 (27.9)
3 (14.3)
and generally recommended for patients aged 18 to 50
Only CD patients manifesting with moderate to severe
cardiomyopathy
Not sure
12 (27.9)
9 (42.9)
No response
14 (32.6)
7 (33.3)
*Rounding
Abbreviation: CD Disease (CD)
♦ Denotes correct answer for the knowledge items
** Specific totals (i.e., with not all 3 questionnaire samples contained the item, thus sub-total is listed)

Infectious
Disease
n= 19
(%)

Cardiology
n= 3
(%)

-

-

8 (42.1)

1 (33.3)

-

-

2 (10.5)
6 (31.6)

1 (33.3)
1 (33.3)

Appendix G: Summary of Key Informant Tracking Table

Study
ID
2008
2104

1105
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1011
1102

0001
1106
1009
2010
1014
1007
2015

Date and
Time
7/30/28;
11am
6/28/18,
4:30
7/2/18;
2:30pm
7/9/18;
4pm
6/28/18;
3pm
7/1/18;
4pm
8/28/18;
1pm
7/6/18;
11am
7/27/18;
7:30pm
9/14;
11am
7/15/18;
8:30pm
7/6/18;
1pm

Managed
Care of
CD
patients

Institution or
Affiliation

Yes UTHouston
Yes JBSA- Lackland
Children's
Hospital of San
Yes Antonio
Baylor College of
Yes Medicine

Current
City

Specialty

# of
Years in
Specialty

Medical
Setting

# of CD
patients
managed

Sex

Houston
San
Antonio

Cardiology

15

Inst.

5

M

Cardiology

3

Inst.

1

M

San
Antonio

Infectious
Disease
Infectious
Disease
Infectious
Disease
Family/
General
Practice
Infectious
Disease
Infectious
Disease

4

Inst.

1

M

38

Inst.

2

F

5

Comm. Clin

3

M

6

Inst.

0

M

9

Inst.

1

M

3

Inst.

10

F

20

Comm. Cln.

1

F

10

Inst.

5

F

Houston

Cardiology
Infectious
Disease
Infectious
Disease

16

Inst.

100

F

Houston

Cardiology

12

Comm. Clin.

0

M

Houston

Yes .

Dallas

UTHealth San
No Antonio
UTHealth San
Yes Antonio

San
Antonio
San
Antonio

Yes UTSouthwestern
Baylor College of
Yes Medicine
UTHealth San
Yes Antonio
Baylor College of
No Medicine
Baylor College of
Yes Medicine

Dallas
Houston
San
Antonio

Study
ID
1103

Date and
Time
6/28/18;
3:45pm

Managed
Care of
CD
patients

Institution or
Affiliation

Current
City
San
Yes Fort Sam Houston Antonio

Specialty
Infectious
Disease

# of
Years in
Specialty
12

Medical
Setting
Inst.

# of CD
patients
managed
25

Sex
F
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